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     Abstract 
 
The Forkhead Box M1 (FOXM1) transcription factor is an important master 
cell cycle regulator that can control a wide spectrum of downstream target genes 
involved in apoptosis, metastasis, DNA repair, oxidative stress, G1/S and G2/M cell 
cycle transition.  Elevated expression or activity of FOXM1 is correlated with poor 
prognosis in breast cancer patients. 
 
In this study, I demonstrated that the novel thiazole antibiotics - thiostrepton 
selectively induces cell cycle arrest and cell death in breast cancer cells through 
down-regulating of FOXM1 at the transcriptional and gene promoter levels.  
Furthermore, thiostrepton also demonstrates efficacy in repressing breast cancer cell 
migration, metastasis and transformation, which are all downstream functional 
attributes of FOXM1.  Interestingly, thiostrepton exhibited minimal cytotoxic effect 
in untransformed MCF-10A breast epithelial cells, suggesting that under in vitro 
conditions thiostrepton represents a novel lead compound for targeted therapy of 
breast cancer with minimal toxicity against non-cancer cells. 
 
Prior to establishing the possibility of employing thiostrepton to circumvent 
acquired cisplatin resistance, I needed to address the hitherto unknown roles that 
FOXM1 might play in acquired cisplatin resistance through its proposed downstream 
DNA repair targets - breast cancer associated gene 2 (BRCA2) and X-ray-cross-
complementing group 1 (XRCC1).  I demonstrated that the cisplatin resistant breast 
cancer cell line (MCF-7-CISR) showed an elevation of both FOXM1 mRNA and 
protein expression levels relative to parental MCF-7 cells. Interestingly, the siRNA 
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knockdown of FOXM1, but not BRCA2 or XRCC1 could reduce the rate of 
proliferation in response to cisplatin treatment in the resistant cells.  This suggests 
FOXM1 could be a better therapeutic target than DNA damage repair genes, as 
FOXM1 controls several other critical cellular functions which are important for 
cancer cell survival. 
 
Moreover, the mitogenic activation protein kinase (MAPK) - ERK-1/2 has 
previously been implicated in conferring acquired cisplatin resistance in ovarian 
cancer cells.  Hitherto, its role in acquired cisplatin resistance in breast cancer is 
unknown.  Given that ERK-1/2 is critical in mediating FOXM1 phosphorylation and 
translocation prior to the mitotic phase of cell cycle, I hypothesized that an up-
regulation of ERK-1/2 could also contribute to cisplatin resistance in breast cancer 
cells through enhancing nuclear FOXM1 translocation.  Surprisingly, I discovered 
that the inhibition ERK-1/2 kinase activity through the use of MEK inhibitors 
PD098059 failed to reverse cisplatin sensitivity in MCF-7-CISR cells.  Furthermore, 
PD098059 failed to inhibit FOXM1 nuclear translocation in MCF-7-CISR cells, but 
not in MCF-7s.  The uncoupling of ERK-1/2 and FOXM1 in MCF-CISR cells confer 
cellular cisplatin resistance independent of ERK mediated mitogenic signals suggests 
that the direct targeting of FOXM1 would be a better strategy in circumventing 
cisplatin resistant breast cancer.  Indeed, thiostrepton exhibited potent cytotoxicity in 
MCF-7-CISR cells either as a single agent, or synergistically with cisplatin.  Taken 
together, the body of pre-clinical research data presented in this thesis has laid 
foundations for future work to further validate thiostrepton as a treatment for patients 
with breast cancer or acquired chemoresistance through the inhibition of FOXM1 
expression. 
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Chapter 1 Introduction 
 
 




Breast cancer is a disease where there is an abnormal proliferation of cells 
within the breast ductal and lobular tissues of the mammary gland (Colditz, Rosner et 
al. 2004).  According to the World Health Organization (WHO), breast cancer 
constitutes approximately 7.3% of all cancer deaths and it is the most common form 
of cancer found in women worldwide (WHO 2006). Breast cancer also occurs in 
males, but at a much lower rate.  It only attributes to about 1 % of the total number of 
breast cancer cases (Atlanta 2006). 
   
There has been a significant rise in the number of breast cancer cases 
diagnosed every year since the 1970s (Atlanta 2006).  There are several 
epidemiological risk factors, both environmental and genetics, which have been 
associated with breast cancer.  So far, only 5 % of all breast cancer cases are familial 
and 95% occurs sporadically (MacMahon 2006).  The exact trigger or cause for 








In the early stages of breast cancer, there are often no symptoms.  In some 
cases, patients can experience breast pain and a lump is often present either under the 
arm or above the collarbone (Boehmke and Dickerson 2005).  At the later stages of 
breast cancer, breast tumours can cause inflammation in the skin, resulting in red, 
swollen and painful sensations (Boehmke and Dickerson 2005).  Eczematoid skin 
changes can also occur around the nipple.  At the final stages of breast cancer, breast 
cancer cells often metastasize to other organs like the brain, liver, lung and bones.  
This could result in weight loss, fevers, chills, neurological complications and 
multiple organ failures (Yoon, Malin et al. 2007).  These severe clinical 
complications would eventually lead to death. 
 
1.1.3 Current treatments 
 
 The treatments given to breast cancer patients are highly dependent on the 
etiologic and clinical pathological factors which include the age of patients, tumour 
histological grade and size, nodal status, HER2 receptor status and hormonal receptor 
status (Guarneri and Conte 2004).  This allows physicians to discriminate high and 
low risk patients, allowing them to make an informed decision on the most suitable 
type of treatment regime including chemotherapy, endocrine therapy, radiotherapy, 
targeted therapy or a combination of any of the above forms of treatment modality 
(Guarneri and Conte 2004).  The choice of therapeutic modality is crucial in 
minimising relapse incidence and maximising disease free survival period post 
treatment. 
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1.1.4 The limitations of chemotherapy 
  
 According to the recommendations based on the St Gallen consensus, the use 
of chemotherapy is widely applicable to patients within the intermediate and high 
risk group.  Chemotherapy involves the administration of chemotherapeutic agents 
that impairs mitosis, resulting in their enhanced cytotoxic effect on rapidly 
proliferating cells like cancer cells (Smith and Chua 2006). 
 
 







treatment or none 
Endocrine treatment or 
none 
Not applicable 
Intermediate Chemotherapy and 
endocrine treatment 
Chemotherapy followed by 
endocrine treatment 
Chemotherapy 
High Chemotherapy and 
endocrine treatment 





Table 1-1  The classification of adjuvant chemotherapy for breast cancer 
patients based on the St Gellen consensus * Diagram adapted from (Smith 










 Unfortunately, most patients eventually develop resistance to a range of 
chemotherapeutic agents and render them ineffective (McGrogan, Gilmartin et al. 
2008).  In the late 1990s, the introduction of targeted therapy was hailed as an 
important breakthrough in cancer therapeutics (Green 2004).  Targeted therapy 
primarily involves the use of small molecule inhibitors and monoclonal antibodies to 
interfere with specific protein interactions needed for carcinogenesis.  For instance, 
the development of a monoclonal antibody Herceptin®, which binds to the 
extracellular segment of HER2 receptor, interfering with downstream MAPK growth 
signalling pathways in breast cancer patients positive for HER2 status had been a 
clinical success (Romond, Perez et al. 2005; Guarneri, Frassoldati et al. 2008). 
 
 Further identification of possible molecular targets, coupled with innovate 
drug design and optimisation is needed to devise new therapeutic regime for breast 
cancer patients.  In recent years, there has been an emerging interest in the study of 
Forkhead box M1 (FOXM1) as a potential molecular target for targeted therapy.  
FOXM1 is a transcription factor which has often been described as a “master cell 
cycle regulator” which is involved in a range of physiologically important processes 
like apoptosis, metastasis, angiogenesis, oxidative stress,
 
G1-S and G2-M cell cycle 
transition, DNA repair and maintaining chromosomal integrity (Myatt and Lam 
2007).  Recent 3D culture models and clinical correlation studies have suggested the 
possible role of using FOXM1 as a prognostic breast cancer signature (Martin, 






1.2 The transcription factor Forkhead box M1  
 
1.2.1 FOXM1 – a forkhead transcription factor 
 
 
FOXM1 is a transcription factor belonging to the Forkhead box (Fox) family, 
which  encompasses at least 43 other members (Katoh and Katoh 2004).   FOXM1 
has also been previously known as Trident, HFH-11, WIN, INS-1, MPP-2 and 
FKHL-16.  In order to simplify the naming system within the Forkhead family, a 
unified nomenclature was introduced for all the members of the Forkhead family 
members in 2000 (Kaestner, Knochel et al. 2000).  Subsequently, FOXM1 has been 
adopted as the standard nomenclature name. 
 
Interestingly, invertebrate organisms like Caenorhabditis elegans possess a 
limited number of subfamily of Fox genes, whereas in vertebrate organisms like 
Homo sapiens contain a total of 17 known Fox gene subfamilies (FoxA-R) with 41 
members (Myatt and Lam 2007).  This suggests that during the evolution from lower 
invertebrate organisms to higher organisms like humans, the duplication and 
expansion of Fox family homologues were needed to allow for functional 
diversification, accommodating to the needs of increasing developmental complexity 






 Phylogenetic analysis also revealed that FOXM1 is evolutionarily most 
closely related to the other FOXO subfamily, which consists of FOXO1, FOXO3A 
and FOXO4 (Myatt and Lam 2007).  Nonetheless, all members of the forkhead 
transcription factors possess the conserved DNA binding forkhead box domain, 
which forms a winged helix structure that can bind to the major groove of DNA to 
activate gene expression (Korver, Roose et al. 1997; Yao, Sha et al. 1997).  Under in 
vitro conditions, the transactivation ability of FOXM1 has been attributed to its 
ability in binding to the consensus sites 5’-TAAACA-3’ and 5’-AGATTGAGTA-3’ 
















Figure 1-1  A phylogenetic tree illustrating the evolutionary relationship 
amongst the different members of the FOX family.  FOXM1 shares the highest 
degree of homology to the FOXO family of genes.  Diagram adapted from 












Figure 1-2  A) Genomic structure of FOXM1 gene B) The protein domains of 
the three FOXM1 isoforms – FOXM1a, FOXM1b and FOXM1c.  Diagram 
adapted from (Laoukili, Stahl et al. 2007). 
 
 
The human FOXM1 gene is located on the chromosome 12p12-3 telomeric 
bands.  It is approximately 25 kb long and consists of 10 exons.  The two exons A1 
(45 bp) and A2 (114 bp) are alternatively spliced to create three different types of 
FOXM1 splice variant transcripts – FOXM1A, FOXM1B and FOXM1C (Yao, Sha 
et al. 1997).  The splice variant FOXM1A contains both the alternative exons A1 and 
A2, splice variant FOXM1B containing only the A1 exon and FOXM1C containing 






FOXM1A is transcriptional inactive due to the insertion of the A1 exon 
within the C terminus of the transactivation domain.  Although FOXM1A is 
transcriptionally inactive, studies have revealed that it could act as a dominant 
negative variant to control cell proliferation.  For instance, FOXM1A showed an 
elevated level of expression in the basal portion of intestinal crypt cells, which are 
multi-potent stem cells (Ye, Kelly et al. 1997).  The relative higher expression of 
FOXM1A, in comparison to FOXM1B suggests that it could act as a dominant 
negative inhibiting excessive proliferation, which could lead to colorectal cancer if 
left unchecked.  
 
For the transcriptional active transcript variants FOXM1B and FOXM1C, 
their expression pattern is tissue-specific.  For instance, the expression of FOXM1B 
is restricted mainly to the skin, testis and liver cells (Chaudhary, Mosher et al. 2000; 
Teh, Wong et al. 2002), whereas the expression of FOXM1C is the predominant 
splice variant ubiquitously expressed in most primary and secondary cell lines, 
including breast cells and neonatal tissues containing active mitotic cells (Yao, Sha et 
al. 1997; Teh, Wong et al. 2002; Ma, Tong et al. 2005).  The reasons behind why 
there two isoforms exist is unknown, but current studies suggest that both FOXM1B 
and FOXM1C show a rather positive correlation with respects to their expression 











 Following the revelation of the tissue-specific distribution of FOXM1 
transcript variants, further experimental observations suggest that FOXM1 is a 
proliferation specific transcription factor.   
 
 Essentially, this means that FOXM1 has only found to be expressed in cells 
that are actively proliferating.  For instance, it has been observed that the expression 
of FOXM1 is salient in the epithelial and mesenchymal cells of embryonic origin 
(Ye, Kelly et al. 1997).  In adult tissues, the expression of FOXM1 is restricted to 
cellular regions which are actively dividing within the thymus, testis, lung and 
intestine tissues (Korver, Roose et al. 1997).  Interestingly, a large scale in-house 
microarray screening involving 10,368 genes identified FOXM1 as one of the genes 
that were down-regulated as neural stem cells differentiate, suggesting that the 
expression of FOXM1 is switched off when neuronal stem cells cease to divide.   
Subsequent in situ hybridization also confirmed that FOXM1 is also over-expressed 
in central nervous system germinal stem cell areas where there is active cellular 
division (Karsten, Kudo et al. 2003; Ahn, Lee et al. 2004).  Furthermore, FOXM1 
has also been found to be involved in T cell development.  Within the bone marrow, 
the division of hematopoietic stem cells present in the thymus give rise to huge 
populations of naïve thymocytes, which are double negative for the surface receptors 
CD4 and CD8 (CD4-CD8-).  They then develop into double positive thymocytes 
(CD4+CD8+) before maturing into single positive which are either CD4+CD8- or 
CD4-CD8+ thymocytes.  FOXM1 expression was only present in the naïve and 
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double positive thymocytes, when they are still actively dividing prior to maturing 
into the terminally differentiated single positive cells.   
 
 Taken together, all the above experimental observations strongly suggest that 
expression of FOXM1 is only switched on in cells during their active phase of 


























Figure 1-3  The specific expression pattern of FOM1 as it undergoes cell cycle 
progression 
 
Not only is FOXM1 a proliferation specific transcription factor, FOXM1 also 
possesses a specific cell cycle expression pattern during proliferation.  FOXM1 is not 
detectable at the quiescent G0 phase of the cell cycle (Korver, Roose et al. 1997).  
However, as cells re-enters the cell cycle, both FOXM1 mRNA and protein levels 
start to increase and peaks at the late S phase and G2/M phase of the cell cycle.  As 
cell cycle exits mitosis, FOXM1 expression is diminished to a low level and only to 





Furthermore, the activity of FOXM1 is also tightly regulated, and its activity 
peaks during the G2-M phase of the cell cycle.  The post-translation modification of 
the protein domains within FOXM1 plays a large role in the tight execution of 
FOXM1 activity. During the G1 phase of the cell cycle, the transcriptional activity of 
FOXM1 is kept inactive through several ways.  Firstly, the N-terminal repression 
domain (NRD) keeps the transcriptional activity of FOXM1C inactive by binding 
directly to the C-terminal transactivation domain (TAD) (Park, Wang et al. 2008).  
Secondly, the central transrepression domain (TRD) recruits retinoblastoma protein 
(pRB), which could trans-repress FOXM1 activity (Wierstra and Alves 2006).  
Thirdly, residues 26 to 44 of the p19ARF binds to the TAD of FOXM1 and direct it 
to the nucleolus, precluding it from activating its downstream gene targets 
(Kalinichenko, Major et al. 2004). 
 
As cell cycle progresses, the presence of different mitogenic signals activate 
FOXM1 through different mechanisms.  As cell cycle progresses from G1 to S phase, 
the expression of cyclin A and cyclin E/cdk2 complexes increase due to the de-
repression of upstream E2Fs (Major, Lepe et al. 2004; Luscher-Firzlaff, Lilischkis et 
al. 2006).  The cyclinE/cdk2 complex then binds to the docking sequence LXL found 
between resides 641 and 643 of the FOXM1 C-terminal domain (Luscher-Firzlaff, 
Lilischkis et al. 2006).  This then leads to the phosphorylation T596 residue, which 
abrogates the repression of the C-terminal TAD.  The phosphorylation of T596 
allows the recruitment of the histone deacetylase p300/CREB binding protein 
(p300/CBP), which is a transcriptional co-activator needed for the activation of 
downstream targets (Major, Lepe et al. 2004).  It is also thought that the 
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phosphorylation of the retinoblastoma protein pRB by cyclin D1/Cdk4 may also be 
required to relieve the repression of FOXM1 by pRB through disrupting their direct 
interaction (Major, Lepe et al. 2004).  
 
As cell further progresses from the S phase of the cell cycle towards the G2 
phase, the docking LXL sequence now preferentially binds to cyclinB/cdk1 complex 
instead.  This encourages the phosphorylation of both T596 and S678 residues, 
which serves as docking sites, binding to the C-terminal Polo-box domain of the 
Polo-like kinase 1 (Plk1) (Fu, Malureanu et al. 2008).  The direct binding of Plk1 to 
FOXM1 protein allows for Plk1 to further hyperphosphorylate FOXM1 residues 
S715 and S724, which are required to fully activate FOXM1(Fu, Malureanu et al. 
2008).  The double mutant expressing the S715A and S724A point mutations leads to 
the abrogation of Plk1 mediated phosphorylation, and also subsequently leads to 
mitotic phase arrest (Fu, Malureanu et al. 2008).  This indicates the importance of 
these two highly conserved phosphorylation FOXM1 sites amongst vertebrates as 
important to the successful execution of the mitotic programme.  
 
The cytoplasmic FOXM1 is then phosphorylated and translocated into the 
nucleus by upstream MAPK kinases through the Raf/MEK1/ERK pathway (Ma, 
Tong et al. 2005).  Upon entry into the nucleus, the fully active FOXM1 then 
activates mitotic genes important in the G2/M phase transition including cyclin B1 
(Leung, Lin et al. 2001), cdc25b (Wang, Chen et al. 2005), cyclin A2 (Wang, Chen 
et al. 2005), Plk1 (Wang, Chen et al. 2005).  The positive feed-back loop between 
FOXM1 and Plk1, FOXM1 and cyclin B1 serves further to ensure that cells undergo 
cell cycle progression completely.  
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As cells exit mitosis, FOXM1 protein is degraded through proteasome 
degradation.  This is regulated by Cdh1 – a cofactor of the anaphase promoting 
complex (APC/C) that directly binds to the D and KEN-box motifs located on the N-
terminus FOXM1, which subsequently leads to the ubiquitination and proteolysis of 
FOXM1 (Laoukili, Alvarez-Fernandez et al. 2008).  FOXM1 expression remains low 
as cells return to the early G1 phase of the cell cycle and its expression will become 
elevated again as cells re-enter another round of cell division, exhibiting a specific 





































Figure 1-4 The protein structure of FOXM1.  The FOXM1 protein consists of 
762 amino acids in total.  It is divided into four main domains – an N-terminal 
repression domain (NRD) between residues 1 and 232; a Forkhead DNA 
binding domain (DBD) between residues 234 and 321; a central trans-
repression domain (TRD) between residues 359 and 425 and a C-terminal 
transactivation domain (TAD) between residues 600 and 763.  Multiple 
phosphorylation sites have been identified in the different regions of FOXM1 
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1.2.5 FOXM1 is a “master” transcription factor that activates 




The expression specific pattern of FOXM1 leads many to believe initially that 
the sole role of FOXM1 is to regulate cell cycle progression.  However, additional 
studies have revealed the range of different genes that FOXM1 activate, which are 
involved in a range of important fundamental cellular processes.   
 
The downstream targets include genes involved in G1/S transition – c-myc 
(Wierstra and Alves 2008), Skp2/Cks1 (Wang, Chen et al. 2005), KIS kinase 
(Petrovic, Costa et al. 2008), JNK1 (Wang, Chen et al. 2008); G2/M transition - 
cyclin B1 (Leung, Lin et al. 2001), cdc25b (Wang, Chen et al. 2005), cyclin A2 
(Wang, Chen et al. 2005), Plk1 (Wang, Chen et al. 2005); angiogenesis - vascular 
endothelial growth factor (VEGF) (Wang, Banerjee et al. 2007); organogenesis – 
TGF-β, Platelet endothelial cell adhesion molecule-1 (Pecam-1), Forkhead 
transcription factor F1 (FoxF1), VEGF receptor type 1 (Flt1), metastasis – matrix 
metallopeptidases (MMPs), MMP2 and MMP9 (Dai, Kang et al. 2007); DNA repair 
– Breast Cancer Type 2 susceptibility protein (BRAC2) and X-ray repair cross 
complementing protein 1 (XRCC1) (Tan, Raychaudhuri et al. 2007), Centromere 
protein A, B and F (CENP-A,B,F) (Laoukili, Kooistra et al. 2005), Aurora kinase A 
and B (Lens and Medema 2003), NIMA (never in mitosis gene a)-related kinase 2 
(Nek2) and Kinesin family member 20A (KIF20A) (Wonsey and Follettie 2005); 
apoptosis – survivin (Wang, Chen et al. 2005) and ERα (Madureira, Varshochi et al. 
2006); oxidative stress – BMI1 polycomb ring finger oncogene (Bmi1), Superoxide 
dismutases (MnSOD), catalase and Peroxiredoxin 3 (PRDX3) (Li, Smith et al. 2008; 




















Figure 1-5 An overview of the FOXM1 signalling network.  FOXM1 regulates a 
cascade of different downstream signalling pathways including 
organogenesis, angiogenesis, stem cell formation, apoptosis, metastasis, 




















































Figure 1-6  The process of organogenesis.  Early human zygote contains three 
different germ layers – ectoderm, mesoderm and endoderm which 
differentiates into different types of cells and organs as the embryo develops.  




 Organogenesis refers to the early embryonic developmental process where 
the gastrula develops into three distinct layers - embryonic ectodermal, endodermal 
and mesodermal layers which then further differentiates into different internal organs 
(NCBI 2004).  The external ectoderm layer differentiates into neuronal and skin 
cells; the mesoderm layers differentiate into skeletal and smooth muscle cells; the 





   Several early experimental studies have indicated that FOXM1 expression is 
strongly correlated with organogenesis.  For instance, in Xeonpus laevis embryonic 
stem cells, the expression of FOXM1 mRNA transcripts was strongly elevated 
during the early development of the nervous system and its expression is restricted to 
the neuroectodermal layer (Pohl, Rossner et al. 2005).  Similar observations that 
FOXM1 expression is elevated were also observed in mouse embryonic stem cells 
(Ahn, Lee et al. 2004).  Further functional studies have indicated any FOXM1 
aberrant deletions or mutations in genetic FOXM1 expression often leads to 
embryonic fatality.  For instance, the generation of transgenic mice carrying 
deletions of both the Forkhead DNA binding domains and transactivation domains 
resulted in embryonic lethality within 18 days.  In homozygous FOXM1-/- embryonic 
mutants, hepatoblast proliferation was significantly retarded (Krupczak-Hollis, Wang 
et al. 2004).  This showed that FOXM1 is needed for the embryonic development 
organogenesis of the liver.  Another study performed using FOXM1-/- embryonic 
mutants also demonstrated that FOXM1 is essential for the proliferation of the 
embryonic pulmonary mesenchyme, which differentiates into arteriolar smooth 
muscle cells and peripheral pulmonary capillaries (Kim, Ramakrishna et al. 2005).    
 
 Interestingly, another study utilising the use of different transgenic mice lines 
carrying either heterozygous FOXM1 or homozygous FOXM1 mutants created by 
inserting a PGK-Neomycin gene cassette within exon 3 of the FOXM1 gene showed 
that FOXM1 has additional roles beyond that of organogenesis.  Although the 
heterozygotes mutants showed no signs of developmental disorder, homozygous 
mutants resulted in embryonic lethality (Korver, Schilham et al. 1998).  Subsequent 
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histological examination of the homozygous mutants revealed deformity in both the 
liver and the heart.  Furthermore, microscopic examination reveals further anomalies 
in both the cardiomyocytes and hepatocytes showed enlarged nuclei with 
chromosomal  polyploidy and moreover, cardiomyocytes had a 50-fold amplification 
in DNA contents, whilst hepatocytes showed a 6-fold amplification (Korver, 
Schilham et al. 1998).  These observations imply that FOXM1 can prevent the onset 
of multiple rounds of S phase replication initiation in both the liver and the heart 





































 Following experimental observations in early organogenesis studies that the 
loss of FOXM1 resulted in chromosomal abnormalities, the roles that FOXM1 might 
play in maintaining genomic integrity was confirmed in subsequent studies.  For 
instance, observed in the increase in incidence of chromosomal abnormalities and 
aneuploidy in FOXM1 depleted cells (Korver, Roose et al. 1997; Laoukili, Kooistra 
et al. 2005; Wonsey and Follettie 2005).  Furthermore, FOXM1 has been shown to 
trans-activate the promoter activity of CENP-F, a kinetochore binding protein 
(Laoukili, Kooistra et al. 2005).  The presence of CENP-F is crucial as it is part of 
the mitotic checkpoint machinery and ensures the proper segregation of non-
defective chromosomes during the anaphase of mitosis, whereas for defective 
chromosomes, the G2 mitotic checkpoint machinery is responsible for trigger mitotic 
catastrophe (Ashar, James et al. 2000; Liu, Hittle et al. 2003; Johnson, Scott et al. 
2004; Laoukili, Kooistra et al. 2005). 
 
 Another study involving the employment of a stable FOXM1 short hairpin 
RNA in BT-20 breast cancer cell lines to inhibit FOXM1 expression has resulted in 
centrosome amplification and mitotic catastrophe (Wonsey and Follettie 2005).  
Subsequent microarray screen performed comparing differential gene expression 
reveals additional downstream targets of FOXM1 including CENP-A, KIF20 and 
Nek2 (Wonsey and Follettie 2005).  All these additional downstream targets were 
known to play pertinent roles in preserving the integrity of mitotic chromosomal 
spindle formation.  Both the CENP-A and KIF20 protein are localized to the 
centromere to ensure proper chromosomal alignment during metaphase and 
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separation during anaphase (Fontijn, Goud et al. 2001; Goshima, Kiyomitsu et al. 
2003).  On the other hand, Nek2 – a microtubule associated motor protein is 
localized to the mitotic spindle during anaphase to allow for proper cytokinesis when 
daughter cells separate during mitosis (Fry, Meraldi et al. 1998).  Therefore, the 
importance of FOXM1 in the maintenance of chromosomal integrity during mitosis 
cannot be underestimated. 
 
 In addition to the role FOXM1 plays in the maintenance of chromosomal 
integrity, recently it has been demonstrated that FOXM1 can activate downstream 
DNA repair targets in response to a variety of DNA damaging agents.  For example, 
osteosarcoma U2OS cells exposed to the treatment of DNA damaging agents 
including 10 Gy of gamma-irradiation, 20 µM of etoposide or 20 J/m2 of UV 
radiation could lead to an increase in CHK2 phosphorylation of FOXM1 protein on 
serine residue 361 (Tan, Raychaudhuri et al. 2007).  This phosphorylation event 
stabilizes FOXM1 and leads to an increase in sustained transcriptional up-regulation 
of two downstream targets – BRCA2 and XRCC1 (Tan, Raychaudhuri et al. 2007).  
BRCA2 is important in the repair of double strand DNA breaks through homologous 
recombination (Pellegrini and Venkitaraman 2004) and XRCC1 is needed for 








1.2.6 FOXM1 and cancer 
 
 




 Following the discovery that FOXM1 has critical roles in proliferation and 
DNA repair, other experimental evidence has begun to hint at the possible roles that 
FOXM1 might have in two critical malignancy transformation processes - 
angiogenesis and metastasis. 
 
 Tumour cells often possess aberrant blood vessel traits including shape 
irregularity, profuse vessel dilation and the prominence of perivascular detachment 
(Brown and Giaccia 1998; McDougall, Anderson et al. 2006).  These combinatorial 
factors restrict blood flow within the tumour microenvironment, drastically reduce 
the oxygen concentration and limiting the ability of cancer cell to proliferate and 
expand under such hypoxic conditions.  Therefore, in order to expand, tumour cells 
must evolve ways to improve the amount of blood flow within its microenvironment.  
In order to achieve this, angiogenesis - a physiological process in which new blood 
vessels are formed from pre-existing vasculature is up-regulated (Pinedo 2000). 
 One of the most important biochemical molecules intimately involved in the 
regulation of angiogenesis belongs to the soluble vascular endothelial growth factor 
(VEGF) family.  VEGF binds to the tyrosine kinase receptors VEGFR-1 and 
VEGFR-2, causing dimerization and transphosphorylation of the two receptors, 
resulting in a downstream amplification cascade of pro-angiogenic signals (Shibuya 
and Claesson-Welsh 2006).  Given the importance VEGF plays in promoting 
angiogenesis, it is unsurprising that it is often over-expressed in a range of primary 
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cancer cells including gastric (Liu, Yu et al. 2005), pancreatic (Tang, Itakura et al. 
2001), colorectal cancer (Yamamura, Matsuzaki et al. 1998) and triple negative 
breast cancer (Iosifidou 2009).  VEGF can support the expansion of blood vessels 
network, fuelling adequate oxygen for growth which was demonstrated under both in 
vtiro and in vivo conditions (Claffey and Robinson 1996). 
 The link between FOXM1 and VEGF was first established in glioblastoma 
cell lines (Zhang, Zhang et al. 2008).  It is known that the glioblastoma 
microenvironment is very hypoxic, and this results in the up-regulation of Hypoxia 
Inducible Factor-1α (HIF-1α).  HIF-1α is a member of the PER-ARNT-SIM (PAS) 
subfamily of the basic-helix-loop-helix family of transcription factors and its 
expression is induced under hypoxic conditions (Wang, Jiang et al. 1995; Smith, 
Brooks et al. 2008).  Under hypoxic conditions, HIF-1α can bind directly to VEGF 
promoter and transactivate its expression (Zhang, Zhang et al. 2008).  However, the 
observation that in the extreme periphery where tumour cells grow under normoxic 
conditions, an elevated level of VEGF was still observed indicated that additional up-
stream regulators were present to stimulate VEGF expression (Zhang, Zhang et al. 
2008).  Indeed, two upstream FOXM1-binding regions were identified within the 
VEGF promoter and ChIP analysis confirmed that FOXM1 binding to these sites 
activated VEGF expression (Zhang, Zhang et al. 2008).  However, elevated levels of 
FOXM1 was also observed in MCF-7, HepG2 and HeLa cancer cells lines under 
hypoxic conditions.  Additional ChIP assays performed indicated that HIF-1α can 
directly bind to the HIF-1 promoter sites located within the FOXM1 promoter region 
(Wang, Banerjee et al. 2007).   Therefore, a new working model developed to 
explain that under normoxic conditions, FOXM1 is sufficient alone to activate VEGF 
and promote angiogenesis, but under hypoxic conditions where there is a severe 
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shortage of oxygen, HIF-1α serves to amplify the angiogenic signalling through 
direct up-regulation of VEGF and a simultaneous activation of FOXM1 levels. 
 
 Immunohistochemical staining also further confirmed the clinical relevance 
between FOXM1 and VEGF, where they are significantly correlated in 59 human 
glioblastoma samples (Zhang, Zhang et al. 2008).  Similar correlation between 
FOXM1 and VEGF was also observed in human gastric cancer (Li, Zhang et al. 
2009).  Knockdown studies performed in pancreatic cell lines have shown that the 
siRNA inhibition of FOXM1 can sufficiently reduce VEGF expression and 
pancreatic cell proliferation (Wang, Banerjee et al. 2007).  In summary, FOXM1 is a 
major contributor to angiogenesis and the down-regulation of FOXM1 could be a 















1.2.6.2 FOXM1 contributes to carcinogenic processes – metastasis  
 
 Not only does angiogenesis serves to allow for uncontrolled proliferation of 
cancer cells, but the observation that the inhibition of angiogenesis also inhibits 
cancer metastasis indicates that angiogenesis serves as a prerequisite for cancer 
metastasis (Kirsch, Schackert et al. 2000; Kirsch, Schackert et al. 2004).  Metastasis 
is the process where cancer cells have evolved the ability to move to a secondary 
distant site, away from its primary origin site.  It consists of a complex series of 
mechanisms, in which malignant cells escape from the primary tumor by the 
degradation of the extracellular matrix proteins (ECM) and migrate through the 
bloodstream, eventually attaching to the ECM of the secondary site (Maru 2009).  In 
breast cancer patients, the common secondary sites for tumour metastasis include the 
bones, lungs and brain (Schlappack, Baur et al. 1988; Kominsky and Davidson 2006; 
Wadasadawala, Gupta et al. 2007).  Metastasis is also the predominant cause of 
mortality in breast cancer patients; therefore the development of suitable treatment to 
suppress metastasis would be of tremendous benefit for breast cancer patients 
(Braun, Auer et al. 2009). 
 
 Both MMP-2 and MMP-9 belong to the family of matrix metalloproteinase, 
which are highly homologous endopeptidases and requires zinc as a co-factor that is 
involved in the degradation of ECM (Birkedal-Hansen, Moore et al. 1993).  Their 
expression is also often up-regulated in a range of cancers including breast (Baum, 
Hlushchuk et al. 2007),  colorectal (Gimeno-Garcia, Santana-Rodriguez et al. 2006), 
gastric cancer (Albo, Shinohara et al. 2002) and oral cavity squamous cell 




 Hitherto, FOXM1 has been shown to be a direct up-stream regulator of both 
MMP-2 and MMP-9 (Dai, Kang et al. 2007; Wang, Banerjee et al. 2007).  The 
inhibition of FOXM1 has been shown to reduce the invasiveness of pancreatic cell 
(Dai, Kang et al. 2007; Wang, Banerjee et al. 2007) whilst the over-expression of 
FOXM1 enhanced the invasiveness of glioma cells (Dai, Kang et al. 2007; Wang, 
Banerjee et al. 2007).  
 
  In summary, FOXM1 serves a critical regulator of carcinogenic processes 
































1.2.6.3 The over-expression of FOXM1 is observed in several primary and 




Given the role FOXM1 plays in promoting carcinogenic processes like 
angiogenesis and metastasis, it is perhaps no surprise that many studies have revealed 
the over-expression of FOXM1 in many different types of cancer, making it a 
plausible universal molecular marker for cancer malignancy. 
 
The performance of large scale gene expression studies have revealed that 
FOXM1 is over-expressed in a range of solid tumours including bladder, liver, 
kidney, lung, ovary, pancreas, glioblastoma, colon, mesothelioma and 
cholangiocarcinoma (Ye, Kelly et al. 1997; Teh, Wong et al. 2002; van den Boom, 
Wolter et al. 2003; Wang, Bhattacharyya et al. 2003; Kalinichenko, Major et al. 
2004; Pilarsky, Wenzig et al. 2004; Wang, Chen et al. 2005; Kim, Ackerson et al. 
2006; Romagnoli, Fasoli et al. 2009; Yokomine, Senju et al. 2009).  Furthermore, the 
chromosome band 12p13 where FOXM1 is located is frequently amplified in 
cervical carcinomas (Heselmeyer, Macville et al. 1997), head and neck squamous 
cell carcinomas (Singh, Gogineni et al. 2001), nasopharyngeal carcinomas 
(Rodriguez, Khabir et al. 2005), breast adenocarcinomas (Spirin, Simpson et al. 
1996), peripheral cytotoxic T cell lymphomas not otherwise specified (PTCL-NOS) 











The revelation that FOXM1 is over-expressed in so many types of clinical 
malignancies indicates that its expression is correlated with cellular malignancy 
transformation.  Several independent clinical studies have then subsequently 
highlighted the importance of FOXM1 in breast cancer carcinogenesis. 
 
For instance, a pioneering investigation in 2005 has revealed that FOXM1 
mRNA expression level is significantly over-expressed in 194 infiltrating breast 
ductal carcinomas, but not in untransformed breast epithelial tissues (Wonsey and 
Follettie 2005).  Further RT-QPCR data revealed that stage II breast carcinomas had 
a 6.5-fold elevation of FOXM1 transcript levels, whereas stage III breast carcinomas 
had a 96-fold elevation of FOXM1 transcript levels (Wonsey and Follettie 2005).  
Therefore, this study suggests that advanced staged breast cancer is correlated with 
an elevation of FOXM1 expression level, which is consistent with FOXM1’s role in 
angiogenesis and metastasis that could increase the invasiveness of breast cancer 
tumours. Subsequently, another study performed in 2008 has also confirmed that the 
up-regulation of FOXM1 mRNA levels was observed in 25 paraffin-embedded 
breast carcinomas relative to untransformed breast tissues (Bektas, Haaf et al. 2008).  
Further immunohistochemistry results from a tissue array revealed that 87% of the 
205 breast carcinomas have nuclear FOXM1 staining, whilst only 41% of the 45 
normal breast tissues possess nuclear FOXM1 staining (Bektas, Haaf et al. 2008).  
Furthermore, breast cancer patients with nuclear FOXM1 expression also had 




1.3 FOXM1 as a molecular target for targeted 
therapy 
 
1.3.1 Why target FOXM1? 
 
 
 Given that FOXM1 is widely elevated in primary breast cancer patient tissues 
and a range of breast cancer cell lines, it is logical to further explore the possibility of 
the development of FOXM1 as a molecular target for breast cancer.  In particular, 
FOXM1 is an extremely attractive molecular target for targeted therapy for several 
reasons.   
 
 Firstly, cancer cells proliferate quicker than normal cells; therefore cancer 
cells are more sensitive to cytotoxic or chemical drugs that damage replicating DNA 
and proteins involved in cell cycle division.  Many chemotherapeutic agent act on 
this principle and has gained a degree of success.  Since FOXM1 is a master cell 
cycle regulator and a proliferation specific transcription factor, the inhibition of 
FOXM1 alone should be able to inhibit cancer cell proliferation effectively (Adami 
and Ye 2007). 
 
Indeed, it has also been demonstrated in several studies that the inhibition of 
FOXM1 can kill cancer cells through the inhibition of cancer cell proliferation.  For 
instance, in pancreatic cell lines, siRNA knockdown on FOXM1 lead to a decrease 
level of MMP-9, MMP-2 and VEGF which resulted in a decrease in metastasis and 
angiogenesis (Wang, Banerjee et al. 2007).  It has also been shown that siRNA 
knockdown of FOXM1 in prostate cancer cell lines like PC-3, LNCaP and DU-145 
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resulted in the decrease of proliferation and anchorage dependent cell growth on soft 
agar (Kalin, Wang et al. 2006).   Furthermore, in vivo mice studies have 
demonstrated the efficacy of using p19ARF, a natural peptide inhibitor that can bind 
to nuclear FOXM1 and inhibit its transactivation ability by compartmentalising it to 
the nucleolus (Kalinichenko, Major et al. 2004).  A miniature prototype of p19ARF 
known as ARF26–44 peptide inhibitor was subsequently created, which consists of an 
addition of 7 arginine residues to allow for easier cell membrane up-take (Gusarova, 
Wang et al. 2007).  Subsequently, the authors also exposed both wild type mice and 
transgenic mice models with endogenous p19ARF deletion (p19ARF-/-) to 
carcinogens diethylnitrosamine and Phenobarbital over a 40-week period to induce 
heptocellular carcinomas (HCCs) (Gusarova, Wang et al. 2007).  Following the 
establishment of mice HCCs model, the new ARF26–44 peptide inhibitor was used to 
treat HCCs mice for a 4 week period that resulted in a marked decrease in HCC 
tumour cell proliferation and angiogenesis, coupled with a concomitant increase in 
apoptosis (Gusarova, Wang et al. 2007).  These studies demonstrated that FOXM1 
inhibition is an effective therapeutic approach to reduce liver cancer cell proliferation 
under in vivo conditions. 
 
Moreover, the in vivo study also demonstrated that the inhibition of FOXM1, 
at least in the liver had no side effects at all and did not result in morbidity 
(Gusarova, Wang et al. 2007).  The experimental observation is consistent with the 
long hypothesized caveat that long term inhibition of FOXM1 will have minimal 
toxicity in humans.  This is because FOXM1 is a proliferation specific transcription 
factor, whose expression is only up-regulated in actively dividing cells and its 
expression is switched off in terminally differentiated tissues.  However, to further 
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confirm that FOXM1 inhibition is non-toxic in humans, further experiments would 
be needed to test the effects of FOXM1 deletion in actively dividing regions within 
the human physiology like the hematopoietic system, the gastrointestinal tracts and 
the testicular cells where sperm gametes are actively growing. 
 
In summary, FOXM1 is a potentially good molecular target for therapeutical 
intervention because of its proliferation specific nature; its inhibition has 
demonstrated minimal toxicity under in vivo studies.  Furthermore, it a master 
transcriptional factor, which holds the keys to the regulation of an array of 
physiological processes including proliferation, angiogenesis, metastasis and DNA 
repair.  Therefore, the inhibition of FOXM1 will lead to the simultaneous 








1.3.2 The search for FOXM1 inhibitors 
 
1.3.2.1 The identification of the first small molecule inhibitor of FOXM1 – 
Siomycin A 
 
Having established the role that FOXM1 is indeed an attractive molecular 
target which plays a fundamental role in promoting breast cancer carcinogenesis, it is 
no surprise that there has been an intense focus on the translational research in the 
development of potential FOXM1 inhibitors. 
 
A novel screening system for novel small molecule FOXM1 inhibitors was 
established by an American group based in the University of Illinois in Chicago 
(Radhakrishnan, Bhat et al. 2006).  An osteosarcoma cell line U2OS, which has been 
previously described to contain a stable transfected construct containing a 
doxycyclin-inducible FOXM1-green fluorescent fusion protein was used 
(Kalinichenko, Major et al. 2004).  The cell line was further co-transfected with a 
plasmid containing 6 repeated FOXM1 promoter elements fused with a firefly 
luciferase reporter gene and pCDNA3.1 which contains neomycin resistance cassette 
for the selection of neomycin clones.  The single cell neomycin resistant clones were 
selected for further co-transfection with the pRML-CMV construct that expresses 
renilla luciferase and pLPCX-puro plasmid which contains the puromycin resistance 
cassette.  Cells were the selected for puromycin resistance and the U2OS 





The C3-Luc cell line now contains a constitutively active renilla luciferase, a 
FOXM1 promoter response element fused firefly luciferase and a doxycyclin-
dependant GFP-fused FOXM1 protein.  In the presence of doxycyclin, the expression 
of GFP-fused FOXM1 protein was selectively induced by 16-fold, but renilla 
luciferase activity remained unchanged.  The C3-Luc cell line was screened against 
compound libraries and Siomycin A was the only compound which repressed 
FOXM1-dependent GFP intensity activity back to basal level (Radhakrishnan, Bhat 
et al. 2006).  To further confirm whether Siomycin A can repress endogenous 
FOXM1 expression level, the C3-Luc cell line was treated with a dose response of 
Siomycin A in the absence of doxcycline induction.  The results revealed that the 
firefly luciferase activity decreased in a dose-dependant manner in relation to 
Siomycin A.  This indicated that Siomycin A mechanistically works by repressing 
the promoter activity of FOXM1 directly.  Accordingly, the mRNA and protein 
expression levels of known downstream targets of FOXM1 including Cdc25B, 











1.3.2.2 Siomycin A possesses anti-cancer properties 
 
 
Not only did the work of Gartel et al have for the first time revealed a novel 
small molecule inhibitor that can repress FOXM1 expression, but further 
experiments performed by the authors also showed that Siomycin A demonstrated 
potent anti-cancer properties under in vitro conditions.   
 
Soft agar colonies were performed to measure the amount anchorage-
independent growth of cancer cells, which is a form of in vitro assay providing 
indications of their metastatic potential.  C3-Luc cells were grown in agar dishes in 
the presence of doxycyclin FOXM1 induction or without FoxM1 induction, in the 
presence of Siomycin A for 28 days.  The induction of FoxM1 led to approximately a 
2-fold increase in the number of colonies, which is consistent with the active role of 
FOXM1 play in promoting angiogenesis and metastasis.  The addition of Siomycin A 
also dramatically reduced colony formation to below than of the basal untreated 
numbers, suggesting that the direct repression of FOXM1 expression can inhibit 
malignancy transformation (Radhakrishnan, Bhat et al. 2006).  Furthermore, 
Siomycin A showed selective induction of apoptosis through caspase-3 activation of 
the SV40-transformed MRC-5 human foetal lung fibroblasts, whereas it did not 
induce apoptosis or caspase-3 activation in the wild type MRC-5 human foetal lung 
fibroblasts (Radhakrishnan, Bhat et al. 2006).  Therefore, the study also revealed that 
the inhibition of FOXM1 can selectively induce cell death in cancer cells, 
minimising potential side effects.   
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1.3.2.3 The thiazole class of antibiotics 
 
 
 Prior to this discovery, Siomycin A was a little known antibiotics isolated 
from the bacterium species Streptomyces sioyaensis (Tokura, Tori et al. 1980).   
 
Siomycin A belongs to the family of thiazole antibiotics consisting of a vast 
number of family members which include thiocillins (Shoji, Hinoo et al. 1976), 
mircococcins (Walker, Olesker et al. 1977), nosiheptide (Benazet, Cartier et al. 
1980), berninamycin (Liesch, McMillan et al. 1976), glycothiohexide α (Northcote, 
Siegel et al. 1994; Northcote, Williams et al. 1994), cyclothiazomycin (Aoki, 
Ohtsuka et al. 1991), GG2270 A (Kettenring, Colombo et al. 1991), thiopeptin 
(Miyairi, Miyoshi et al. 1970; Miyairi, Miyoshi et al. 1972) and  thiostrepton 
(Donovick, Pagano et al. 1955).  All thiazole antibiotic family members contain the 









Figure 1-7  Thiazole functional group is consists of a 5-membered ring where 
two vertices of the ring are sulphur and nitrogen atoms, where the other three 








1.3.3.1 Introducing thiostrepton – the prototype of the thiazole antibiotic family 
 
Within the thiazole antibiotic family, thiostrepton is considered the “flagship” 
member of the family and it is one of the most widely studied members of the 










Thiostrepton was first discovered and isolated from the bacterium 
Streptomyces azureus in 1955 by Donovick et al. who discovered its anti-bacterial 
properties under in vitro studies (Donovick, Pagano et al. 1955).  It was isolated in 
other closely related members of the actinomycetes group of bacterium Streptomyces 
including, Streptomyces laurentii and Streptomyces sioyaensis (Dutcher and 
Vandeputte 1955; Shoji, Hinoo et al. 1976; Trejo, Dean et al. 1977; Nagai, Kamigiri 
et al. 2003; Suzumura, Yokoi et al. 2003; Bagley, Dale et al. 2005) .   
 
Thiostrepton contains a very complex chemical structure consisting of a 
dehydropiperidine ring, a bisdehydroalanine tail, two macrocycles of a 26 membered 
thiazole containing ring and a 27-membered quinaldic acid ring (Jin 2005).  Both X-
ray crystallography and 1-HMR studies have revealed that thiostrepton adopts a  
tertiary structure with a globular conformation where the two large macrocycles of 
the thiazole containing ring and the quinaldic acid ring overlaps into a folding 
position (Anderson, Hodgkin et al. 1970; Hensens, Albers-Schonberg et al. 1983). 
  
Naturally, thiostrepton possesses antibacterial activity against prokaryotic 
cells. In bacteria cells, thiostrepton has been shown to inhibit protein translation by 
directly binding to the GTPase region in 23 rRNA nucleotides 1067A and 1095A 
(Rosendahl and Douthwaite 1994).  Furthermore, NMR spectroscopy experiments 
have shown that thiostrepton stabilizes the binding interface between ribosomal 
protein L11 domain and 23rRNA, resulting in structural rigidity that prevents it adopt 
a different orientation (Jonker, Ilin et al. 2007).  As a result, other translation and 
elongation factors EF-G are prevented from binding to the transcript, inhibiting 
translation initiation and causing bacteria cell death.   
 
 64 
Furthermore, it has been shown that thiostrepton has proven effective against 
multi-drug resistant bacteria strains like methicillin-resistant Staphylococcus aureus 
(MRSA) and vancomycin resistant Enterococcus faecalis (VREF) (Nicolaou, Zak et 























1.3.3.2 Thiostrepton also inhibits cancer cell growth 
 
 
 The biosynthesis of thiostrepton from the tsr gene operon cluster involves a 
complex series of biosynthetic pathway involving ribosomal synthesized precursor 
peptides and posttranslational modifications (Liao, Duan et al. 2009).  Large scale 
laboratory production of thiostrepton has been made possible with the recent 
advancements in organic chemistry, allowing for the chemical synthesis of 
thiostrepton (TS) and four smaller synthetic fragments - dehydropiperidine core 
(DC), bis-dehydroalanine tail (BT), the thiazoline-thiazole (TT) moiety and the 
quinaldic acid subunit (QA) (Nicolaou, Zak et al. 2005; Kelly, Pan et al. 2009).  Not 
only did the five fragments exhibited anti-bacterial properties, but an in vitro screen 
reveals that they displayed varying degrees of anti-cancer properties against a range 
of cancer cell lines including human breast, ovarian, colon, chronic myelogenous 
leukaemia, taxol-resistant and epothilone A resistant ovarian cancer cell lines 
(Nicolaou, Zak et al. 2005). 
 
 The study reveals that the both the thiostrepton and dehydropiperidine 
showed significant anti-tumour activities whilst the other three fragments - bis-
dehydroalanine tail, thiazoline-thiazole moiety and the quinaldic acid subunit showed 
little or no significant anti-tumour activity (Figure 1-9).   Closer scrutiny of the IC50 
values revealed that the smaller dehydropiperidine core were significantly lower 
across all the cancer cell lines tested, indicating that the dehydropiperidine core could 
be the pharmacophore, which confers thiostrepton its anti-tumour activity (Nicolaou, 
Zak et al. 2005).  However, the exact mechanism of how thiostrepton confers anti-
tumour activity remains hitherto unknown.  
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Figure 1-9  1) The complete structure of thiostrepton 2) Structure of the 
dehydropiperidine core 3) Structure of the bis-dehydroalanine tail 4) Structure 
of the thiazoline-thiazole moiety 5) Structure of the quinaldic acid subunit  

















Figure 1-10  The anticancer potency of thiostrepton and its 4 synthetic 
fragments.  NCI-H460 - human non-small cell lung cancer cell line; HCT-116 -
human colon cancer cell line; SK-OV-3 – human ovarian cancer cell line; MCF-
7 – human breast cancer cell line; K-562 – human chronic myelogenous 
leukemia cancer cell line; 1A9 – ovarian cancer cell line; PTX10 – taxol 
resistant ovarian cancer cell line; A8 – Epothilone A resistant ovarian cancer 
cell line; AD10 – P-glycoprotein – overexpressing ovarian cancer cell line.  NA 

















                                                              IC50 (µM) 
                                              Cancer cell lines 
  
NCI-H460 HCT-116 SK-OV-3 MCF-7 K-562 1A9 PTX10 A8 AD10 
TS 1.5 1.6 2.8 3.8 1.7 0.96 1.1 0.9 91.0 
DC 0.9 0.6 1.2 0.9 0.8 0.07 0.1 0.2 0.4 
BT NA NA NA NA NA NA NA NA NA 
TT 5.7 7.3 8.0 17.0 6.0 NT NT NT NT 








 Intriguingly, scrutiny of the chemical structure of thiostrepton has revealed 
that is shares almost an identical structure with Siomycin A (Figure 1-11).  There 
were only three chemical differences located within the quinaldic acid subunit, where 
minor alterations of varying carbon side chains were replaced.  The primary different 
sites are R1 – thiostrepton contains an ethyl group but Siomycin A contains a methyl 
group; R2 – thiostrepton contains a methyl group but Siomycin A contains a 
methylene group. R3 – thiostrepton contains a hydrogen atom but Siomycin A 
contains a methylene group.   
 
 Due to the close structurally analogy between Siomycin A and thiostrepton, 
coupled with the experimental observations that both compounds exhibit anti-cancer 
activity under in vitro conditions.  Therefore, it is highly likely that akin to Siomycin 
A, thiostrepton could also selectively inhibit the FOXM1 promoter activity and elicit 
cell death in cancer cells.  I consequently put forward the hypothesis that thiostrepton 




















Figure 1-11 The structural differences between thiostrepton and Siomycin A.  
The primary different sites are R1 – thiostrepton contains an ethyl group but 
Siomycin A contains a methyl group; R2 – thiostrepton contains a methyl 
group but Siomycin A contains a methylene group. R3 – thiostrepton contains 
a hydrogen atom but Siomycin A contains a methylene group.  (Diagram 




1.4 Platinum based chemotherapy 
 
1.4.1 Cisplatin – a new recruit for breast cancer chemotherapy 
regime 
 
 Apart from the development of novel FOXM1 inhibitors in the treatment of 
breast cancer, there has also been a recent surge of interest in expanding the range of 
chemotherapeutic available for the clinical treatment of breast cancer patients.  
Cisplatin is one of the new emerging modality that is been considered (Ott and Gust 
2007). 
 
   The advent of the use of platinum-based chemotherapy has its roots dated 
back to 1965, where platinum electrodes were accidentally to been found to retard 
the growth of the bacterium species Escherichia coli.  Further chemical analysis 
revealed two active chemical complexes – cis-diamniodichloroplatinum and cis-
diamminetetrachloroplatinum (Rosenberg, Vancamp et al. 1965; Rosenberg, Van 
Camp et al. 1967). Subsequently,   cis-diamniodichloroplatinum was developed into 
cisplatin and approved by the US Food and Drug Administration (FDA) for the 
treatment of testicular and bladder cancer in 1978 (Kelland 2007).  Unfortunately, 
like other chemotherapeutic agents the use of cisplatin is not without its side-effects.  
The common side effects include ototoxicity (Reddel, Kefford et al. 1982; Rybak and 
Whitworth 2005), peripheral neuropathy (Meijer, de Vries et al. 1999), 




  Due to the high toxicity of cisplatin, a safer alternative cis-diammine-[1,1 – 
cyclobutanedicarboxylato] platinum (Carboplatin) was developed in 1982 
(Cvitkovic, Spaulding et al. 1977).  The lower toxicity is attributed to the 
replacement of the chloro groups with an inferior leaving group of higher Pka value; 
this renders the cisplatin complex more stable.  Carboplatin has since been approved 
for the treatment of ovarian, colorectal, cervical, head and neck, relapsed lymphoma 
and lung cancer (Rabik and Dolan 2007).  
 
 Although traditionally cisplatin is not used in the treatment of breast cancer, 
recent clinical data suggests an emerging role for platinum based chemotherapy for 
advanced breast cancer patients (Muggia and Fojo 2004).  An independent phase II 
clinical trial conducted in 1988 demonstrated for the first time that the employment 
of cisplatin as a first line, single agent therapy achieved a partial response in 47% of 
metastatic breast cancer patients (Sledge, Loehrer et al. 1988).  Following this trial, 
there have been recommendations suggested to include cisplatin and other platinum 
analogues as part of a first line chemotherapeutic treatment for breast cancer patients 
(Sledge 1992).  Since then, four independent phase II clinical trials involving HER2 
positive or advanced metastatic breast cancer patients treated with a combination of 
Herceptin with cisplatin and docetaxol showed clinically significant improvement of 
survival rates (Lee, Doliny et al. 2004; Pegram, Pienkowski et al. 2004; Hurley, 
Doliny et al. 2006).  Furthermore, a recent clinical trial data also suggested that triple 
negative breast cancer patients who are ER-negative, PR-negative and had low 
HER2 expression levels had better survival rate in response to a combination therapy 
of cisplatin and the anti-EGFR antibody Cetuximab (Oliveras-Ferraros, Vazquez-
Martin et al. 2008). 
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1.4.2 Mechanism for the cytotoxic effect of cisplatin 
 




 The successful application of cisplatin in clinical settings could not have 
happened without a sound of knowledge of the mode of mechanism of the cytotoxic 
effect of cisplatin.  Indeed, many studies have contributed to the establishment of a 
working model on how cisplatin works.   
 
 Firstly, cisplatin enters the cell in its neutral state through passive diffusion or 
active uptake involving Na+-K+ ATPase gated ion channels (Gately and Howell 
1993).  Upon entering the cell, aquation process occurs and the chloro ligands are 
replaced by the positively charged H3O+ species (El-Khateeb, Appleton et al. 1999; 
el-Khateeb, Appleton et al. 1999).  This renders it a very reactive electrophile, which 
then reacts with the nucleophilic N7 sites of the purine bases adenine and guanine to 
form DNA cross links (Eastman 1987; Eastman and Barry 1987).  The predominant 
85 to 90 % of the DNA intrastrand adducts formed are 1, 2 intrastrand ApG and GpG 
cross links (Pinto and Lippard 1985; Sherman, Gibson et al. 1985, Bellon, 1991 #65).   
 
 The formation of cisplatin induced DNA-adducts results in tangible 
malconformation that are recognised by a range of different types of recognition 
proteins including the nonhistone chromosomal high mobility group 1 and 2 
(HMG1/2) proteins, human RNA polymerase I transcription upstream binding factor 
(hUBF), the transcriptional activator TATA binding protein (TBP), the hMSH2 and 
hMutSα components of the mismatch repair complex (MMR) (Donahue, Augot et al. 
1990; Fink, Nebel et al. 1998).   
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 These proteins either work independently or cooperating with one another to 
transduce an array of downstream signalling which transduce and activates three 
main types of pathways – apoptosis, G1/S/G2-M cell cycle arrest and DNA repair 























1.4.2.2  Cisplatin-DNA adducts induce a cascade of downstream pro-survival, 
pro-apoptotic and cell cycle check-point mediated DNA repair pathways 
 
 The outcome of the cell fate – whether it decides to undergo apoptosis or 
continue with DNA repair, would ultimately depend on the cross talk between the 
p53 mediated pathways, the HER2 mediated PI3K/AKT pro-survival pathway and 
the multitude of DNA repair signaling pathways activated by the formation of 
cisplatin-DNA adducts (Figure 1-12). 
 
 In the presence of cisplatin-DNA adducts, one of the most important 
biochemical signalling cascades involved the activation of the important tumour 
suppressor protein p53.  The protein p53 can be activated in three different manners, 
either through the up-regulation of the activity of ATR which can activate p53 
through the direct phosphorylation at serine 15 (Persons, Yazlovitskaya et al. 2000), 
or through the activation of CHK1 kinase that can lead to the phosphorylation of p53 
at serine 20, activating p53 protein activity (Shieh, Ahn et al. 2000).  Moreover, the 
damage recognition proteins HMG1 and HMG2 have also been found to aid the 
binding of p53 to cisplatin-DNA adduct, which can serve to further stimulate its 
transactivation (Jayaraman, Moorthy et al. 1998; Imamura, Izumi et al. 2001).  Once 
p53 is activated, it is involved in the regulation of number different downstream 
molecular targets.  Firstly, the direct activation of p21 by p53 leads to a G1 cell cycle 
arrest.  Simultaneously, the cell cycle arrest provides an opportunity for p53-
dependent DNA repair through the activation of GADD45A (Delmastro, Li et al. 
1997; Hershberger, McGuire et al. 2002).  To complicate the matter, p53 also 
activates BAX, a pro-apoptotic protein which can trigger the intrinsic apoptotic 
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pathway (Makin and Dive 2001), or though FAS/FASL (Muller, Scaffidi et al. 1998), 
which can trigger the extrinsic apoptotic pathway. 
  
 Therefore, p53 activates cell cycle arrest, DNA repair and cell death at the 
same time.  The ultimate outcome of cell fate would be highly dependent on the 
intensity of various signals and the strength of cross-talks from other relevant 
pathways including the activation of HER-2 mediated PI3-AKT pro-survival 
pathway, the ERK and JNK MAPK signaling pathways and the involvement of a 
multitude number of DNA damage repair genes like ERCC1, XRCC1, XPA and 
Topo-II (Wang, Martindale et al. 2000).   
 
  It is speculated that once a certain threshold of DNA damage is crossed 
beyond the cell’s capability to repair DNA damage, cells will then activate apoptosis.  
The complexity of the network of signaling leading to the ultimate decision of 
whether the cancer cell undergoes cell death, cell cycle arrest or DNA repair requires 
further elucidation.  
 













Figure 1-12  The signalling cascade induced by the formation of cisplatin-DNA 
adducts.  The ultimate cell fate is based upon the relative intensity of the 
biochemical pathways involved in apoptosis, cell cycle arrest and DNA repair. 
 
Cisplatin-DNA adducts

























1.4.3 The emergence of cisplatin resistance 
  
 Although cisplatin is a potent chemotherapeutic agent with relatively well 
established mode of action, the exposure of tumour cells to successive rounds of 
cisplatin inevitably leads to acquired cisplatin resistance in most patients.  For 
instance, the initial response rate for cisplatin chemotherapy in ovarian cancer 
patients are 70%, but more than half of the patients will relapse soon after resulting 
in a five year survival rate of less than 25% (Tewari and Monk 2005).  Moreover, a 
phase II clinical trial of a combination therapy of cisplatin and radiotherapy for small 
cell lung cancer demonstrated a staggering relapse rate of 95% within a 2 year period 
(Abratt, Willcox et al. 1992).  The problem of cisplatin resistance also affects breast 
cancer patients and the lack of a coherent understanding of the cisplatin resistance 
mechanisms are hampering progress in the developing efficient efficacies to 
circumvent acquired cisplatin resistance (Chuthapisith, Layfield et al. 2007). 
 
 The resistance mechanisms involved can broadly be divided into six 
categories – i) a reduction in intracellular cisplatin accumulation, ii) an increase in 
the inactivation of intracellular cisplatin, iii) an increase in DNA damage repair, iv) 
an increase in cell survival mechanism, v) increasing ability to bypass replication 
checkpoint, vi) increasing ability to evade apoptosis.   For each resistance category, a 




1.4.3.1 Decrease in intracellular cisplatin concentration 
 
 The first category of resistance mechanisms rely on the active reduction of 
the intracellular cisplatin concentration.  To achieve this, cisplatin resistance cells 
need to inhibit influx mechanisms and up-regulate efflux mechanisms to achieve 
maximal resistance against the cytotoxic effect of cisplatin.  The predominant protein 
responsible for the influx mechanism is the surface plasma membrane transporter – 
copper transporter-1 (CTR1) (Ishida, Lee et al. 2002).  Studies have been performed 
to indicate that the loss of CTR1 expression directly leads to a 65% decrease in 
cisplatin uptake, and this correlates with a 3 fold increase in cisplatin resistance 
amongst Ctr1-/- mouse embryonic fibroblasts (Safaei, Holzer et al. 2004).  In ovarian 
cancer cells, the exposure of cisplatin rapidly inhibits the expression of CTR1 
through internalization of the plasma membrane which subsequently leads to 
proteasome-based degradation (Holzer and Howell 2006).  This loss of CTR1 
expression also resulted in enhanced cisplatin resistance.  Working in conjunction 
with the influx mechanisms, tumour cells have also devised ways to maximise efflux 
mechanisms to minimize the accumulation of intracellular cisplatin.  For instance, 
there are numerous reports on the up-regulation of ATP-dependent efflux pumps 
including multidrug resistance protein (MRP) –MRP2, (Kool, de Haas et al. 1997; 
Borst, Evers et al. 2000) and the copper transporter ATPase dependent proteins 
ATP7A and AP7B can confer cisplatin resistance through the reduction of 
intracellular cisplatin concentration (Komatsu, Sumizawa et al. 2000; Katano, Kondo 
et al. 2002; Nakayama, Kanzaki et al. 2002).  The alteration of the balance of influx 
and efflux mechanisms in resistance cells ultimately lead to an overall reduction in 
the accumulation of intracellular cisplatin. 
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1.4.3.2  Inactivation of intracellular cisplatin 
 
 For residual cisplatin that escapes the influx/efflux regulatory system, 
additional inactivation mechanisms are present to reduce the reactivity of cisplatin in 
intracellular environment.  It has been observed that in both in vitro and clinical 
studies, the elevated concentration of reactive thiol species like glutathione (GSH) is 
directly correlated with cisplatin resistance (Wolf, Hayward et al. 1987; Mistry, 
Kelland et al. 1991).  The resistance was attributed to the ability of GSH to conjugate 
with cisplatin to form a cisplatin-thiol conjugate which prevents cisplatin from 
reacting with DNA to form lethal intrastrand lesions.  Further elucidation of the GSH 
metabolic pathways have revealed that, other molecular targets involved in the 
metabolic pathway that could up-regulation of GSH could also contribute to cisplatin 
resistance.  For instance, elevated levels of glutamylcysteine synthetase (-GCS) 
and GSH-S-transferase π (GSTπ) have also been found responsible (Godwin, Meister 
et al. 1992; Hamaguchi, Godwin et al. 1993).  Since cysteinylglycine is 10-fold more 
reactive than GSH, the up-regulation of -glutamyltransferase (-GT) which 
catalyses the conversion of GSH to cysteinlyglycine is also an important factor in 
mediating cisplatin resistance.  Furthermore, metallothioneins which are thiol 
containing cysteine rich compounds also inactivate cisplatin in the same manner as 
GSH and the up-regulation could contribute to the development of cisplatin 







1.4.3.3 Evasion from apoptosis 
 
 For the remaining cisplatin that conjugates with DNA to form intrastrand 
adducts, other resistance mechanisms are present to overcome the cytotoxic effect of 
cisplatin-DNA adducts.  Under equilibrium conditions, cells have a balance of pro-
survival and pro-apoptotic signals to allow for normal controlled proliferation.  In 
order for cells to avoid or evade apoptosis in the presence of lethal doses of cisplatin, 
cancer cells will have to adjust the equilibrium to prevent apoptosis by up-regulating 
pro-survival signals, whilst simultaneously down-regulating pro-apoptotic signalling.  
The pro-survival signalling pathways often up-regulated includes the HER2 (Slamon, 
Godolphin et al. 1989; Hengstler, Lange et al. 1999), PI3/AKT (Zhou, Liao et al. 
2001; Zhou, Liao et al. 2001), Ras/ERK MAPK (Fuchs, Adler et al. 1998; Fuchs, 
Adler et al. 1998; Gebauer, Mirakhur et al. 2000; Kartalou and Essigmann 2001; Pan, 
Yao et al. 2002) pathways.  On the other hand, the down-regulation of pro-apoptotic 
pathways normally act through the loss of p53 function (Kastan, Onyekwere et al. 
1991; Kastan, Radin et al. 1991; Pietenpol, Tokino et al. 1994; Siddik, Mims et al. 
1998; Hagopian, Mills et al. 1999; Siddik, Hagopian et al. 1999) or an increase in the 
expression level of anti-apoptotic proteins like survivin, XIAP and bcl-2 have also 
been widely implicated in the development of cisplatin resistance (Hockenbery, 
Oltvai et al. 1993; Asselin, Mills et al. 2001; Ikeguchi, Liu et al. 2002; Ikeguchi, 
Nakamura et al. 2002).  Furthermore, an increase tolerance of DNA damage through 
the up-regulation of DNA polymerases beta and eta, which can bypass cisplatin-
DNA adducts though translesion synthesis can also increase the cell’s ability to 
tolerate cisplatin toxicity (Bassett, Vaisman et al. 2002; Albertella, Green et al. 
2005).   
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1.4.3.4 Up-regulation of DNA damage repair pathways 
 
 However, the fundamental cellular defence mechanism against DNA 
damaging agent like cisplatin is through the up-regulation of DNA repair pathways.  
The integrity of the four primary DNA repair pathways, including the nucleotide-
excision repair, base-excision repair, mismatch repair and double strand break repair 
is critical in mediating the successful removal of cisplatin-DNA adducts (Kelland 
2007).  The deregulation of any one of the four pathways been implicated in 
conferring cisplatin resistance.  For instance, the up-regulation of the rate limiting 
components of the nucleotide-excision repair (NER) complex – excision repair cross-
complementing-1 (ERCC1) and xeroderma pigmentosum complentation group F 
(XPF) has been correlated with cisplatin resistance in ovarian cancer patients 
(Dabholkar, Bostick-Bruton et al. 1992; Ferry, Hamilton et al. 2000; Chang, Kim et 
al. 2005).  Clinical evidence also further points to the involvement of polymorphisms 
in ERCC1 in certain colorectal cancer patients that could sensitize them to platinum-
based chemotherapeutic agents (Reed 2005).  Interestingly, BRCA1 protein, which is 
involved in transcription-coupled nucleotide excision repair are also linked to an 
increase in cisplatin resistance in breast and ovarian cancers (Gowen, Avrutskaya et 
al. 1998). 
 
 It is pertinent to emphasize the multifactorial nature of cisplatin resistance.  
Therefore, the development of strategies to circumvent cisplatin resistance should 
involve targeting genes which have multiple roles, allowing for simultaneous 




1.5 Could FOXM1 confer cisplatin resistance? 
 
1.5.1 Exploring the role of FOXM1 in cisplatin resistance 
 
1.5.1.1 Up-regulation of FOXM1 could contribute to cisplatin resistance 
 
 
 Although FOXM1 is known to regulate several important physiological 
processes, it has never been postulated to be involved in acquired cisplatin resistance.   
However, several experimental observations have provided hints that FOXM1 could 
play an indispensable role. 
 
 Firstly, it has been observed that both FOXM1 mRNA and protein expression 
levels is directly proportional to the tumour grade of breast cancer patients (Bektas, 
Haaf et al. 2008).  With increasing FOXM1 expression levels, I would expect the 
downstream targets of FOXM1 to increase accordingly.  As FOXM1 expression 
levels increases, it could dramatically increase the intensity of pro-survival signalling 
through the activation of genes involved in G1/S transition like c-myc (Wierstra and 
Alves 2008), Skp2/Cks1 (Wang, Chen et al. 2005), KIS kinase (Petrovic, Costa et al. 
2008), JNK1 (Wang, Chen et al. 2008) and G2/M transition - cyclin B1 (Leung, Lin 
et al. 2001), cdc25b (Wang, Chen et al. 2005), cyclin A2 (Wang, Chen et al. 2005), 
Plk1 (Wang, Chen et al. 2005).  Furthermore, it has also been demonstrated that 
FOXM1 can activate downstream DNA repair targets in response to a variety of 
DNA damaging agents.  For example, osteosarcoma U2OS cells exposed to the 
treatment of DNA damaging agents including 10 Gy of gamma-irradiation, 20 µM of 
etoposide or 20 J/m2 of UV radiation could lead to an increase in CHK2 
phosphorylation of FOXM1 protein on serine residue 361 (Tan, Raychaudhuri et al. 
2007).  This phosphorylation event stabilizes FOXM1 and leads to an increase in 
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sustained transcriptional up-regulation of two downstream targets – BRCA2 and 
XRCC1 (Tan, Raychaudhuri et al. 2007).   
 
 BRCA2 is important in the repair of double strand DNA breaks through 
homologous recombination (Pellegrini and Venkitaraman 2004).  Approximately 
10% of familial breast cancer patients carry mutations in the BRCA2 gene, which 
results in a 55% increase in lifetime risk for developing breast cancer (Narod, Ford et 
al. 1995; Ford, Easton et al. 1998).  This is attributed to the loss of efficient DNA 
repair, increasing the chances of the development of somatic mutations (Tutt, 
Bertwistle et al. 2001; Tutt, van Oostrom et al. 2002).  Ironically, like its Achilles 
heels that in both cisplatin-resistant cell lines and clinical patient samples, it has been 
observed that a secondary frame shift mutation has been discovered to re-activate 
BRCA2 expression in these cells, resulting in secondary resistance to cisplatin 
treatment (Sakai, Swisher et al. 2008).  Therefore, I can surmise that in the remaining 
90% of breast cancer incidence which are non-familial with no mutations in BRCA2, 
the development of cisplatin resistance could arise from a further up-regulation of 
BRCA2 expression level by FOXM1. 
 
 On the other hand, XRCC1 is a DNA repair protein complexes with DNA 
ligase III, poly-ADP-ribose and β-polymerase to repair DNA single strand break 
through the base excision repair pathway (Thompson and West 2000; Brem and Hall 
2005).  Furthermore, epidemiological studies have revealed that large number of 
single nucleotide polymorphisms (SNPs) of XRCC1 is present in cancer patients, but 
their significance is still unclear.  Nonetheless, XRCC1 is also found to up-regulation 
in non-small cell lung cancer cells and it is correlated with cisplatin resistance 
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(Weaver, Crawford et al. 2005).  Hence, it would be reasonable to hypothesize that 
an increase in FOXM1 levels could activate and increase XRCC1 expression levels, 
conferring higher resistance levels by repairing DNA-cisplatin adducts. 
 
 In summary, both BRCA2 and XRCC1 proteins have been found to be 
important in the repair cisplatin-DNA which results in enhanced cisplatin resistance.  
Therefore, a direct increase in FOXM1 mRNA and protein expression levels could 
contribute to acquired cisplatin resistance by up-regulating its downstream DNA 


















1.5.1.2 ERK1/2, an up-stream regulator of FOXM1 is implicated in mediating 
pro-survival in the presence of cisplatin 
 
 
 There are three major mitogen activated protein kinases (MAPKs) signalling 
pathways present in eukaryotic mammalian cells.  The Raf/MEK/ERK signalling 
pathway is involved in cell proliferation, differentiation and development, whereas 
both the c-Jun N-terminal kinase/stress activated protein kinase (JNK/SAPK) and 
p38 MAP kinase pathway are involved in stress and inflammation response 
(Hagemann and Blank 2001; Roux and Blenis 2004; Bradham and McClay 2006; 














Figure 1-13  An overview of the three different MAP kinase signalling 
cascades.  Both the p38 and JNK mediated pathways are involved in stress 
and inflammation whereas the ERK-1/2 mediated pathway is involved in 
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 The MAP kinase cascade is a signal transduction pathway amplifies different 
biological signals, mediating a range of diverse downstream responses (Ferrell 1996; 
Pearson, Robinson et al. 2001).  The MAPK kinase cascade involves three analogous 
proteins – MAP kinase kinase kinase (MAPKKK), MAP kinase kinase (MAPKK) 
and MAP kinase (MAPK).  Initially, MAPKKK activates MAPKK by the 
phosphorylation of two serine residues within the activation loop of MAPK.  
Activated MAPKK then dual phosphorylate a tyrosine residue, followed by the 
threonine residue within the activation loop of the kinase subdomain VIII to fully 
activate it (Ferrell 1996; Pearson, Robinson et al. 2001).  It is important to note that 
in all three kinases, both amino acid residues are needed to be phosphorylated to 
allow for complete activation.  This essentially helps to filter off background noise 
signals and amplify important signalling in response to external stimuli (Ferrell 1996; 
Pearson, Robinson et al. 2001). 
 
 Amongst these MAPK signalling pathways, various experimental work has 
shown that the ERK-1/2 regulated pathways is the most relevant in breast cancers 
(Santen, Song et al. 2002).  ERK-1 and ERK-2 are two highly conserved isoforms 
ubiquitously expressed in all tissues and they possess over 83% of the amino acid 
similarity (Chen and Lin 2001; Chen, Tang et al. 2001).  Moreover, ERK-1/2 have 
been documented to be strongly activated mainly in the presence of various mitogen 
and growth serum, whilst cytokines, microtubule disorganisation and the ligands of 
heterotrimeric G protein-coupled receptors have also been implicated in its activation 
to a lesser extent (Joneson, Fulton et al. 1998).  The typical physiological response to 
ERK-1/2 activation results in cellular proliferation, differentiation or apoptosis 
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(Janknecht, Ernst et al. 1993; Wadman, Hsu et al. 1994; Price, Cruzalegui et al. 
1996). 
 
 Interestingly, the link between ERK-1/2 and FOXM1 activity was  first 
established when FOXM1 was shown to be activated and translocated to the nucleus 
by the direct phosphorylation by ERK-1/2 prior to mitotic entry in cell cycle 
progression (Ma, Tong et al. 2005).    Interesting, three independent studies of human 
breast cancer tissues have revealed that ERK-1/2 kinase activity is up-regulated 
relative to normal breast tissues (Sivaraman, Wang et al. 1997; Salh, Marotta et al. 
1999; Mueller, Flury et al. 2000).  Therefore, an increase in ERK-1/2 activity 
observed in breast cancer cells could potentially lead to lead to an increase amount of 
FOXM1 been translocated into the nucleus during cell cycle.  This could possibly 
result in an increase in the expression of its proposed downstream target DNA repair 
genes XRCC1 and BRCA2, which could then confer cisplatin resistance in breast 
cancer cells.   
 
 In summary, I hypothesize the following model where an intrinsic up-
regulation of both FOXM1 transcript and protein expression level, coupled with an 
increase in capacity of nuclear translocation conferred by increase in ERK1/2 activity 
in response to cisplatin, could result in the up-regulation of DNA repair genes 
BRCA2 and XRCC1 that could contribute to increase resistance in breast cancer cells. 
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1.6 Aims of the thesis 
 
 
Due to the increase in emergence in clinical resistance to a range of 
chemotherapeutic and targeted therapeutic agents, the development of novel drugs is 
urgently needed for breast cancer patients.  Thiostrepton, a novel thiazole antibiotic 
which has been previously demonstrated to possess anti-tumour activity in various 
human breast, ovarian, colon and chronic myelogenous leukaemia cancer cell lines 
under in vitro conditions (Nicolaou, Zak et al. 2005).  However, the exact mechanism 
of how thiostrepton confers anti-tumour activity is hitherto unknown. Intriguingly, 
scrutiny of the chemical structure of thiostrepton has revealed that is shares almost an 
identical structure with siomycin A.  Siomycin A has previously been identified to 
down regulate FOXM1 activity specifically through the inhibition of FOXM1 
promoter activity and the post translational modification of FOXM1 protein 
(Radhakrishnan, Bhat et al. 2006). Due to the close structurally analogy between 
siomycin A and thiostrepton, I consequently put forward the hypothesis that 
thiostrepton could also selectively target breast cancer cells through the down-
regulation of FOXM1.   
 
 Furthermore, cisplatin has also recently been recently recruited as a new 
chemotherapeutic agent for the clinical treatment of breast cancer patients (Muggia 
and Fojo 2004).  However, the emergence of cisplatin resistance is undermining the 
efficacy of the platinum based combination therapies.  The elucidation of cisplatin 
resistance is critical and the identification of new molecular targets can facilitate the 
development of new targeted therapies.  Recent evidence has emerged highlighting 
that CHK2 mediated phosphorylation of FOXM1 is important in DNA repair through 
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the activation of its downstream targets BRCA2 and XRCC1 (Tan, Raychaudhuri et 
al. 2007).  Furthermore, based on the observations that both FOXM1 mRNA and 
protein expression levels and ERK-1/2 activity are correlated with breast cancer 
tumour grades (Sivaraman, Wang et al. 1997; Salh, Marotta et al. 1999; Mueller, 
Flury et al. 2000; Bektas, Haaf et al. 2008), I subsequently put forward another 
hypothesis that the direct up-regulation of FOXM1 mRNA and protein level, coupled 
with an increase in ERK1/2 phosphorylation, could result in an increase in nuclear 
FOXM1 activity, enhancing the activation of downstream DNA repair targets 
BRCA2 and XRCC1, conferring cisplatin resistance in breast cancer cells.  
Furthermore, if FOXM1 activation were found to be an important molecular target of 
cisplatin resistance, thiostrepton could potentially be used in combination with other 
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2.1.1 Chemicals and Reagents 
 
All chemicals were purchased from Sigma Aldrich unless otherwise stated.  All 
endonucleases enzymes used in this study were obtained from New England Biolabs 
unless otherwise stated.  All the plastic consumables used were purchased from 
Appleton unless otherwise stated.   
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2.1.2 Overview of antibodies used in this study 
 
Antibody Company Clone Species Dilution 
 
Tubulin-β Santa Cruz H-235 Rabbit 1/1000 
Actin Chemicon MAB150R Mouse 1/1000 
Calmodulin Upstate 07-482 Rabbit 1/2000 
 
    
FOXM1 Santa Cruz MPP2 (H-300) Rabbit 1/1000 
FOXM1 Santa Cruz C-20 (J2803) Rabbit 1/1000 
FOXO3a Sigma Aldrich FKHL1 Mouse 1/1000 
FOXO3a Upstate C-20 Rabbit 1/2000 
 
    
cdc25b Santa Cruz C-20 Mouse 1/1000 
ER-alpha Santa Cruz F-10 Mouse 1/1000 
Plk Upstate 06-813 Rabbit 1/1000 
Plk Santa Cruz F-8 Mouse 1/500 
Cyclin B1 Santa Cruz H433 Rabbit 1/1000 
Cdc2/p34 Santa Cruz C-19 Rabbit 1/1000 
P27 Santa Cruz F-8 Rabbit 1/1000 
Bcl-2 Pharmingen 554279 Rabbit 1/1000 
BRCA2 Upstate 5.23 Mouse 1/1000 
XRCC1 AbD Serotec AHP832 Rabbit 1/1000 
 
    
E2F1 Santa Cruz KH95 Mouse 1/500 
Cyclin A1 Santa Cruz C-19 Rabbit 1/1000 
P53 Calbiochem AB-3 Mouse 1/1000 
ERK-1-P Cell Signalling 9101S Rabbit 1/1000 
Cyclin D1 Santa Cruz 72-I3G Mouse 1/1000 
p21 Santa Cruz M877 Mouse 1/1000 
p19ARF Abcam R562 Rabbit 1/1000 
p16 Santa Cruz H-156 Rabbit 1/500 
 
    
Anti rabbit HRP DakoCytomation  Goat 1/2000 
Anti mouse HRP DakoCytomation  Goat 1/2000 
Anti sheep HRP DakoCytomation  Rabbit 1/2000 
 
Table 2-1 Overview of the antibodies used in this study
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2.1.3 Overview of plasmids 
 
Plasmids Size Description Source/Reference 
 
pGL3 4.8 kb 
Basic luciferase vector 
containing the luciferase 
reporter gene 
Promega PGL3 Luciferase 
Reporter Vectors  
pCRTOPO 3. 9 kb 
Basic TOPO vector containing 
TA ends  
Invitrogen TOPO cloning 
technology 
 
FoxO3a wt 6.2 kb 
Backbone pGL3 vector 
containing the wild type 
Foxo3A promoter site 
Karen Pomeranz et al, 
Imperial College London 
FOXM1 wt  2.4 kb 
Wild type FOXM1 gene cloned 
into pBluescript SK 
(Korver, Roose et al. 1997) 
ApaI 0.3 kb 
Contains a 2.1 kb N-terminal 
truncation, using ApaI 
restriction enzyme  
(Korver, Roose et al. 1997) 
PVUI 0.43 kb 
Contains a 1.97 kb N-terminal 
truncation, using PVUI 
restriction enzyme 
(Korver, Roose et al. 1997) 
HindIII 1.4 kb 
Contains a 1 kb N-terminal 
truncation, using HindIII 
restriction enzyme 
(Korver, Roose et al. 1997) 
 
pCR-TOPO-
FOXM1 6.2 kb 
TOPO vector containing 
FOXM1  
Jimmy Kwok (In this 
study) 
 
pTRE Flag WIN 7.8 kb 
FOXM1c cloned into pCDNA 
3.1 with a CMV promoter 
K.-M. Yao et al, Hong 
Kong University 
∆N-FOXM1 6.5 kb 
FOXM1c with a truncated N-
terminus cloned into pCDNA 
3.1 with a CMV promoter 
K.-M. Yao et al, Hong 
Kong University 
pBABEpuro 5.2 kb 





Table 2-2  Overview of the plasmids used in this study.  The size of the FOXM1 













2.2.1 Cell manipulation 
 
2.2.1.1 Tissue Culture 
 
Name of cell line Description Source 
BT474 Breast cancer, epithelial tissue, human ATCC HTB-22 
COS1 Kidney fibroblast tissue, African green 
monkey 
ATCC CRL-1650 
MCF-7 Breast cancer, epithelial tissue, human ATCC HTB-20 
MCF10A Untransformed mammary epithelial tissue, 
human 
ATCC CRL-10317 
MDA-MB-231 Breast cancer, epithelial tissue, human ATCC HTB-26 
SKBR3 Breast cancer, epithelial tissue, human ATCC HTB-30 
T47D Breast cancer, epithelial tissue, human ATCC HTB-133 
ZR-75-1 Breast cancer, epithelial tissue, human ATCC CRL-1500 
MCF7-CISR MCF7 breast cancer epithelial tissue 
resistant to 100 nM of cisplatin, human 
Barrie Peck, 
Imperial College 
MCF-7-FOXM1 Stable MCF-7 cells transfected with the 
pTRE Flag WIN plasmid 
Jimmy Kwok, 
Imperial College 





Table 2-3  Overview of the cell lines used in this study 
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Table 2-3 shows the cell lines used in this study, information are based on the 
ATCC (American Type Culture Collection).  All cell lines were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% (v/v) FCS, 2 
mM glutamine, 100 u/ml penicillin and 100 µg/ml streptomycin unless otherwise 
stated.  The cells were all incubated in humidified Galaxy R incubator (Wolf 
Laboratories) with 10 % CO2.  Cell lines MDA-MB-231, Cos-1, SKBR3 and T47D 
were maintained at 37°C in a humidified Galaxy R incubator (Wolf Laboratories) 
with 5 % CO2 instead.  MCF10-A was cultured in DMEM HAM-F12 / 1:1 mix, 
supplemented with 5% horse serum, 10 mg/ml insulin, 5 mg/ml hydrocortisol, 100 
ng/ml cholorotoxin and 20 ng/ml of Epidermal Growth Factor (EGF), 100 u/ml 
penicillin and 100 µg/ml streptomycin. 
 
2.2.1.2 Tissue Culture 
 
Cells were harvested by trypsinisation and collected by centrifugation at 1200 
rpm for 10 min.  The cell pellet was washed in PBS once and resuspended in 2 ml of 
90% (v/v) FCS and 10% (v/v) DMSO.  The cell suspension was then transferred into 
a Cryo tube (Nalgene).  The Cryo tubes were stored in a Cryo freezing container 
which was incubated at - 80°C.  After 72 hours, the Cryo tubes are then transferred 
and stored in liquid nitrogen. 
2.2.1.3 Cell defrosting 
 
Cells were thawed out quickly in a 37°C water bath.  Cells were then 
collected by centrifugation at 1200 rpm for 10 min.  The media was discarded and 
cells were resuspended in their culture media.  Cells were then plated in a T75 flask. 
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 A dose concentration was performed using a varying a concentration of 
puromycin (InvivoGen) ranging from 0 to 10 µg/ml.  The lowest concentration 
required to kill over 90% of MCF7 cells was determined by trypan blue staining.  
Briefly, cells were harvested and spun at 1500 rpm for 5 min.  The cell pellet was 
then resuspended in 1 ml of DMEM media.  50 µl of the cell suspension was mixed 
with an equal volume of 0.4% trypan blue solution and incubated at room 
temperature for 5 min.  10 µl of the cell mixture was added onto a hemocytometer, 
the average number of cells per ml was determined by multiplying the total number 
of cell count in each quadrant by 104.  The percentage of the number of dead cells 
was determined by dividing the number of cells stained blue with the total number of 
cells, multiplied by a 100.  A kill curve was then plotted to determine the lowest dose 
required to kill over 90% of the MCF7 cells.   
 
 Once the selection concentration of 2.0 µg/ml was established, Fugene-6 
(Roche) was used to co-transfect MCF7 cells with the selection plasmid pBABEpuro 
(Addgene) that contains a puromycin selection marker, and the respective pTRE 
FLAG WIN plasmid for MCF7-FOXM1 cell line and ∆N-FOXM1 for MCF7-∆N-
FOXM1 cell line.  Initially, the cell lines were selected using 2.0 µg/ml of puromycin 
to for up to 4-weeks until no further dead cells were observed.  Western blot analysis 
was then performed to determine that FOXM1 is over-expressed in the stable cell 
lines.  The stable cell lines were then subsequently maintained at 0.75 µg/ml of 
puromycin. 
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2.2.3 DNA preparation & manipulation 
 
2.2.3.1 Bacterial Strains & preparation 
 
The Escherichia coli strain XL-10 gold competent cells (Stratagene, UK) 
were used for subcloning procedures.  The E.coli strain XL-1 Blue competent cells 
(Stratagene, UK) were used for both mini and maxi DNA preps.  Bacteria were 





Firstly, 100 µl competent cells were thawed on ice for 30 min.  Up to 1 µg of 
DNA was added to the competent cells and thoroughly mixed, followed by 
incubation for 15 min.  The competent cells were then transferred the eppendorf tube 
into 42°C water bath for 1 min.  The mixture was then incubated for 2 min on ice.  1 
ml of LB was added and the bacteria were outgrown for 1 hour in 37°C water bath.  
Bacterial cells are the centrifuged at 8000 rpm for 1 min.  Supernatant was then 
removed and 200 µl of LB was added to resuspend the bacteria.  Bacteria were then 
spread out on a 1% agarose plate with the appropriate antibiotics concentration and 
incubated at 37°C overnight. 
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2.2.3.3 Miniprep  
 
 
Bacteria cells with the transformed plasmids were grown overnight in 10 ml 
of LB in the appropriate antibiotics at 37°C with constant shaking.  The bacteria cells 
were harvested by centrifugation at 13, 000 rpm for 10 min.   The bacterial cells were 





Bacteria cells with the transformed plasmids were allowed to grow for 6 
hours in 10 ml of LB at 37°C with constant shaking.  150 ml of LB solution was then 
inoculated with 500 µl of the bacteria.  Bacteria cells with the transformed plasmids 
were then grown overnight at 37°C with constant shaking.  The bacteria cells were 
harvested by centrifugation at 10, 000 g at 4°C for 20 min.   The bacterial cells were 
then lysed and purified according to the protocol provided by the Qiagen Maxiprep 
kit. 
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2.2.4 Protein Manipulation 
 
2.2.4.1 Preparation of whole cell extract 
 
To obtain the protein lysate, cells grown on 10 cm dish were harvested by 
washing with 10 ml of PBS followed by 5 min incubation with 1 ml of trypsin.  5 ml 
of DMEM media was then added to stop the reaction and the cells were spun down at 
1500 rpm for 10 min.   
 
The supernatant was then discarded and cells were resuspended in 100 µl of 
lysis buffer (50 mM Tris pH7.5, 150 mM NaCl, 0.1% Triton X-100, 10µl / ml 
protease inhibitor cocktail, 25 mM sodium orthovanadate and 1 mM 
phenylmethylsulfonyl fluoride (PMSF).  The protein lysate was incubated on ice for 
30 min, and then centrifuged at 13,000 rpm to pellet the cell debris.  The supernatant 
was then collected and transferred into a new eppendorf tube. 
 
2.2.4.2 Bio-Rad DC protein assay concentration assay 
 
The Bio-Rad DC Protein Assay was used to determine the concentration of 
proteins in the cell lysate.  All procedures were performed according to the 
manufacturer’s protocol.  The absorbance at 750 nm was measured by the 
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2.2.4.3 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
25 µg of protein was added to 10 µl of 2x Sample Buffer (0.12M Tris-HCL, 
pH6.8, 4% SDS, 20% glycerol, 0.2M DTT, 0.008% bromophenol blue).  The protein 
mixture was then boiled for 5 min at 100°C on a heat block.  Subsequently, the tube 
was then placed on ice for 1 min and spun in the centrifuge at 13,000 rpm for 1 min.  
SDS-PAGE gels consist of both the resolving gel and a standard 5 % stacking gel, 




























      Resolving gel    Stacking gel  
7% 14% 5% 
Water (ddH2O) 
  7.2 ml 
30% (v/v) acrylamide   1.5 ml 
1M Tris pH 8.8 5.0 ml 5.0 ml ________ 
1M Tris pH 6.8 _____ _____ 1.25 ml 
10 % SDS 200 µl 200 µl 100 µl 
25% (w/v) APS 10 µl 10 µl 5 µl 
TEMED 10 µl 10 µl 5 µl 
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 Proteins of molecular weight of less than 50 Dalton was visualized with a 14% 
gel, proteins of molecular weight of more than 50 Dalton was visualized with a 7% 
gel.  The prepared protein samples were the loaded onto each lane in a SDS-PAGE 
acrylamide gel contained in a running tank filled with 1X SDS-PAGE running buffer 
(25 mM Tris, 192 mM glycine, 0.1% SDS, pH8.5).  The Full Range Rainbow™ 
Molecular Weight Marker (GE Healthcare) was used as a size standard and the gel 
was run at a constant 80 V until the blue dye front runs off. 
 
2.2.4.4 Western blots 
 
 The proteins were then transferred to a nitrocellulose membrane at a constant 
90V for 90 min in a transfer tank filled with fresh transfer buffer (1x: 25 mM Tris, 
192 mM glycine, p7.5, 20% methanol).  10X TBS buffer (1500 mM NaCl, 100 mM 
Tris pH8.0) was then prepared and diluted to make TBST-buffer ( 0.1% v/v Tween-
20 in 1X TBS buffer).   When the transfer was completed, the nitrocellulose blot was 
blocked with blocking buffer (5% non-fat dry milk in TBST) for 30 min at room 
temperature.  The blot was washed for 3x 5 min with TBST, followed by incubation 
with primary antibody solution overnight at 4°C on a shaker.  Next, the blot was 
washed 3 x 30 min in TBST with shaking on a rocking platform.  The appropriate 
HRP-conjugated secondary antibodies were then added and incubated with shaking 
for 30 min.  The blot was then washed 3 x 30 min in TBST with shaking.  ECL 
solution was then added (Amersham) and left for 1 min before exposing it on X-ray 
films (Amersham). 
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2.2.4.5 Subcellular protein fractionation 
 
 
 Subcellular protein fractionation was performed using modified protocol 
based on the NE-PER Nuclear and Cytoplasmic Extraction kit (#78833, Thermo 
Scientific). 
 
 Cells were prepared as described in section 2.2.4.1 and transferred to a 1.5 ml 
eppendorf tube, followed by the addition of 100 µl of ice-cold reagent CER I.  
Samples were then vortexed vigorously and incubated on ice for 30 mins.  5.5 µl of 
the reagent CER II was then added to the samples followed by vortexing and 
incubated for a further 5 min.  Cells were centrifuged at 4 ºC at 13, 000 rpm for 10 
min and the supernatant was harvested as the cytoplasmic fraction.  Care was taken 
to remove all the supernatant at this step to avoid contamination into the nuclear 
fraction.  The cytoplasmic fraction was frozen and stored at -80 ºC immediately. 
 
 50 µl of the ice-cold reagent NER was then added to the remaining pellet and 
re-suspended by vortexing.  The samples were then incubated on ice for 1 h.  At 15 
min intervals, samples were vortexed to re-suspend the pellet.  Following the 
incubation, samples were then centrifuged at 4 ºC at 13, 000 rpm for 10 min and the 
supernatant was harvested as the nuclear fraction. The nuclear fraction was frozen 
and stored at -80 ºC immediately. 
  








2.2.5.1 Overview of RT-qPCR primers used in this study 
 
Primers               Sequence Tm (°C) 
L19_Forward (L19F) GCGGAGAGGGTACAGCCAAT 62.3 
L19_Reverse (L19R) GCAGCCGGCGCAAA 58.5 
FOXM1_Forward (FOXM1F) TGCAGCTAGGGATGTGAATCTTC 62.8 
FOXM1_Reverse (FOXM1R) GGAGCCCAGTCCATCAGAACT 64.5 
FOXO3a_Forward (FOXO3AF) CCCAGCCTAACCAGGGAAGT 66.3 
FOXO3a_Reverse (FOXO3AR) AGCGCCCTGGGTTTGG 67.5 
BRCA2_Forward (BRCA2_F) GCTGGCTTCAACTCCAATAATATTC 70.9 
BRCA2_Reverse (BRCA2_R) GTCTACTATTGGGAACATTCCTTCCT 72.9 
XRCC1_Forward (XRCC1_F) AAAGGGAAGAGGAAGTTGGATTTG 70.5 
XRCC1_Reverse (XRCC1_R) GCAATTTAGGTCTCTTGGGAACA 70.0 
 
Table 2-5  Overview of the primers used in this study 
 
 
 The L19, FOXM1 and FOXO3a primers had previously been used and 
optimized.  In this study, I have also designed the RT-qPCR primers for amplifying 
the cDNA of BRCA2 and XRCC1 with the aid of the Primer Express® software v2.0 
(Applied Biosystems).  For the BRCA2 mRNA, the BRCA2 primers were designed 
between the boundaries of exon 1 and exon 2, with an amplicon size of 123 bp 
(Figure 2-1).  On the other hand, the XRCC1 primers were selected between exon 8 
and exon 9 , with an amplicon size of 100 bp (Figure 2-2). 
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2.2.5.2 Optimisation of primer concentrations BRCA2 and XRCC1 RT-QPCR 
primers  
   
 
 In the optimisation of primer concentrations for RT-QPCR reactions, it is 
pertinent to determine the minimum primer concentrations needed to provide and 
maximum amount of non-specific amplification in the lowest number of threshold 
cycles (CT).  In order to identify the ideal concentrations of each primers to be used 
in RT-QPCR, a final volume containing 50 µl of 9 different master mixes containing 
25 µl of Power SYBR Green PCR Master Mix (2x), 100 ng of MCF-7 cDNA 
template and the nine different combinations of forward and reverse primer 
concentrations were used (Table 2-6).  Each of the nine different conditions were 
plated out in triplicates onto a 96-well plate. 
Reverse primer (nM)  
Forward primer (nM) 50 300 900 
50 50/50 300/50 900/50 
300 50/300 300/300 900/300 
900 50/900 300/900 900/900 
 
Table 2-6  The nine different combinations of forward and reverse primers to 
be used for optimization. 
 
 The 96 well plates were run in the machine 7900 HT Fast Real-time PCR 
System (Applied BioSystems).  The 96 well plates were run in the machine 7900 HT 
Fast Real-time PCR System (Applied BioSystems).  The cycling program was set up 
as follows: denature at 95°C for 20 min, followed by 40 cycles of 95°C for 15 s and 
60°C for 1 min.  The optimum primer concentration chosen was based on the lowest 
concentration that gave a CT value between 20 – 25 in the absence of nonspecific 
amplification.
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2.2.5.3 RNA extraction 
 
 
Total RNA from cultured cells were extracted using the Qiagen RNeasy Mini 
Kit and all procedures were done according the protocol.  The extracted RNA was 
stored at -80°C.  The concentration of RNA obtained was quantified using the 
Nanodrop. 
 
2.2.5.4 Making cDNA 
 
1 µg of RNA, 1 µl of 10mM dNTP mix and 1 µl of oligo (dT) were 
reconstituted in Diethylpyrocarbonate (DEPC) water to a final volume of 13 µl.  The 
mixture was then heated to 65°C for 5 min and incubated on ice for 5 min.  
Subsequently, 4 µl of 5X First-Strand Buffer, 1 µl of 0.1M DTT and 1 µl of 
SuperScript™ III reverse transcriptase (Invitrogen) were added.  The reaction 
mixture was then heated to 50°C for 50 min.  The synthesis process was inactivated 
by heat at 70°C for 15 min.  The cDNA obtained was then quantified by Nanodrop 
and stored at -80°C. 
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2.2.5.5 RT-qPCR assay 
 
For real-time quantification of mRNA, a master mix containing SYBER-
Green Master Mix (Applied BioSystems) and the appropriate volume of primers 
were made (Table 2-7).  The standard curves were created by a 4-fold serial dilution 
(copy number of 256 to 4) of the master mix of all cDNA samples.  Each cDNA 
sample was also diluted in 1:8 ratios; this would ensure that the relative 
concentrations of mRNA obtained will fall within the range of the standard curve.  
Subsequently, 23 µl of the master mix was then added to 2 µl of samples in each 
individual well of the 96 well plates.  Each sample was assayed in triplicate.  
 
The 96 well plates were run in the machine 7900 HT Fast Real-time PCR 
System (Applied BioSystems).  The cycling program was set up as follows: denature 
at 95°C for 20 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.  The 
results were analysed with the ABI Prism software (Applied BioSystems) and results 
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FOXM1 master mix Volume per 96 well (µl) 
SYBR green mix 12.5 
FOXM1F (20 µM) 0.38 
FOXM1R (20 µM) 1.13 
DEPC H2O 8.99 
 
FOXO3a master mix Volume per 96 well (µl) 
SYBR green mix 12.5 
FOXO3aF (20 µM) 0.38 
FOXO3aR (20 µM) 0.38 
DEPC H2O 9.74 
 
L19 master mix Volume per 96 well (µl) 
SYBR green mix 12.5 
L19F (20 µM) 1.13 
L19R (20 µM) 0.38 
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BRCA2 master mix Volume per 96 well (µl) 
SYBR green mix 12.5 
FOXM1F (20 µM) 0.38 
FOXM1R (20 µM) 1.13 








XRCC1  master mix Volume per 96 well (µl) 
SYBR green mix 12.5 
FOXM1F (20 µM) 0.38 
FOXM1R (20 µM) 1.13 




Table 2-7  An overview of the conditions for each master mix used in the RTQ-
qPCR reactions.
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2.2.6 Luciferase reporter assay 
 
 
Cells were seeded to 30-50% confluency on the day of transfection.  A master 
mix of transfection reagent containing Fugene-6 and the plasmid DNA in a ratio of 
3:1 dissolved in optimem was then incubated for 30 min at room temperature.  100 µl 
of the transfection mix was then added to the each well.  Cells were then incubated at 
37°C, 10% CO2 for 6 hours.  Fresh media was then added to replace the transfection 
reagent and cells are allowed to grow overnight.  In titration experiments, 
thiostrepton of varying concentration from 1 µM to 20 µM was then added for the 
required amount of time. 
 
To determine the luminescence of the reporter genes, the PerkinElmer 
Luclite® assay system was used.  The Luclite reagent was prepared by the addition 
of 10 ml of Luclite buffer to the Luclite luciferase reagent as stated in the protocol.  
In addition, 10 µl of MgCl2 and 4 µl of MgCl2 are added to the luciferase reagent.  It 
was then diluted with 10 ml of PBS to obtain the working solution.  The plates are 
washed three times with PBS to remove any traces of media that contain phenol red.  
100 µl of the Luclite reagent was then added to each well and incubated for 30 min at 
room temperature in the dark.  Luminescence of the luciferase was then read by the 
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 Following this, the reading of renilla luciferase was obtained as a transfection 
and expression efficiency control for the experiments.  A master mix of Renlite 
reagent was prepared by mixing 5 ml HEPES (0.5M, pH 7.8, 400 µl 0.5 M EDTA 
and 50 µl Coelenterazine (1mg/ml).  25 µl of the Renlite reagent was added to each 
well.  This was followed by incubation for 30 min in the dark.  Luminescence of the 
renilla was then read by the same Perkin Elmer plate reader. 
 
 The normalised luciferase activity was then calculated by using the formula: 
 =   Luciferase activity reading ÷ renilla activity reading  
 
 Readings were made in triplicates and the average normalised readings were 
used for each experiment. 
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2.2.7 SRB proliferation assay 
 
 The SRB assay was first pioneered in 1990 and its principle is based on based 
on the ability of the purple protein dye sulforhodamine B to bind electrostatically in a 
pH dependent manner to the basic amino acid residues of protein molecules (Skehan, 
Storeng et al. 1990).  Therefore, the intensity of the colorimetric dye will be directly 
proportional to the number of cells and proteins present.  This will give an indication 
of the proliferation and the number of viable cells present.  This is a well established 
assay used to determine chemosensivity of cancer cell lines to various drug 
compounds (Voigt 2005).  The following protocol is a modification of the original 
method. 
 
Approximately 500 cells were seeded in each of the 96 well plates.  To 
harvest cells, 100 µl of trichloroacetic acid (TCA) was added to each well.  Cells 
were then incubated for 1 hour at 4°C.  The plates were then washed with deionised 
water for three times.  100 µl of 0.4% SRB in 1% acetic acid was then added to each 
well and left at room temperature for an hour.  The plates were then washed with 
deionised water for three times and air-dried.  100 µl of 10 mM Tris base was then 
added to the wells to solubilise the bound SRB dyes. The plates were then read at 
492 nm by the Anthos 2001 spectrophotometer plate reader. 
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2.2.8 Caspase assays 
 
2.2.8.1 Caspase 8 assay 
 
 The Caspase Caspase-Glo® 8 assay kit (Promega) was used to determine 
caspase 8 activity.  The principle of the assay is based on the use of a luminogenic 
substrate which contains the LETD consensus amino acid sequence.  In the presence 
of active caspase 8, it cleaves at this site and releases aminoluciferin, a substrate for 
luciferase.  This results in the production of light.  Therefore, the activity of caspase 
8 is directly proportional to the quantity of light given off, which can be quantified 
by the use of a luminometer. 
 
The caspase assays were performed according to the protocol using the 
Caspase-Glo® 8 assay kit (Promega).  The caspase-Glo® 8 reagent was reconstituted 
by mixing together 2.5 ml of Caspase-Glo® buffer, 7.5 µl MG-132 inhibitor and a 
bottle of Caspase-Glo® substrate.  50 µl of the reconstituted caspase-Glo® 8 reagent 
was then added to 50 µl of cell culture.  This was followed by incubation with 
shaking at room temperature for an hour in the dark.  Luminescence was then read by 
the luminometer Perkin Elmer plate reader, TOPCOUNT 9904, serial number 
426160.  
 
2.2.8.2 Caspase 9 assay 
 
 The Caspase Caspase-Glo® 9 assay kit (Promega) was used to determine 
caspase 9 activity.  The principle is exactly the same, but the luminogenic substrate 
contains the LEHD consensus amino acid sequence instead, which is recognised only 
by active caspase 9. The caspase 9 assays were performed according to the protocol 
using the Caspase-Glo® 9 assay kit (Promega), as mentioned before.   
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2.2.9 Wound healing assay 
 
Cells were seeded to complete confluence in a monolayer on a 6 well plate.  
A wound was created by scratching firmly with a 2 µl pipette tip.  Automatic time-
lapsed images were taken by the ImageXpress Micro (Molecular Device) where the 
plates incubated at 10% CO2 and a temperature of 37°C over 24 hours.  
Subsequently, images were then analysed by the ImageXpress 2.0 software. The 
average relative distances between the edges of the wounds at least at five different 
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2.2.10 MMP-9 assay 
 
 Cells were grown in either the presence of 10 µM or absence of thiostrepton.  
Supernatants were then harvested directly from the cultured plates.  The media was 
then spun down and pelleted at 1500 rpm for 15 min.  The extracts were prepared 
and MMP-9 assay were performed according to the protocol provided by the MMP-9 
ELISA assay kit (Merck Biosciences).  
 Standards for a standard curve were created by a 4-fold serial dilution of the 
samples obtained.  The 96-well provided in the kit contains an immobilized antibody 
that recognises human MMP-9 protein.  50 µl of the biotinylated detector antibody 
and 50 µl of each sample or standard were added in triplicates onto each 96-well 
provided and incubated for 2 h in the dark.  The wells were then washed with 1X 
Wash Buffer for three times to remove unbound antibodies.  100 µl of 1X Conjugate, 
containing the horseradish peroxidase-conjugated streptavidin was then added to 
each well and incubated in the dark for a further hour.  The wells were washed 
thoroughly for three times by flooding the entire plate.  The plates were left to air dry 
for 10 min prior to the addition of 100 µl of tetra-methylbenzidine (TMB) and 
incubated at room temperature in the dark for 30 min.  100 µl of Stop solution was 
added to each well in the same order that TMB was added.  The horseradish 
peroxidase catalyzes the conversion of the TMB from a colorless solution to a blue 
solution, the intensity is directly proportional to the quantity of MMP-9 protein.  The 
plate was read immediately using a spectrophotometer at dual wavelengths of 
450/595 nm.  
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 The absorbance of 450 nm represents the intensity of the blue solution and 
the absorbance of 595 nm represents the background absorbance.  The true intensity 
of the absorbance of each sample was calculated by (Intensity at wavelength 450 nm 
– intensity at wavelength 595 nm).  The absorbance values were then averaged and 
the standard curve was interpolated to determine the concentrations of MMP-9 
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2.2.11 Soft agar colony assay 
 
 
Soft colony assay was performed according to a modified protocol based on 
the protocol provided by the Cell Transformation Detection Assay Kit (Millipore).  
Firstly, a 0.8% base agar layer needed to be set.  To accomplish this, 0.1 g of agar 
powder was measured and dissolved in 7.5 ml of sterilised cell culture grade water in 
an autoclaved 50 ml falcon tube.  The solution was boiled at 100 ºC in a water bath 
until the agar powder has completely dissolved.  The solution was then cooled to 
room temperature for 10 min, followed by adding 7.5 ml of 2X DMEM media 
supplemented with 20% (v/v) FCS, 2 mM glutamine, 100 u/ml penicillin and 100 
µg/ml streptomycin.  The solution was mixed thoroughly and 50 µl of the solution 
was pipetted into each 96-well.  The 96 well plates were then incubated in the fridge 
at 4 ºC for an hour to set the base 0.8 % layer.   
 
Next, a 0.4% top agar layer containing MDA-MB-231 cells need to be casted 
to allow it to be poured over the base 0.8% layer.  To make the 0.4% agar solution, 
0.05 g of agar powder was dissolved in 3.75 ml of sterilised cell culture grade water 
in an autoclaved 50 ml falcon tube.  The solution was boiled at 100 ºC in a water 
bath until the agar powder has completely dissolved.  The 0.4 % agar solution was 
then cooled to 37 ºC and 3.75 ml of 2X DMEM media was added to the solution.  
The 96-well plates containing the 0.8% layer was then pre-heated to 37 ºC on a heat 
block for 5 min prior to use.  Approximately 900,000 cells were then added to the 
0.4% top agar layer solution and mixed with thoroughly by pipetting up and down.  
50 µl of the 0.4 % agar solution containing approximately 6000 cells each is then 
plated onto each well of the preheated 96 well plate containing the base 0.8 % layer.  
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The top 0.4% agar solution was allowed to set at 37 ºC in the incubator for an hour.  
50 µl of 2X DMEM containing either DMSO (vehicle control) or 10 or 20 µM of 
thiostrepton were added to the 96 well plates.  The appropriate cell media was then 
changed periodically every 2-3 days for a 21 day period. 
 
At the end of 21 days, cells were either stained for morphological 
visualization or quantification.  For morphological quantification, a cell stain 
solution was prepared by dissolving 5 mg of cell stain powder provided in the kit 
with 5.0 ml of 50 % ethanol to obtain a 1 mg/ml working solution.  The 2X DMEM 
media were removed from individual wells and replaced with 50 µl of stain solution.  
The cells were incubated with the cell stain solution overnight at 37 ºC for 24h.  
Stained colonies were then visualized by a bright field microscope, at 20X 
magnification.  On the other hand, for the quantification of colonies, 70 µl of cell 
quantification solution was added to each well and cells were incubated at 37 ºC for 
1 h.  Luminescence reading at 490 nm was then measured and recorded by a 
spectrophotometer.  The intensity of the luminescence measurement is directly 
proportional to the number of colongenic cells present in each individual well .





Cells were pulsed with 10 µM of BrdU (Sigma) for 2 h before being 
harvested.  Cells were pelleted by centrifugation at 1,500 rpm for 10 mins.  The 
pellet was then washed with 5 ml of ice cold PBS.  Cells were fixed by dropping 5 
ml of 90% ice-cold ethanol very slowly with vigorous vortexing.  Cells were then left 
overnight at 4°C for optimum fixation.  The fixed cells were centrifuged at 2000 rpm 
for 15 min at 4°C.  Supernatant was then discarded.  Cells are re-suspended in 1 ml 
of 2N HCL/Triton x-100 for 30 min at room temperature.  Cells are then spun down 
to remove the supernatant and re-suspended in 1 ml of 0.1 M sodium borate, pH 8.5.  
Cells were then spun down again and re-suspended in a 75 µl master staining mix of 
50 µl 0.5% TIen20/ 1% BSA /PBS, 20 µl anti-BrdU-FITC (Becton Dickinson) and 5 
µl 10 ml/ml RNAse.  Samples were incubated at 4°C to achieve optimum antibody 
staining.  The stained cells were then spun down and re-suspended in 0.5 ml of PBS 
containing 5 µg/ml of PI and 10 µg/ml of RNAse (Sigma).  Samples were then 
incubated in the dark at room temperature for 15 min.  The BD FACS Cantos 
machine was then used to record and analyse the results.




Cells were pelleted by centrifugation at 1,500 rpm for 10 mins.  The pellet 
was then washed with 5 ml of PBS.  Cells were fixed by dropping 5 ml of 90% ice-
cold ethanol very slowly with vigorous vortexing.  Cells were then left overnight at 
4°C for optimum fixation.  The fixed cells were centrifuged at 2000 rpm for 15 min 
at 4°C.  Supernatant was then discarded.  Cells were re-suspended in 0.5 ml of PBS 
containing 10 µg/ml of PI and 10 µg/ml of RNAse (Sigma).  Samples were then 
incubated in the dark at room temperature for 15 min.  The BD FACS Cantos 
machine (BD Biosciences) was then used to record and analyse the results. 
2.2.14 siRNA transfection 
 
 Prior to siRNA transfection, cells were grown in 10 mm dishes until they 
reach 50 – 60% confluence.  For each 10 mm dish, 10 µl of oligofectamine was 
incubated with 120 µl of optimem for 5 min at room temperature.  Next, 100 nM of 
BRCA2, XRCC1, FOXM1, Non-targeting specific (NS) siRNA (Dhamarcon) or 
DMSO (Mock) and the appropriate volume of optimem was added to make up a final 
volume of 600 µl.  The solution was incubated for another 20 min at room 
temperature to allow the oligofectamine-DNA complexes to form.  A further 400 µl 
of optimem was added to make up a 1 ml of transfection mix.  DMEM media was 
removed and cells were washed with 5 ml PBS.  The 1 ml of transfection mix was 
then added evenly across the surface of the 10 mm plate and the cells were incubated 
at 37°C for 4 h.  3 ml of DMEM media was then added to the cells for a further 24 h 
to ensure a complete knockdown of the target gene.  
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2.2.15 Immunofluorescent staining 
 
2.2.15.1 Phospho-ƳH2AX immunofluorescent staining 
 
 
 In order to perform anti-H2AX (Ser139) immunofluorescent staining, cells 
cultured on BD Falcon™ 4-well CultureSlide (BD Biosciences) were first fixed with  
1ml of 4% paraformaldehyde (Sigma) for 15 min.  This was followed by 3x washes 
with 1 ml of PBS.  Fixed cells were then permeabilised by incubation with 1 ml of 
0.1% Triton X-100 in 10% FCS for 10 min. This was followed by another 3x washes 
with 1 ml of PBS.  Cells were then blocked with 250 µl of 5% goat serum in 10% 
FCS for 30 min followed by another 3x washes with 1 ml of PBS.  The cells were 
then incubated overnight with the primary rabbit anti-phospho- H2AX (Ser139) 
(1:120; Cell Signaling).  Following three washes with 2 ml of PBS, cells were 
incubated with 250 µl of secondary goat anti-rabbit IgG-fluorescein isothiocyanate 
(1:500, Invitrogen) for an hour in the dark.  Cells were then washed 3x with 1 ml of 
PBS prior to counterstaining with 0.5 ml of 1 µg/ml of 4', 6'-diamidino-2-
phenylindole (DAPI, Invitrogen).  Glass slides were then mounted onto the slides 
with VECTASHIELD® Mounting Medium (Vector laboratories).  
 
 Images were captured and the fluorescence intensity was quantified using the 
Zeiss Axiovert 100 confocal laser scanning microscope and software Zeiss LSM 500 
(Zeiss Ltd).  The parameters used to capture DNA damage foci were as follows- 
DNA foci: min width: 0.05µm, max width: 8µm, intensity above background: 200 
gray levels.  Nuclei: min width 10µm, max width: 20µm, intensity above 
background: 400 gray levels.  The average integrated fluorescence of each well was 
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then determined by dividing the total fluorescence intensity of the FITC stain divided 
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2.2.15.2 FOXM1 immunofluorescent staining 
 
 In order to perform FOXM1 immunofluorescent staining, cells cultured on 
BD Falcon™ 4-well CultureSlide (BD Biosciences) were first fixed with 1ml of 4% 
paraformaldehyde (Sigma) for 15 min.  This was followed by 3x washes with 1 ml of 
PBS.  Fixed cells were then permeabilised by incubation with 1 ml of 0.1% Triton X-
100 in 10% FCS for 10 min. This was followed by another 3x washes with 1 ml of 
PBS.  Cells were then blocked with 250 µl of 5% goat serum in 10% FCS for 30 min 
followed by another 3x washes with 1 ml of PBS.  The cells were then incubated 
overnight with the primary rabbit anti-FOXM1 (1:100; c20 clone, Santa Cruz).  
Following three washes with 2 ml of PBS, cells were incubated with 250 µl of 
secondary goat anti-rabbit IgG-fluorescein isothiocyanate (1:200, Invitrogen) for an 
hour in the dark.  Cells were then washed 3x with 1 ml of PBS prior to 
counterstaining with 0.5 ml of 1 µg/ml of 4', 6'-diamidino-2-phenylindole (DAPI, 
Invitrogen).  Glass slides were then mounted onto the slides with VECTASHIELD® 
Mounting Medium (Vector laboratories). 
 
 Confocal images were then captured by the use of Zeiss LSM510 META 
confocal microscope (Zeiss Ltd) and the images were processed accordingly using 
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Chapter 3 Results 
 




 FOXM1 belongs to the forkhead box transcription factor family which are 
characterised by the forkhead box domain (Korver, Roose et al. 1997). FOXM1 is a 
critical regulator of cell cycle progression and loss of FOXM1 is associated with 
G2/M phase cell cycle arrest and loss of mitotic spindle integrity in vitro, and is 
embryonic lethal in utero due to a failure to enter mitosis (Laoukili, Stahl et al. 2007; 
Schuller, Zhao et al. 2007). Conversely, an increase in the activity or expression of 
FOXM1 is associated with the development and progression of numerous cancers of 
the breast, liver, prostate, brain, and lung, whilst the ectopic expression of the 
FOXM1 accelerated the development, proliferation, and tumour growth in mouse 
models of prostate cancer (Kalin, Wang et al. 2006). Chromosomal amplification of 
the FOXM1 gene locus is frequently observed in multiple tumour types (Spirin, 
Simpson et al. 1996) and enhanced activity of FOXM1 may also occur through the 
deregulation of upstream kinases which regulate the activity and stability of FOXM1 
during the cell cycle progression. FOXM1 expression increases during G1 to S phase 
and nuclear translocation occurs prior to G2/M phase following cyclin E/CDK2 
(Major, Lepe et al. 2004) and the Raf/MEK/ERK (Ma, Tong et al. 2005)-mediated 
phosphorylation. Phosphorylation of the retinoblastoma protein pRB by cyclin 
D1/Cdk4 may also be required to relieve the repression of FOXM1 by pRB through 
disrupting their direct interaction (Wierstra and Alves 2006). An increase in FOXM1 
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activity may promote tumorigenesis through driving proliferation and cell cycle by 
regulating downstream targets such as cyclin B1 (Leung, Lin et al. 2001), Skp2-Csk1 
ubiquitin ligase complex (Wang, Chen et al. 2005), CDC25b phosphatase and Polo-
like kinase 1 (PLK-1) (Costa 2005). Moreover, FOXM1 can also activate other genes 
involved in metastasis and angiogenesis such as the matrix metalloproteinase-2 
(MMP-2), matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth 
factor (VEGF) (Wang, Banerjee et al. 2007).  
 
 Several studies have demonstrated that a reduction in FOXM1 expression 
results in dramatic decrease in tumour growth. For instance, knockdown of FOXM1 
expression in prostate cancer cell lines resulted in proliferation and anchorage-
independent cell growth on soft agar (Kalin, Wang et al. 2006) whilst knock-out 
mice with foxm1-/- genotype also showed a significant reduction in the number of 
lung adenoma cells (Kim, Ackerson et al. 2006).  Remarkably, loss of the foxm1 
gene in hepatocytes of 6 week old transgenic mice, resulted in resistance to the 
induction of hepatocellular carcinoma following exposure to carcinogens 
(Kalinichenko, Major et al. 2004). In pancreatic cell lines, siRNA knockdown of 
FOXM1 expression lead to a decrease level of metallomatrix proteinase-9 (MMP-9), 
metallomatrix proteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) 
thereby decreasing metastasis and angiogenesis respectively (Wang, Banerjee et al. 
2007).   
 
 Within the last decade, an emerging class of naturally occurring thiopeptide 
antibiotics, which are characterised by highly complex sulphur-containing 
heterocyclic rings, have demonstrated a wide range of physiological activities 
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including anti-bacterial, anti-parasitic and anti-cancer properties. A thiazole ring 
containing antibiotic - thiostrepton, originally isolated from Streptomyces azureus 
ATCC 149215 (Horgen, Kazmierski et al. 2002) has been reported to possess anti-
tumour activities (Nicolaou, Zak et al. 2005). Despite the discovery that in 
prokaryotic cells thiostrepton is an inhibitor of protein translation through binding to 
the 23sRNA with L11 ribosomal protein (Jonker, Ilin et al. 2007), little is known 
about its mechanism of action, its cellular target(s) and its specificity in eukaryotic 
cells. I have therefore investigated the anti-cancer potential of thiostrepton using 
breast carcinoma and untransformed cell lines as models. In this study, I have 
identified thiostrepton as a potential anti-cancer agent which selectively induces cell 
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Within the last decade, an emerging class of naturally occurring thiopeptide 
antibiotics, which are characterised by highly complex sulphur-containing 
heterocyclic rings, have demonstrated a wide range of physiological activities 
including anti-bacterial, anti-parasitic and anti-cancer properties. A thiazole ring 
containing antibiotic, thiostrepton - originally isolated from Streptomyces azureus 
ATCC 149215 has been reported to possess anti-tumour activities. Despite the 
discovery that in prokaryotic cells thiostrepton is an inhibitor of protein translation 
through binding to the 23sRNA with L11 ribosomal protein, little is known about its 
mechanism of action, its cellular target(s) and its specificity in eukaryotic cells. I 
have therefore investigated the anti-cancer potential of thiostrepton using breast 
carcinoma and untransformed cell lines as models.  Thiostrepton has previously been 
reported to demonstrate cytotoxic effects towards a number of cancer cell lines in a 
compound screen of thiazole antibiotics.  However, the mechanism of action of 
thiostrepton remains unknown. To define its mechanism of action, I first treated the 
breast carcinoma cell line MCF-7 with 10 µM of thiostrepton over a time-course 
lasting 24 h (Figure 3-1).  The activity of Akt and ERK1/2, as revealed by their 
phosphorylation status, decreased marginally after 16 to 24 h of thiostrepton 
treatment. Similarly, there were no significant changes in expression and 
phosphorylation status of FOXO3a, a direct downstream target of both Akt and 
ERK-1/2. In contrast, there was a pronounced decrease in FOXM1 expression as 
early as 4 h after thiostrepton treatment, suggesting that FOXM1 could be one of the 
primary cellular targets of thiostrepton. Consistent with this, the expression of polo-
like kinase 1 (PLK-1), a downstream target of FOXM1, decreased after the 
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repression of FOXM1 expression by thiostrepton. It is notable that there were no 
significant changes in the expression of p14ARF and activity of FOXO3a and 
ERK1/2, all known regulators of FOXM1 expression. To assess further the 
relationship between thiostrepton and FOXM1 expression, I next examined the dose-
dependent effect of thiostrepton on the expression of FOXM1, its upstream 
regulators and downstream effectors. To this end, MCF-7 cells were treated with 
various doses of thiostrepton from 0 to 20 µM for 24 h before harvested for western 
blot analysis (Figure 3-1). FOXM1 expression decreased with increasing thiostrepton 
concentrations, and a significant FOXM1 reduction was observed at a concentration 
of 5 µM. In concordance with my earlier results, I observed no dramatic changes in 
the expression and phosphorylation of upstream regulators, including p14ARF, Akt, 
ERK1/2 and FOXO3a, associated with increasing levels of thiostrepton. Similarly, 
the repression of FOXM1 by increasing doses of thiostrepton was again mirrored by 
down-regulation of the expression of FOXM1 targets; including cyclin D1, PLK-1 
and CDC25B.  Furthermore, thiostrepton demonstrated specificity against FOXM1 






























Figure 3-1 Thiostrepton reduces FOXM1 protein expression.  MCF-7 cells were 
treated with thiostrepton for A) 10 µM for 0-24 h or B) with 0-20 µM for 24 h, 





















Figure 3-2  Thiostrepton reduces FOXM1 mRNA expression.  MCF-7 cells were 
treated with 10 µM thiostrepton for 0-24 h. FOXM1 and FOXO3a mRNA 
transcript levels determined by RTQ-PCR. Results of two independent 
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To investigate further the mechanism by which thiostrepton down-regulates 
FOXM1 expression, I established an MCF-7 cell line, MCF-7-pCMVFOXM1, 
expressing a CMV promoter driven FOXM1. This MCF-7-pCMVFOXM1 cell line 
was then treated with various doses of thiostrepton in parallel with the parental MCF-
7 cell line (Figure 3-3A). Western blot analysis showed that in response to increasing 
levels of thiostrepton FOXM1 expression was down-regulated in the parental MCF-7 
cell line, while the expression level of the ectopic FOXM1 remained relatively 
constant in the MCF-7-pCMVFOXM1 cells, indicating that thiostrepton inhibits 
FOXM1 expression primarily at gene promoter level, and not through mechanisms 
modulating protein and mRNA stability (Figure 3-3A). Consistently, RTQ-PCR 
assays should that increasing levels of thiostrepton failed to repress the expression 
level of the exogenous FOXM1 mRNA in the MCF-7-pCMVFOXM1 cells (Figure 
3-3B). I next sought to determine if de novo protein synthesis is required for the 
thiostrepton-mediated repression of FOXM1 mRNA expression. To this end, MCF-7 
cells were pre-treated with or without cycloheximide for 30 min and then stimulated 
with or without 10 µM thiostrepton for an extra 2 h (Figure 3-3C). Consistent with 
earlier results, RTQ-PCR analysis showed that thiostrepton repressed FOXM1 
mRNA expression at 2h. The RTQ-PCR result also revealed that cycloheximide 
treatment alone reduces FOXM1 mRNA levels (C). Nevertheless, cycloheximide 
pre-treatment failed to abrogate the additional reduction in FOXM1 transcript level 
in MCF-7 cells treated with thiostrepton. These data therefore suggest that 
thiostrepton-mediated FOXM1 repression is, at least partially, independent of de 
novo synthesis of other transcription factors. Notably, I was unable to extend the time 
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course of the experiment as lengthier cycloheximide treatment abolishes almost all 
FOXM1 mRNA expression (data not shown). Finally, I transiently transfected 
various FOXM1 promoter/reporter constructs into MCF-7 cells and incubated these 
transfected cells with increasing amounts of thiostrepton.  The transfection results 
demonstrated that all FOXM1 promoter constructs are responsive to thiostrepton-
mediated repression and that FOXM1 gene promoter activity can be effectively 
repressed by thiostrepton in a dose-dependent manner. In contrast, the FOXO3a 


























Figure 3-3 MCF-7 cells were either transfected with FOXM1 under the control 
of the CMV promoter or empty vector and 24 h later treated with 0-20 µM 
thiostrepton for 24 h. A) FOXM1 expression was determined by western blot 
analysis. B) Relative FOXM1 mRNA level was determined by RTQ-PCR 
analysis. Experiments were performed in triplicate and presented as mean 
(±SD). C) MCF-7 cells were treated with cyclohexamide (100 µM) or vehicle and 
incubated for 30 min prior to being treated with 10 µM thiostrepton or vehicle 
for 0 and 2 h and FOXM1 mRNA determined by RTQ-PCR analysis. 
















Figure 3-4 MCF-7 cells were transfected with a series of FOXM1 luciferase 
reported constructs containing the wild-type, truncated FOXM1 promoters 
(containing HindIII, PvuI, or ApaI fragments), or wild-type FOXO3a promoter. 
Cells were incubated for 24 h and treated with 0-20 µM thiostrepton for 24 h 
and promoter activity determined by luciferase detection and normalised to 
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3.1.3 Thiostrepton inhibits the migration and transformation 




 Besides cell proliferation, FOXM1 is also needed for cell migration and 
transformation and as such I reasoned that thiostrepton should repress cell migration 
and transformation in breast cancer cells through the down-regulation of FOXM1 
expression. To test this hypothesis, I performed wound-healing assays on MCF-7 
breast cancer cells in the presence of 0, 10 and 20 µM of thiostrepton (Figure 3-5). 
The level of wound-healing was measured by the average decrease in distance 
between the edges of the wounds at least from five different points. The wound-
healing assays revealed that MCF-7 cells not treated with thiostrepton healed 
effectively with wounds decreasing to about 30% of the original distance after 24 h. 
Treatment with 20 µM of thiostrepton completely repressed wound healing in MCF-
7 cells, while those treated with 10 µM of thiostrepton should some degree of healing 
in the first 12 h, probably reflecting the time required for the drug to become fully 
effective. These wound healing assays should that thiostrepton can indeed inhibit 


















Figure 3-5 Thiostrepton reduces the migration activity of breast cancer cells.  
MCF-7 cells were seeded to complete confluence in a monolayer and a wound 
created by scratching firmly with a 2 µl pipette tip. Cells were then treated with 
thiostrepton (0, 10, 20 µM; 0, 12, 24 h) and automatic time-lapsed images taken 
and shown on the left. The average relative distances between the edges of 
the wounds at least at five different points were shown. Results of two 
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 To further confirm this observation, I studied the effect of thiostrepton on the 
activity of the metastatic marker MMP-9 (Wang, Banerjee et al. 2007), a known 
direct target of FOXM1 (Figure 3-6). MMP-9 assays performed indicated that MMP-
9 activity decreases with increasing concentrations of thiostrepton, further supporting 
the wound-healing results. I next studied the effect of thiostrepton on cell 
transformation by soft agar colony formation assays using the highly transformed 
MDA-MB-231 breast carcinoma cell line. MDA-MB-231 cells treated with either 10 
µM or 20 µM of thiostrepton resulted in an approximately 30% reduction in the 
number of colonies formed (Figure 3-6). Student t-test comparing the number of 
colonies between 0 µM and either 10 µM or 20 µM thiostrepton revealed a value of 
p<0.01. Together these findings suggest that thiostrepton can significantly repress 
FOXM1 expression and reduce breast cancer cell migration, invasiveness, and the 
transformation ability by down-regulating FOXM1 target gene expression such as 
















Figure 3-6  Thiostrepton reduces breast cancer cell invasiveness and 
transformation activity of breast cancer cells.  A) MDA-MB-231 colony 
formation was determined following continuous exposure to thiostrepton (0-
20 µM) or vehicle using bright field microscopy  (magnification 20x) and 
quantitative measurement of colony number at relative absorbance of 450/520 
nm. Results of two independent experiments in triplicate were presented as 
mean (±SD). Statistical analysis was performed using Student’s t-test. * p< 
0.001, indicating very significant.  B) MMP-9 activity was determined in MCF-7 
cells following treatment with 0, 10 or 20 µM; thiostrepton for 0, 24 and 48 h. 
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3.1.4 Thiostrepton inhibits breast cancer cell proliferation and 
induces caspase-dependent and independent cell death 
 
  
 To further characterise the anti-proliferative effects of thiostrepton, SRB 
proliferation assays were performed on a panel of breast carcinoma cell lines, 
including BT474, SKBR3, MCF-7, MDA-MB-231, T47D and ZR-75-1, following 
treatment with various doses of thiostrepton over a time course of 48 h (Figure 3-7). 
The entire breast cancer cell lines tested showed a decrease in the rate of 
proliferation in a dose-dependent manner over 48 h, indicating that thiostrepton is 
effective in inhibiting breast cancer cell proliferation. Next, caspase-8 and caspase-9 
assays were performed to determine whether thiostrepton induced apoptosis via the 
intrinsic or extrinsic cell death pathway (Figure 3-7). All the breast cancer cell lines, 
apart from MCF-7, demonstrated caspase-8 and caspase-9 activation in the presence 
of thiostrepton, indicating thiostrepton causes caspase-dependent apoptosis in these 
breast cancer cell lines. Cell lines MDA-MB-231, SKBR3 and T47D should 3 to 5- 
fold activation in peak caspase-8 and -9 activities. BT474 should a remarkable peak 
of 16 and-8 fold activation in caspase-8 and-9 activation, respectively.  This indicates 
that thiostrepton triggered both the extrinsic and intrinsic pathways of apoptosis to 
cause cell death in breast cancer cells. However, MCF-7 cells showed no activation 
in caspase activity. This is because MCF-7 cells are known to be deficient in 
caspase-3 and -7 expressions (Kagawa, Gu et al. 2001), therefore alternative death 
pathways must have been invoked to induce cell death.  Nonetheless, these data 
together showed that thiostrepton is capable of inhibiting breast cancer cell 
proliferation and induces apoptosis in a caspase-dependent and -independent manner. 
 
 




Figure 3-7 Thiostrepton reduces proliferation and induces cell death in breast 
cancer cell lines. A) BT474, SKBR3, MDA-MB-231, MCF-7, T47D and ZR-75-1 
cells were treated with thiostrepton (0-20 µM; 0-48 h) and proliferation 
determined by SRB assay. Results of experiments in triplicate were presented 
as mean (±SD). B) Caspase-8 and 9 activity assays were performed in BT474, 
SKBR3, MDA-MB-231, MCF-7, T47D and ZR-75-1 cells following treatment with 
0 or 10 µM thiostrepton for 0, 24 and 48 h. Results of two independent 
experiments in triplicate were presented as mean (±SD).  
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3.1.5 Thiostrepton specifically inhibits the proliferation of MCF-
7 but not MCF-10A cells 
 
To compare the effect of thiostrepton on cell proliferation and survival of 
cancerous and untransformed breast epithelial cells, I analyzed the cell cycle phase 
distribution of MCF-7 and MCF-10A cells following treatment with 10 µM 
thiostrepton over a time course of 72 h. The results showed that thiostrepton can 
cause cell cycle arrest and cell death in MCF-7 breast carcinoma cells, but has little 
effects on the cell cycle progression and cell death of MCF-10A. Following 
thiostrepton treatment, a significant number of MCF-7 cells started to accumulate at 
G1 from 8 h, and this was accompanied by a decrease in cells in S and G2/M phases 
and an increase in a population of cells with sub-G1(2N) DNA content, indicative of 
cell death (Figure 3-8).  By 48 and 72 h following thiostrepton treatment, the 
majority of cells had sub-G1 DNA content. In contrast, there was little change in cell 
cycle distribution of MCF-10A cells following thiostrepton treatment, signifying that 
MCF-10A cells are resistant to thiostrepton.  
 
The flow cytometric analysis also indicated that the untransformed MCF-10A 
cells progressed through the cell cycle with slower kinetics, with the majority of the 
cells in G1 and G2/M phases. To confirm these results, I next performed BrdU-
incorporation analysis on MCF-7 and MCF-10A cells before and after 24 h 10 µM 
thiostrepton treatment (Figure 3-8). The result should that thiostrepton treatment 
almost completely abrogated BrdU-uptake in MCF-7 cells, but it had little effect on 
BrdU incorporation in MCF-10A cells. Consistent with a slower rate of proliferation, 
the level of BrdU-uptake in MCF-10A cells was low compared to MCF-7 cells. 
Collectively, these data indicate that thiostrepton can effectively block DNA 
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incorporation as well as S and G2/M phase entry in MCF-7 but not MCF-10A cells 
(Figure 3-8).  They also suggested that thiostrepton specifically induces cell cycle 
arrest and cell death in breast carcinoma cells but not in untransformed breast 
epithelial cells. I then explored if FOXM1 has a role in mediating the cytostatic and 
cytotoxic effects of thiostrepton in breast cancer cells and studied the expression 
pattern of FOXM1 in both MCF-7 and MCF-10A following 10 µM thiostrepton 
treatments by western blot analysis. Consistent with my earlier observation that 
MCF-10A has a slow proliferative rate, western blot analysis also revealed that 
FOXM1 was expressed at lower levels in MCF-10A cells compared with MCF-7 
cells.  
 
Nonetheless, I found that FOXM1 expression level remained unchanged 
following thiostrepton treatment in MCF-10A cells; in contrast to MCF-7 cells which 
displayed drastically reduced levels of FOXM1 after thiostrepton treatment. These 
data together suggest that FOXM1 has a role in mediating the anti-proliferative 
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Figure 3-8 A) MCF-7 and MCF-10A cells were treated with 10 µM thiostrepton 
for 0-72 h and cell cycle analysis performed after propidium iodide staining. B) 
MCF-7 and MCF-10A cells were treated with 10 µM of thiostrepton for 0 and 24 
h and S-phase cells determined by BrdU and PI staining and FACS analysis. 
Results of experiments in triplicate were presented as mean (±SD). C)  MCF-7 
and MCF-10A cells were treated with 10 µM thiostrepton for 0-72 h and FOXM1 
protein level determined by western blot analysis. * MCF-10A blot was over-
exposed to allow for visualization of FOXM1. 
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3.1.6 Expression of a constitutively active FOXM1 circumvents 





Figure 3-9  MCF-7 cells were either untransfected, or transfected with empty 
vector or ∆N-FOXM1, a constitutively N-terminal truncated FOXM1 mutant and 
24 h later untreated or treated with 10 µM thiostrepton for 24 h.  FOXM1 and 
∆N-FOXM1 expression was determined by western blot analysis.  
 
 
 To show definitively that FOXM1 is a crucial cellular target of thiostrepton, 
MCF-7 cells are either untransfected or transfected with the empty expression vector 
or an expression vector encoding for a constitutively active N-terminal truncated 
form of FOXM1, ∆N-FOXM1, and then stimulated with 10 µM thiostrepton for 24 h. 
Western blot analyses demonstrated that the endogenous FOXM1 was expressed in 
the untreated transfected MCF-7 cells, but its expression was repressed by 
thiostrepton. However, the CMV promoter driven ∆N-FOXM1 was expressed at high 
levels before and after thiostrepton treatment (Figure 3-9). 
 




Figure 3-10  MCF-7 cells were either untransfected, or transfected with empty 
vector or ∆N-FOXM1, a constitutively N-terminal truncated FOXM1 mutant and 
24 h later untreated or treated with 10 µM thiostrepton for 24 h.  Cell 
proliferation was measured by SRB assay. Two independent experiments 
each in triplicate were performed and presented as mean (±SD). Statistical 
analysis was performed using Student’s t-test: * p< 0.01, indicating 
significant. 
 
Proliferative assays performed on these cells should that cell proliferation 
was significantly repressed by thiostrepton in the mock transfected and empty vector 
transfected MCF-7 cells, but not in the MCF-7 cells expressing the constitutively 
active ∆N-FOXM1 (Figure 3-10). It is notable that I have performed the over-
expression experiment with the wild-type FOXM1 construct, but it was ineffective in 
blocking the anti-proliferative effects of thiostrepton.  
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3.1.7 Summary 
 
This study demonstrates for the first time that the novel thiazole antibiotic 
thiostrepton selectively induces cell death in breast cancer cells through the down-
regulation of FOXM1 expression. Furthermore, thiostrepton treatment, accompanied 
by a loss of FOXM1 expression, results in a reduction in the proliferation, 
invasiveness, and transformation ability of breast cells. Critically, thiostrepton has no 
effect on the proliferation of non-transformed breast epithelial cells.  
 
 Thiostrepton has previously been identified as an anti-cancer agent in a study 
of thiazole antibiotics and derivatives. I sought to identify the mechanism by which 
thiostrepton may induce cell death in breast cancer cells, and determined the 
expression level and activity of a series of cell fate regulators in response to 
thiostrepton treatment. No change was observed in the phosphorylation status of the 
pro-survival factors Akt and ERK, whilst phosphorylation of FOXO3a, which I have 
previously reported as a critical mediator of chemotherapeutic drug-induced cell 
death, remained unchanged by thiostrepton. However, thiostrepton induced a dose-
dependent, rapid, and sustained loss of FOXM1 protein expression and mRNA 
transcript level, suggesting that FOXM1 may be a key target of thiostrepton. FOXM1 
has previously been reported to regulate key effectors of G1/S and G2/M phase 
transition, and loss of FOXM1 following thiostrepton treatment was followed by a 
concomitant decrease in target gene expression, including PLK and CDC25b. 
However, no change in upstream regulators of FOXM1, such as ERK1/2, p14ARF, 
FOXO3a or Akt, was observed prior to the reduction FOXM1 levels, suggesting that 
thiostrepton may affect the expression of FOXM1 at the transcriptional level. 
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Consistent with this hypothesis thiostrepton failed to repress an ectopic FOXM1 
driven by a CMV promoter.  
 
 It is also significant that the co-treatment of breast cancer cells with 
thiostrepton and cycloheximide, an inhibitor of translation, did not prevent the 
repression of FOXM1 mRNA levels by thiostrepton, indicating that the repression of 
the FOXM1 promoter activity is not dependent upon de novo protein synthesis.  
 
 Cell cycle analysis showed that thiostrepton induces cell cycle arrest at G1 
and S phase, whilst BrdU staining demonstrated a reduction in DNA synthesis 
following treatment with thiostrepton. This can lead to a block of cells at the G1/S 
boundary and cells entering G2/M from S phase, culminating in an apparent 
accumulation of cells at G1 and S phase and a corresponding decrease in G2/M cell 
population. My data also demonstrated that thiostrepton can induce cell death 
through caspase-dependent intrinsic and extrinsic apoptotic pathways as well as 
caspase-independent death mechanisms, as observed in MCF-7 cells, which are 
deficient of caspase-3 and -7 and show no detectable activation of caspase-8 and -9. 
These findings are consistent with the role of FOXM1 in cell proliferation and 
survival. Furthermore, in in vitro assays thiostrepton has demonstrated efficacy in 
repressing breast cancer cell migration, metastasis and transformation, which are all 
functional attributes of FOXM1. The finding that over-expression of a constitutively 
active form of FOXM1, which lacks the N-terminal repressor domain (∆N-FOXM1), 
can block the anti-proliferative function of thiostrepton establishes FOXM1 as a 
critical cellular target of thiostrepton. This hypothesis is further supported by the 
observation that the non-transformed breast epithelial cells, MCF10A, which show 
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no change in FOXM1 expression in response to thiostrepton, also display no 
alteration in cell cycle status in response to thiostrepton. 
 
Crucially, my data also indicate that thiostrepton induces cytostatic and 
cytotoxic effects specifically in breast cancer cell lines while non-transformed MCF-
10A breast epithelial cells are refractory to thiostrepton. The resistance of MCF-10A 
cells to thiostrepton suggests that compound toxicity may be within tolerable limits 
of non-cancer cells. Breast cancer cells often express high levels of FOXM1, and as 
such the susceptibility of these cells to repression of FOXM1 expression may be 
higher than untransformed cells. However, the exact mechanism by which 
thiostrepton represses FOXM1 expression in breast cancer cells but not in MCF-10A 
cells remains to be elucidated.  
 
Studies of thiostrepton in prokaryotes have shed some light upon the potential 
mechanism of action of thiostrepton. At high concentrations, thiostrepton binds to the 
23S sub-unit of rRNA to inhibit translation and protein synthesis (Bausch, Poliakova 
et al. 2005). However, this is unlikely to be the primary mode of action of 
thiostrepton in breast cancer cells because this would lead to a global non-specific 
down-regulation in the expression of all proteins, and not specifically FOXM1.  
Although this mechanism does not confer specificity to FOXM1, it raises the 
possibility that thiostrepton may be used to increase the efficacy of DNA-damaging 
agents by preventing protein translation and tumour cell recovery. However, the 
enhanced repression of FOXM1 mRNA by co-treatment with cyclohexamide and 
thiostrepton versus cyclohexamide alone would suggest that in mammalian cells 
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thiostrepton has additional mechanisms of action in addition to inhibition of protein 
translation.  
 
FOXM1 has previously been reported to be a valid therapeutic target in 
cancer; the use of a cell-penetrating ARF peptide inhibitor of FOXM1 has been 
shown to selectively induce apoptosis in human hepatocellular carcinoma cell lines 
and mouse models (Gusarova, Wang et al. 2007). In addition, a related antibiotic 
thiazole compound, Siomycin A, has been reported to down-regulate the 
transcriptional activity and expression of FOXM1 (Radhakrishnan, Bhat et al. 2006). 
It is interesting to note that Radhakrishnan et al. have shown that overexpression of 
wild-type FOXM1 is sufficient to block the anti-proliferative effects of thiostrepton, 
while I found here that only expression of a constitutively active ∆N-FOXM1, but 
not the wild-type FOXM1, can rescue cells from the anti-proliferative effects of 
thiostrepton. These differences may reflect the cell lines used or discreet mechanisms 
of action of the thiazole antibiotics; however, it remains intriguing to speculate that 
other members of the thiazole antibiotics including sporangiomycin, mircococcin, 
and cylcodidemnamide B might display similar anti-cancer properties through the 
inhibition of FOXM1 expression.  
 
Moreover, FOXM1 has also been shown to be a downstream target of another 
Forkhead box transcription factor FOXO3a, a physiological target for a number of 
chemotherapeutic drugs, including paclitaxel, anthracyclins and gefitinib in breast 
and other cancers (Krol, Francis et al. 2007). Based on these observations, it is 
possible that thiostrepton and other thiazole antibiotics may synergise with 
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chemotherapeutic drugs in combinatorial anti-cancer therapies to improve the 
efficacy of currently available treatments.  
 
In conclusion, my study demonstrates that thiostrepton can specifically 
inhibit FOXM1 expression at the transcriptional level to selectively target cancer but 
























- Having established and summarised that thiostrepton can specifically repress 
FOXM1 transcription factor, I would like to expand on how my work reconcile with 
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3.1.8.1 Insights gained from thiostrepton - COX1 studies 
 
 Firstly, the only other piece of experimental research that had attempted to 
elucidate the mode of action of thiostrepton in mammalian cells was performed by 
Bowling et al (Bowling, Doudican et al. 2008).  They have unravelled that the 
treatment of melanoma cell lines with 1 µM of thiostrepton resulted in a reduction in 
protein levels of the mitochondrial-encoded protein cytochrome oxidase I (COX1) 
levels, which sensitized cells to Arsenic trioxide treatment.  COX1 is the terminal 
enzyme found ubiquitously expressed in the mitochondrial respiratory chain in most 
cells (Fontanesi, Soto et al. 2008).   COX1 is responsible for the final step of aerobic 
respiration, which involves both the catalyzing the transfer of electrons from 
cytochrome c to molecular oxygen and protons translocation from the mitochondrial 
matrix to intermembrance space.  Therefore, the expression of COX1 is absolutely 
crucial for the execution of aerobic respiration and ATP synthesis.  However, 
Bowling et al failed to show that thiostrepton directly repressed COX1 at the 
promoter level, suggesting that the repression of COX1 protein level was an indirect 
effect of thiostrepton. 
 
 There are two possible explanations that could be put forward to reconcile the 
different experimental observations.  Firstly, from my experimental observation that 
the direct repression of FOXM1 can leads to an increase in caspase 9 activity, 
suggesting the intrinsic apoptotic pathway was activated.  Therefore, with the release 
of mitochondrial cytochrome c into cellular cytoplasm, different mitochondrial 
protein expression levels would have been altered and this could explain why COX1 
expression level was correlated with the use of thiostrepton.  Furthermore, the loss of 
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cytochrome c from the intermembrane space during apoptosis favours the 
mitochondrial formation of reactive oxygen species (superoxide) because 
cytochrome c is an antioxidant and as the respiratory chain becomes more reduced 
(saturated with electrons) due to the gradual cessation of electron flow between 
Complex III and Complex IV (Cai and Jones 1998).  This is also consistent with 
Bowling et al’s observation that ROS levels increase when thiostrepton was used.  
Therefore, I could argue that the observations made by Bowling et al is a 
consequence of the further remote events observed as cells undergo apoptosis due to 
the direct repression of FOXM1.  The second explanation could be that COX1 is a 
downstream target of FOXM1.  However, the lack of FOXM1 binding element in the 
promoter region of COX1 and that FOXM1 is not known to be localised in the 
mitochondria, this would be rather unlikely. 
 
 Therefore, I reason that the decrease in COX1 expression level and increase 
in concentrations of reactive oxygen species detected in melanoma post thiostrepton 
treatment is a result of the activation of the intrinsic apoptotic pathway when 
FOXM1 is repressed.  Furthermore, my experimental observation also indicated that 
thiostrepton does not kill untransformed breast cells.  Therefore, if thiostrepton were 
to directly repress COX1 expression levels.  I would have expected thiostrepton to 
exhibit cytoxicity towards untransformed breast tissues as well. 
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3.1.8.2 Insights from the study of prokaryotic models Streptomyces lividian 
 
 Having reconciled that the decrease in COX1 expression was correlated with 
the execution of intrinsic apoptotic pathway as a direct result of FOXM1 repression, 
I have also looked at prokaryotic studies on the mode of action of thiostrepton where 
it has been extensively studied.  Thiostrepton at a high concentration of >10-7 M 
binds to prokaryotic ribosomes and prevents the global translation of all proteins.  
Intriguingly, at lower concentrations of < 10-9, in the prokaryotic species 
Streptomyces lividian, the dehydroalanine residues on thiostrepton can directly bind 
to the cysteine residues of transcriptional activator Tip AL-AS protein complex 
covalently.  This activates the binding of Tip AL to the ptipA promoter activating its 
expression (Chiu, Folcher et al. 1996; Chiu, Folcher et al. 1999).  NMR studies have 
also revealed that the binding of thiostrepton to Tip AS can induce conformational 
changes to the N-terminal part of Tip AS protein, which then forms the linker to the 
DNA-binding domain in Tip AL, enhancing its affinity to the promoter region of 
ptipA promoter (Kahmann, Sass et al. 2003). 
 
 Based on my experimental observations, it is unlikely that thiostrepton works 
in eukaryotic cells by binding to eukaryotic ribosome causing a global down 
regulation of translation of all proteins because only FOXM1 activity was observed 
to have been affected in the breast cancer cell lines.  Therefore, it is more likely that 
thiostrepton is binding either to an upstream activator protein, preventing its direct 
binding to FOXM1 promoter or binding to an upstream repressor protein, enhancing 
its direct binding to FOXM1 promoter.  Both scenarios will reduce the expression of 
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 It is interesting that unpublished ChIP data produced by our laboratory (data 
not shown) and Gartel at al, FOXM1 can in fact bind to the its own promoter, 
engaging in a positive feedback loop activating its own activity (Halasi and Gartel 
2009).  Therefore, thiostrepton could bind to FOXM1 protein, preventing its binding 
to its own promoter, which in turn could down regulate FOXM1 promoter activity.  
Indeed, by the protein alignment of Tip AL- AS and FOXM1 protein sequences 
using ClustalW reveals that FOXM1 protein does harbour similar positioned cysteine 
molecules that could potentially bind covalently to thiostrepton (Figure 3-11).  







Figure 3-11  Sequence alignment between TipAL-AS and FOXM1 proteins 
reveal conserved cysteine locations between the segment 157 to 169 amino 
acid regions on FOXM1 
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 Clinical chemoresistance is a widespread and multi-faceted problem 
involving the de-regulation of a multitude of pathways.  To determine whether 
thiostrepton could be recruited to circumvent chemoresistance in breast cancer 
patients, I then address the hitherto unknown roles that FOXM1 might play in 
acquired cisplatin resistance. 
 
 The transcription factor FOXM1 is a key regulator of cell proliferation and is 
over-expressed in many forms of primary cancers, leading to uncontrolled cell 
division and genomic instability.  Platinum based chemotherapeutics, such as 
cisplatin, (cis-diammine-dichloro-platinum) have long been established in the routine 
treatment of ovarian, testicular, and non-small cell lung cancer patients under clinical 
settings (Kelland 2007). Cisplatin treatment results in the formation of intrastrand 
and interstrand DNA-adducts (Siddik 2003), triggering the nucleotide excision repair 
(NER) pathway (Dabholkar, Bostick-Bruton et al. 1992; Ferry, Hamilton et al. 2000; 
Chang, Kim et al. 2005). Failure to activate or execute appropriate DNA repair leads 
to the accumulation of DNA strand breaks, and ultimately to cell death (Nowosielska 
and Marinus 2005).   Recent clinical data suggests an emerging role for platinum 
based chemotherapy for advanced breast cancer patients. For example, three 
independent phase II clinical trials involving HER2 positive or advanced metastatic 
breast cancer patients treated with a combination of Herceptin with cisplatin and 
docetaxol showed clinically significant improvement of survival rates (Lee, Doliny et 
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al. 2004; Pegram, Pienkowski et al. 2004; Hurley, Doliny et al. 2006). Furthermore, 
recent clinical trial data also suggests that triple negative breast cancer patients who 
are ER-negative, PR-negative, and with low HER2 expression levels, show better 
survival rates in response to cisplatin chemotherapeutic treatment (Sirohi, Arnedos et 
al. 2008).  
 
 However, acquired cisplatin resistance is a major clinical obstacle for patients 
that relapse after initial favourable responses. Cisplatin resistance is a complex and 
multifaceted problem which involves multiple pathways including increased cisplatin 
efflux, inactivation of intracellular cisplatin, evasion of apoptotic pathways, 
replication checkpoint bypass, increased cell proliferation, and increased DNA 
damage repair (Kelland 2007; Stewart 2007). A number of targets have been 
implicated to have a role in breast cancer cisplatin resistance including amphiregulin 
(Eckstein, Servan et al. 2008), BCL2 (Yde and Issinger 2006), BCL2L12 (Hong, 
Yang et al. 2008), cyclin D1(Yde and Issinger 2006), Siva-1 (Chu, Barkinge et al. 
2005) and the miRNA regulator Dicer (Bu, Lu et al. 2009). However,   a better 
understanding of the molecular mechanism underlying chemotherapeutic resistance 
is needed for the development of effective platinum-based therapeutic strategies for 
treatment of breast cancer.  
 
 FOXM1 is a transcription factor which belongs to the wider forkhead 
transcription factor family (Korver, Roose et al. 1997) and is required for normal cell 
cycle execution during G1 to S (Wang, Chen et al. 2005; Petrovic, Costa et al. 2008), 
G2 and M phase transitions (Leung, Lin et al. 2001), apoptosis (Madureira, 
Varshochi et al. 2006; Wierstra and Alves 2007), angiogenesis (Wang, Banerjee et 
al. 2007), metastasis (Dai, Kang et al. 2007) and DNA damage repair (Wonsey and 
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Follettie 2005; Tan, Raychaudhuri et al. 2007). Overexpression of FOXM1 in 
primary breast cancer tissues has also been associated with breast cancer 
tumorigenesis (Francis, Myatt et al. 2009) and poor prognosis (Wonsey and Follettie 
2005; Bektas, Haaf et al. 2008). Intriguingly, several lines of studies have indicated 
that in breast cancer patients, the loss of functional BRCA2 and XRCC1 expression 
contributes to breast cancer development (Goode, Ulrich et al. 2002; Turner, Tutt et 
al. 2004), although this is also hypothesized to render the cells more susceptible to 
DNA damage and cytotoxic chemotherapies. Increasing evidence has emerged to 
demonstrate that re-gaining the expression of DNA repair genes such as BRCA 1, -2 
and XRCC1 could lead to cisplatin resistance in these cells (Goode, Ulrich et al. 
2002; Sakai, Swisher et al. 2008; Swisher, Sakai et al. 2008).   
 
 In this chapter, I have investigated the role of FOXM1 and its proposed 
downstream targets BRCA2 and XRCC1 in DNA damage and cisplatin sensitivity 
and resistance.  Furthermore, I have also investigated the possibility of employing 
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3.2.2 FOXM1 and targets BRCA2 and XRCC1 are up-regulated in 
cisplatin resistant MCF-7 cells 
 
 
 Previously, it has been demonstrated that the over-expression of FOXM1 is 
indicative of poor prognosis in breast cancer patients (Wonsey and Follettie 2005; 
Bektas, Haaf et al. 2008). FOXM1 has also been reported to regulate the expression 
of the DNA damage repair genes, BRCA2 and XRCC1 (Tan, Raychaudhuri et al. 
2007). Hitherto, the role of FOXM1 in cisplatin resistance through the repair of 
cisplatin-DNA adducts resistance has not been established.  In the first instance, we 
established a new cisplatin resistant cell line, MCF-7-CISR, through repeated 
exposures of MCF-7 cells to successive rounds of cisplatin until resistance up to 1.2 
µM was reached as indicated by SRB proliferation assay (Figure 3-12).  Subsequent 
western blot analysis reveals that MCF-7 cells expressed a higher level of FOXM1 
relative to the untransformed MCF-10A breast epithelial cells. Interestingly, MCF-7-
CISR showed an even higher FOXM1 level compared with the parental MCF-7 cells 
(Figure 3-12).  Furthermore, MCF-7-CISR also had higher levels of DNA repair 
proteins BRCA2 and XRCC1.  Relative FOXM1 protein expression level was on 
average 2.5 fold higher in MCF-7-CISR cells compared with MCF-7 cells (Figure 
3-12).   The results were mirrored at mRNA level, where MCF-7-CISR had a 2-fold 











Figure 3-12  Cisplatin resistant cell line shows elevated FOXM1 protein and 
mRNA expression levels.  MCF-7 and MCF-7-CISR cells were treated with 
increasing concentrations of cisplatin and their rates of proliferation 
measured by SRB assay. B) Western blot analysis determining the relative 
protein expression levels of FOXM1, BRCA2 and XRCC1 in MCF-10A, MCF-7 
and MCF-7-CISR cells. C) FOXM1 protein expression level was quantified using 
ImageJ normalized against tubulin levels. D) FOXM1 mRNA transcript levels 
were being determined by RTQ-PCR analysis.  Results shown were derived 
from at least three independent experiments. The error bars show the 
standard deviation (mean ± SD). Statistical analysis was performed using 
Student’s t tests. *, P < 0.01, significant.    
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3.2.3 FOXM1 and DNA repair are up-regulated in the resistant 
MCF-7-CISR cells but not in MCF-7 cells 
 
 
 Next, I sought to determine the molecular mechanism which confers acquired 
cisplatin resistance in breast cancer cell lines.  Cell cycle analysis showed that 
following cisplatin treatment (100 nM; 0-72 h) high numbers of MCF-7 cells 
contained sub-G1 DNA content, indicative of DNA fragmentation and cell death, 
whilst no significant changes in sub-G1 population were observed for MCF-7-CISR 
cells (Error! Reference source not found.).  A series of short time courses revealed 
that no significant changes in FOXM1, BRCA2 and XRCC1 levels occurred prior to 
24 h of cisplatin treatment (Kwok, Peck et al. 2010). However, MCF-7 cells treated 
with cisplatin (0-72 h) showed a decrease in FOXM1 expression, and that of its 
downstream targets CDC25B and PLK, in addition to the DNA repair proteins 
XRCC1 and BRCA2  (Error! Reference source not found.). In contrast, FOXM1 
and BRCA2 expression levels were further increased following cisplatin treatment in 
MCF-7-CISR cells, whilst CDC25B, PLK and XRCC1 levels remained relatively 
constant.  Consistently, RTQ-PCR analysis revealed that in MCF-7 cells FOXM1 
mRNA level decreased by 50% at 72 h, whilst FOXM1 transcript level increased by 
2-fold  in MCF-7-CISR cells (Error! Reference source not found. 3-13), suggesting 
that the ability to maintain elevated FOXM1 expression in acquired cisplatin resistant 
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 Interestingly, although BRCA2 mRNA levels closely mirrored FOXM1 
mRNA levels, XRCC1 mRNA levels did not change significantly in both MCF-7 and 
MCF-7-CISR cells, this suggests that an increase in FOXM1 expression level could 
stabilize XRCC1 expression indirectly through its other downstream targets.  
Furthermore, the quantification of γH2AX staining demonstrated that MCF-7 cells 
had significantly higher levels of DNA  damage after cisplatin treatment compared 
with MCF-7-CISR cells, indicating that MCF-7-CISR are more efficient than MCF-7 
cells in the repair of damaged DNA induced by cisplatin, which correlates with a 





























Figure 3-13  Both MCF-7 and MCF-7-CISR cells were treated with 0.1 µM of 
cisplatin for 0h or 6h and stained with γH2AX antibodies and DAPI. Images 
were visualized by confocal microscopy and the average integrated 
fluorescence intensity quantified by Zeiss Axiovert 100 confocal laser 
scanning microscope using Zeiss LSM 500 software. Images: original 
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3.2.4 Over-expression of ∆N-FOXM1 is sufficient to confer 
cisplatin resistance in MCF-7 cells 
 
 To prove definitively that FOXM1 is important in acquired cisplatin 
resistance, we employed the use of the MCF-7-∆NFOXM1 cell line previously 
described, which over-express a constitutively active form FOXM1 (Kwok, Myatt et 
al. 2008).  Consistently, expression of ∆N-FOXM1 was accompanied by slightly 
higher levels of BRCA2 and XRCC1 at both the protein and mRNA level (Figure 
3-14A and B). I next examined the level of cisplatin-induced (0.1 µM) DNA damage 
in MCF-7 and MCF-7-∆N-FOXM1 cells; a 3.5 fold increase in DNA damage was 
observed in MCF-7 cells, whilst no significant increase in DNA damage was 
observed following cisplatin treatment in MCF-7-∆N-FOXM1 cells (Figure 3-14C).   
Therefore, MCF-7-∆NFOXM1 demonstrated an enhanced ability for DNA repair. 
 
 Furthermore, the expression levels of FOXM1, BRCA2 and XRCC1 were 
maintained at both the protein and mRNA levels in the MCF-7-∆N-FOXM1 cell line 
following cisplatin treatment (0.1 µM; 0-72 h), whilst in MCF-7 cells FOXM1 
expression decreased rapidly after 24 h of cisplatin treatment (Figure 3-15A and B).  
Significantly, SRB assay also revealed that the over-expression of ∆N-FOXM1 alone 
was sufficient to confer resistance to MCF-7 (Figure 3-15). These data suggest that 
the introduction of constitutive active ∆N-FOXM1 can protect breast cancer cells 
against cell death by enhancing cisplatin-induced DNA damage repair. 
 







Figure 3-14 Expression of ∆N-FOXM1 protects MCF-7 cells from sustaining 
cisplatin induced DNA damage.  The relative expression levels of FOXM1, 
BRCA2 and XRCC1 in MCF-7 and MCF-7-∆N-FOXM1 were determined by A) 
Western blotting and B) RTQ-PCR analysis, respectively.  C) MCF-7 and MCF-
7-∆N-FOXM1 cells were treated with 0.1 µM of cisplatin for 0h or 6h and 
stained with γH2AX antibodies and DAPI. Images visualized by confocal 
microscopy; the average integrated fluorescence intensities are shown. 
Original magnification X 40 . The average results of three independent 
experiments in triplicates are shown  Mean ± SD. Statistical analyses were 


















Figure 3-15 The relative expression levels of FOXM1, BRCA2 and XRCC1 in 
MCF-7 and MCF-7-∆N-FOXM1 were determined by A) Western blotting and B) 
RTQ-PCR analysis.  C) MCF-7 and MCF-7-∆N-FOXM1 cells were treated with 
0.1 µM of cisplatin for 0h or 6h, stained with γH2AX antibodies and DAPI. 
Images visualized by confocal microscopy and the average integrated 
fluorescence intensity are shown. Original magnification X 40 (top panels). 
The average results of three independent experiments in triplicates are shown  
Mean ± SD.  ** Statistical analysis was done using Student’s t tests. *, P < 0.01, 
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3.2.5 FOXM1 can also promote cisplatin resistance through 
DNA damage repair pathway 
 
 
 Having identified FOXM1 as a mediator of cisplatin resistance in breast 
cancer cells, we next examined whether BRCA2 and XRCC1 are the only 
downstream targets of FOXM1 required in conferring cisplatin resistance in breast 
cancer cells.  Surprisingly, the siRNA-mediated knockdown of FOXM1 did not 
result in a down-regulation of BRCA2 and XRCC1 expression in either the MCF-7 
or MCF-7-CISR cell lines at the protein or mRNA level (Figure 3-17), suggesting 
that FOXM1 is not the primary or sole regulator of BRCA2 and XRCC1 expression 
in these cells.  The requirement of FOXM1, BRCA2, and XRCC1 expression for 
MCF-7-CISR cisplatin resistance was next examined using siRNA-mediated 
knockdown of these genes.  The knockdown of FOXM1, BRCA2 and 
BRCA2/XRCC1 in MCF-7-CISR cells increased the amount of DNA damage by 1.5 
to 3- fold) (Figure 3-17).  Interestingly, following knockdown of FOXM1 the 
expression levels of BRCA2 and XRCC1 were maintained, and yet an increase in 
DNA damage was observed, suggesting that other FOXM1 downstream targets are 
involved.  Moreover, SRB proliferation assay revealed that only the knockdown of 
FOXM1 was potent at re-sensitising MCF-7-CISR cells to cisplatin treatment and not 
the knockdown of BRCA2, XRCC1 or in combination (Figure 3-17).  This suggests 
that other unknown DNA repair targets or proliferative targets of FOXM1 could 
overcome the loss of one or two individual DNA repair. Thus, the inactivation of 
FOXM1 is essential for reversing cisplatin resistance and targeting FOXM1 could 
potentially be a better therapeutic strategy for overcoming cisplatin resistance, rather 
than just through the inactivation of DNA repair pathways.




Figure 3-16  BRCA2 and XRCC1 may have additional regulators and FOXM1 
confers cisplatin resistance through additional DNA repair targetsMCF-7 and 
MCF-7-CISR cells were either untransfected (Mock), transfected with non-
specific (NS) siRNA (100 nM) or siRNA smart pool against FOXM1 (100 nM) , 
BRCA2 (100 nM), XRCC1 (100 nM) or BRCA2 plus XRCC1 (100 nM) for 24h.  A) 
The expression levels of FOXM1, BRCA2 and XRCC1 in MCF-7 and MCF-7-
CISR cells were determined by Western blotting. B) RTQ-PCR analysis was 
performed to determine the relative FOXM1, BRCA2 and XRCC1 mRNA 
transcript levels.   





Figure 3-17  MCF-7-CISR cells were then treated with 0.1 µM of cisplatin for 
either 0h or 6h and stained with γH2AX antibodies and DAPI.  A) Images 
visualized by confocal microscopy and the average integrated fluorescence 
intensity are shown. Original magnification X 40. B) SRB assay was performed 
to gauge the changes in percentage in cell proliferation in the presence and 
absence of cisplatin treatment in MCF-7-CISR cells. Results shown were 
derived from at least three independent experiments. The error bars show the 
standard deviation (mean ± SD). Statistical analysis was done using Student’s 
t tests. *, P < 0.01, significant. 
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3.2.6 Thiostrepton can overcome cisplatin resistance in breast 
cancer cells through the down-regulation of FOXM1 
 
 
 To test if FOXM1 inactivation is a viable strategy for overcoming cisplatin 
resistance, we  studied the effects of MCF-7-CISR cells treated with the thiazole 
antibiotic thiostrepton, which has previously been showed to specifically inhibit 
FOXM1 expression (Kwok, Myatt et al. 2008), alone (10 µM), and in combination 
with cisplatin (100 nM). SRB proliferative assays indicated that MCF-7-CISR cells 
treated with thiostrepton, or in combination with cisplatin showed a significant 
decrease in rate of cell proliferation (Figure 3-18A).  Cell cycle analysis revealed that 
MCF-7-CISR cells treated with thiostrepton alone showed an 18.7 % cell death rate 
by 72 h, whilst in combination, cisplatin and thiostrepton showed synergy, exhibiting 
a cell death rate of 64.1% at 72 h in this experiment (Figure 3-18B). In MCF-7-CISR 
cells treated with thiostrepton or thiostrepton and cisplatin, the down-regulation of 
FOXM1 and its downstream targets CDC25B and PLK occurred at 48 h and 24 h 
following treatment respectively (Figure 3-18C). The shorter time to FOXM1 down-
regulation in the combination treatment may reflect the higher levels of cell death 
observed when both drugs were administered together. In conclusion, inhibition of 













Figure 3-18 Thiostrepton can overcome cisplatin resistance in MCF-7-CISR 
breast cancer cells.  MCF-7-CISR cells were treated with DMSO (vehicle 
control), 0.1µM cisplatin, 10 µM thiostrepton or a combination of 0.1 µM 
cisplatin and 10 µM thiostrepton for 72 h.  A) SRB proliferation assays were 
performed on these cells and the percentage of viable cells at each time point 
is shown. B) Cells were fixed at 0, 24, 48, and 72 h after treatment, and cell 
cycle phase distribution was analyzed by flow cytometry after propidium 
iodide staining. Percentage of cells in each phase of the cell cycle (sub-G1, 
G1, S, and G2/M) is indicated. Representative data from three independent 
experiments are shown. C) Cell lysates were prepared at the times indicated, 
and the expression of FOXM1, CDC25B, XRCC1, BRCA2, and β-tubulin 
analyzed by Western blotting. 
 
 




 In the present study I have demonstrated for the first time that FOXM1 
possesses a crucial role in cisplatin resistance in breast cancer cells through 
enhancing DNA-damage repair pathways. Several observations suggest that FOXM1 
expression is an important determinant of cisplatin sensitivity and resistance.  Firstly, 
the basal levels of FOXM1 protein and mRNA were higher in the cisplatin resistant 
MCF-7-CISR cells relative to the parental MCF-7 cells.  Following cisplatin 
treatment, FOXM1 was down-regulated in the sensitive MCF-7 cells while the 
resistant MCF-7-CISR cells, there was an up-regulating of both FOXM1 mRNA and 
protein expression levels. Moreover, expression of the constitutively active ∆N-
FOXM1 was sufficient to confer resistance to the cisplatin-sensitive MCF-7 breast 
cancer cells whereas the depletion of FOXM1 through siRNA knockdown reversed 
cisplatin resistance in MCF-7-CISR breast cancer cells. 
 
 FOXM1 has previously been reported to regulate the expression of the DNA 
repair genes BRCA2 and XRCC1 (Tan, Raychaudhuri et al. 2007).  However, 
despite the fact that BRCA2 and XRCC1 levels are elevated in the MCF-7-CISR and 
MCF-7-∆N-FOXM1 expressing cells, evidence suggests that FOXM1 is not the sole 
regulator of BRCA2 and XRCC1.  For instance, both BRCA2 and XRCC1 
expression was not down-regulated upon FOXM1 silencing in both MCF-7 and 
MCF-7-CISR breast cancer cells.   Additionally, we have cloned a BRCA2 gene 
promoter whose activity is repressible by cisplatin but is not responsive to FOXM1 
transactivation (Kwok, Peck et al. 2010). This promoter is different from a 
previously published BRCA2 promoter (Tan, Raychaudhuri et al. 2007), which 
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locates further downstream the BRCA2 gene (Kwok, Peck et al. 2010). Furthermore, 
despite the fact the expression levels of BRCA2 and XRCC1 were higher in the 
MCF-7-∆N-FOXM1 cells compared with the parental cells, transient transfection of 
MCF-7 with ∆N-FOXM1 failed to up-regulate either BRCA2 or XRCC1 expression 
(Kwok, Peck et al. 2010).  All the supplementary evidence implies that additional 
regulators are needed, though FOXM1 plays a part in their activation. 
 
 Furthermore, it was also interesting to observe that although both BRCA2 
and XRCC1 knockdown sensitized MCF-7-CISR with an elevated amount of 
cisplatin-induced DNA damage but SRB proliferation assay revealed that whilst 
BRCA2 and XRCC1 knockout did not show an appreciable anti-proliferative effect,  
the knockdown FOXM1 significantly reduced the proliferative rate of MCF-7-CISR 
cells in response to cisplatin.  These findings also suggest that besides DNA repair, 
other possible roles for FOXM1 such as the promotion of cell cycle progression or 
inhibition of cell cycle checkpoints and apoptosis, may also contribute to cisplatin 
resistance.  
 
 These observations may have implications in the development of a treatment 
regime for cisplatin resistance patients, suggesting it would be more efficient to 
target a “master” oncogene such as FOXM1, rather than targeting a subset of DNA 
repair machinery, where potential compensatory mechanisms could be present to 
hamper the treatment. Moreover, the inhibition of FOXM1 and co-treatment with 
DNA-damaging agents may be hypothesized to enhance therapeutic response. In 
order to test this hypothesis, we employed the specific FOXM1 inhibitor thiostrepton 
(Kwok, Myatt et al. 2008). Our results indicate that thiostrepton synergised with 
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cisplatin to reverse acquired cisplatin resistance in breast cancer cells, and caused a 
substantial increase in the amount of cisplatin-induced cell death. This probably 
reflects the role of FOXM1 in several aspects of physiological processes including 
proliferation, cell cycle transition and DNA repair, and thus a reduction in the ability 
of cisplatin resistant cells evade the cytotoxic effects of cisplatin. As a consequence, 
we have also demonstrated for the first time that the employment of a FOXM1 
inhibitor like thiostrepton, in conjunction with chemotherapy, might provide a 
mechanism for reversing the phenomenon of wide-spread chemoresistance in breast 
cancer patients. Moreover, the fact that thiostrepton exclusively targets cancer cells 
and not non-malignant cells can further enhance the specificity of cisplatin in 
combinatorial treatments (Kwok, Myatt et al. 2008). 
 
 The mechanism by which FOXM1 activity and/or expression is up-regulated 
in MCF-7-CISR cells requires further investigation. Treatment with DNA damaging 
agents, including γ-irradiation, etoposide and UV, has been reported to increase 
CHK2-induced phosphorylation of FOXM1, potentially stabilizing the protein and 
leading to the transcriptional up-regulation of downstream DNA repair genes (Tan, 
Raychaudhuri et al. 2007). However, several previous studies suggest that it is 
unlikely that CHK2 phosphorylation of FOXM1 is relevant in acquired cisplatin 
resistant breast cancer cells. For example, clinical assessment of a selective CHK2 
inhibitor VRX0466617 has shown that it can sensitise cancer cells to apoptosis 
following exposure to ionizing radiation but not cisplatin (Carlessi, Buscemi et al. 
2007). Moreover, loss or down-regulation of CHK2 expression has been shown to 
contribute to cisplatin resistance in ovarian cancer and lung cancer (Zhang, Wang et 
al. 2004; Zhang, Gao et al. 2005). Thus, it is possible that additional mechanisms are 
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responsible for the enhanced levels of FOXM1 in MCF-7-CISR cells. Indeed, our 
studies have showed that resistant cells up-regulated FOXM1 expression at the 
mRNA level in response to cisplatin. This adds a new dimension to the FOXM1 
signalling network whereby following DNA damage FOXM1 activity and expression 
may be modulated differentially depending on cellular background. In consequence, 
it will also be interesting to unravel further the exact molecular mechanisms by 
which FOXM1 mRNA expression levels are regulated in response to cisplatin. 
 
  In summary, FOXM1 is a critical mediator of cisplatin sensitivity and 
resistance in breast cancer cells. Therefore, FOXM1 can be a useful marker for 
predicting and monitoring cisplatin response. Through the inhibition of FOXM1, it is 
possible that acquired cisplatin resistance can be reversed, and FOXM1 could be a 










 Having investigated and identified FOXM1 as a novel marker and possible 
therapeutic target in acquired cisplatin resistance, it would be interesting to further 
evaluate whether FOXM1 is also involved in conferring other types of 
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   Patients diagnosed with breast cancer are routinely treated with 
chemotherapeutic agents like doxorubicin.  Doxorubicin belongs to the class of anti-
tumour antibiotics known as the anthracyclines, which is derived from the bacterim 
species Streptomyces peucetius var. caesius (Arcamone, Cassinelli et al. 1969; 
Arcamone, Cassinelli et al. 2000).  Other members of the anthracycline family that 











Figure 3-19  The chemical structure of the anthracycline antibiotics including 
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 Doxorubicin is administered intravenously in the form of hydrochloride salt 
and is sold under different brand names like Adriamycin PFS®, Adriamycin RDF® or 
Rubex®.  Doxorubicin is a long established anthracycline antibiotic which exhibits 
potent cytoxicity in mammalian cells (Di Marco, Gaetani et al. 1969).  The exact 
mode of mechanism remains to be fully elucidated, but current evidence is that it can 
act through multiple ways, including the intercalation to DNA and RNA (Momparler, 
Karon et al. 1976), direct inhibition of enzyme topoisomerase II (Tewey, Rowe et al. 
1984) and helicase enzyme (Bachur, Yu et al. 1992; George, Ghate et al. 1992; 
Bachur, Lun et al. 1998).  There are also reports that it can induce DNA strand 
breaks (Maehara, Emi et al. 1989).   
 
 Nonetheless, additional data performed also indicated that both FOXM1 
mRNA and protein expression level is also up-regulated in a doxorubicin-resistant 
breast cancer cell line (MCF-7-DOXR) relative to parental MCF-7 cells (Monteiro 
2009).  Furthermore, the ectopic expression of the constitutive ∆N-FOXM1 in MCF-
7 rescues doxorubicin sensitivity completely in MCF-7 breast cancer cells too 
(Monteiro 2009).  However, thiostrepton did not induce cell death in MCF-7-DOXR 
cells because of a failure to repress FOXM1 expression in these cells (Monteiro 
2009).  The reason why thiostrepton is unable to suppress FOXM1 expression is 
unclear, but it could be due to the presence of multi-drug resistance (MDR) drug 
efflux pumps which have been widely reported to export drug compounds in 
doxorubicin resistant cell lines (Hembruff, Laberge et al. 2008; Hui, Francis et al. 
2008).   Modifications of thiostrepton derivatives could be employed in the future to 
see whether it could circumvent doxorubicin resistance.  Furthermore, a similar set of 
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results obtained by my colleague Ursula McGovern has also show that the both 
FOXM1 protein and mRNA were up-regulated in breast cancer patient samples 
exhibiting epirubicin resistance.  Furthermore, the over-expression of ∆-N-FOXM1 
in MCF-7 cells conferred cellular epirubicin-resistance (McGovern 2009). 
 
 In summary, FOXM1 plays a crucial role in acquired cisplatin resistance, 
could open up to further possibilities that FOXM1 could be involved in other types 
of chemoresistance resistance breast cancers like doxorubicin and epirubicin 
resistance.  Therefore, further in vivo and clinical studies would be needed to 
determine the efficacy of thiostrepton, as a standalone or in combination with other 
chemotherapeutic agents to circumvent the widespread problem of acquired 
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I have demonstrated in the previous chapters that elevated levels of FOXM1 
mRNA transcript and protein levels are involved in acquired cisplatin resistance.  
Interestingly, the direct upstream MAPK regulator of FOXM1 - ERK-1/2 has also 
been shown to also be elevated in primary breast cancer tissues by the use of MAP 
kinase enzyme assay, western blotting and immunohistochemical methods 
(Sivaraman, Wang et al. 1997; Salh, Marotta et al. 1999; Mueller, Flury et al. 2000).   
 
The first study that provided a positive correlation ERK-1/2 activation and 
breast cancer was performed by Sivaraman et al (Sivaraman, Wang et al. 1997).  
They used an EGF receptor peptide substrate based MAP kinase enzyme assays to 
determine the ERK-1/2 activity in 37 breast tissue samples, which included the 
biopsies from a controlled non-malignant group comprising of five normal 
individuals, one with gynecomastia, five with fibrocystic breast condition, one with 
both fibrocystic and fibroadenoma, two with chronic inflammatory disease and 
another 11 biopsies from breast cancer patients with primary breast carcinoma.  On 
average, MAP kinase activity returned an average statistical return value of 1.4 ± 
0.19 pmol/min/mg protein in the controlled non-malignant group, and 6.39 ± 0.71 in 
the breast cancer patients.  Further in situ reverse transcription polymerase chain 
reaction revealed that the elevated MAP kinase mRNA expression was 
predominantly localised in the malignant epithelial cells. 
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A subsequent study performed by Salh et al also provided an improved 
understanding of ERK-1/2 activity in primary human breast cancer cells (Salh, 
Marotta et al. 1999).  23 human breast cancers and control tissues were obtained 
from different portions of the same tissue samples revealed an elevation of ERK-1/2 
expression levels in the malignant samples.  Moreover, specific immunoprecipitation 
studies indicated that ERK-1/2 activity was up-regulated by 2.5-fold in 50% of 
tumour samples.  Interestingly, immunohistochemical studies revealed that that 
cellular distribution of ERK-2 was similar in both control and tumour tissues.  
Similar results were obtained on a study involving larger numbers of subjects were 
performed by Mueller et al , where ERK-1/2 kinase activity was significantly 
increased in 131 primary breast tumour tissues relative to 18 normal breast tissues 
located in the vicinity of the site of primary tumours (Mueller, Flury et al. 2000).  
Furthermore, it has been suggested that phosphorylated ERK1/2 MAPK could be 
used as an independent prognostic indicator of lower patient survival for ERα 
positive breast cancer patients (Gee, Robertson et al. 2001). 
 
Interestingly, some studies have also implicated that ERK-1/2 could also 
confer cisplatin resistance in ovarian cell lines (Wang, Zhou et al. 2007; Chan, Liu et 
al. 2008).  However, whether ERK-1/2 plays an important role in conferring acquired 
cisplatin resistance in breast cancer is hitherto unknown.  However, given that when 
cells undergo cell cycle transition, FOXM1 is phosphorylated by ERK-1/2 at the late 
G2 phase cell cycle, facilitating FOXM1 nuclear translocation (Ma, Tong et al. 2005) 
and the inhibition of active ERK-1/2 activity through MEK inhibitor PD098059 
abrogates FOXM1 nuclear translocation and results in G2/M phase arrest (Ma, Tong 
et al. 2005).  Therefore, the up-regulation of ERK-1/2 activity could increase the 
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amount of FOXM1 translocation into the nucleus.   With an increase amount of 
nuclear FOXM1 present, it can then increase the rate of transcription and activation 
of a range of DNA repair targets like BRCA2, XRCC, CENP-A,B,F and Nek2 which 
might be important in conferring acquired cisplatin resistance. 
  
 Thereforth, I have dedicated the final chapter of my thesis into determining 
whether active ERK-1/2 plays a role in cisplatin resistance in MCF-7-CISR cells 
through enhancing nuclear FOXM1 translocation.  When MCF-7-CISR cells are 
exposed to cisplatin, an induction of P-ERK1/2 activity might lead to an increase of 
FOXM1 phosphorylation, which could then lead to an increase in the amount of 
FOXM1 translocated into the nucleus.  This could be another signalling mechanism 
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3.3.2 The inhibition of ERK-1/2 activity in MCF-7-CISR cells 
slowed the proliferation rate but it failed to re-sensitize 
MCF-7-CISR cells to cisplatin treatment 
 
 
   In order to confirm whether ERK1/2 activity is crucial in conferring 
acquired cisplatin resistant in MCF-7-CISR cells, I have selected to use two well 
established MEK inhibitors - UO126 and PD098059 to repress ERK-1/2 activity in 
both MCF-7 and MCF-7-CISR cells (Figure 3-20). 
    
  
 
Figure 3-20  A flow diagram illustrating the Raf/MEK/ERK MAPK signalling 
pathway.  The chemical structure of both MEK inhibitors U0126 and PD 098059 
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 PD098059 is an small organic compound first discovered in an in vitro 
screening of a compound library against MEK1 activity (Dudley, Pang et al. 1995).  
Subsequent validations have found that PD098059 inhibits MEK1/2 by preventing 
the Raf mediated phosphorylation of MEK1/2 under both in vitro and in vivo 
conditions (Alessi, Cuenda et al. 1995).  On the other hand, U0126 is a non-
competitive MEK inhibitor and binds to specific sites in MEK1 and MEK2, curbing 
its further downstream activating potential (Favata, Horiuchi et al. 1998).  
Nonetheless, the inactivation of MEK1/2 by both inhibitors switches off the MAPK 
signalling cascade through the inhibition of downstream ERK-1/2 activity. 
 
 Initially, both the MCF-7 and MCF-7-CISR cells were treated with an 
increasing dose response of both MEK inhibitors - U0126 (0-30 µM) and PD098058 
(0-30µM) for 24h.  SRB assay revealed that MCF-7 cells were sensitive to both 
U0126 and PD098058 treatment, showing an IC50 of approximately 10 µM and 20 
µM respectively at 24h (Figure 3-22).  On the other hand, MCF-7-CISR cell showed 
no significant difference in percentage of viable cells at 24 h post treatment with 
either U0126 or PD098059.  This indicates that MCF-7-CISR cells were completely 
insensitive to MEK inhibitor treatment.  Moreover, this tentatively suggests that in 
MCF-7-CISR cells, they have evolved mechanisms to by-pass the need of an active 
Raf/MEK/ERK MAPK signalling cascade for normal cell proliferation.  Since no 
significant differences were observed between the effects of the two MEK inhibitors 
have on MCF-7-CISR cells, I have chosen just to use PD098059 as the MEK 
inhibitor for the rest of the study. 





Figure 3-21  Both PD98058 and U0126 reduces proliferation in MCF-7 cells but 
not in MCF-7-CISR cells. A) MCF-7 cells and B) MCF-7-CISR cells were treated 
with U0126 (0-30µM) or PD (0-30 µM; 0-24 h) and proliferation determined by 
SRB assay. Results of experiments in triplicate were presented as mean 
(±SD).  
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   Next, in order to establish whether ERK1/2 activity is needed for cisplatin 
resistance in MCF-7-CISR cells, I have then treated both MCF-7 and MCF7-CISR 
cells with DMSO (vehicle control), 0.1µM cisplatin, 20 µM PD098059 or a 
combination of 0.1 µM cisplatin and 20 µM PD098059 for 72 h.  SRB assay revealed 
that for MCF-7 cells treated with cisplatin, PD098059 alone or with a combination of 
0.1 µM cisplatin and 20 µM PD098059 showed approximately a reduction in 30% of 
cell proliferation by 72h (Figure 3-22).  This suggests that PD098059 can inhibit cell 
proliferation and induce cell death, but it did not show significant synergy or any 
additive effect in conjunction with cisplatin.  This result is consistent with previous 
studies showing that ERK-1/2 activity is critical for cell proliferation in response to 
mitogenic stimulation, and the abrogation of ERK-1/2 mediated signalling would 
result in significant reduction in cell proliferation (D'Abaco, Hooper et al. 2002; 
Lunghi, Tabilio et al. 2003; McCubrey, Milella et al. 2008; Steelman, Abrams et al. 
2008).   
 
 On the other hand, MCF-7-CISR cells treated with DMSO or cisplatin shown 
an increase in proliferation of 350%, much higher than the untreated MCF-7 cells 
which only showed an increase in proliferation by 200%.  This is consistent with the 
finding that MCF-7-CISR cells expressing a higher level of basal FOXM1 levels 
which could confer it the ability to accelerate oncogenic growth rate.  Interestingly, 
MCF-7-CISR cells treated with PD098059 alone showed a reduction in proliferation 
relative to MCF-7-CISR cells treated with DMSO or cisplatin, nonetheless MCF-7-
CISR cells still showed an increase in proliferation by 200% by 72 h.  This suggests 
that ERK-1/2 can contribute to cellular proliferation in MCF-7-CISR cells, but it is 
not absolutely critical.  Furthermore, the combination treatment using both 
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PD098059 and cisplatin also slowed proliferation rate relative to the untreated 
control to 200% by 72 h (Figure 3-24).  This further indicates that the inhibition of 
ERK-1/2 activity could not rescue cisplatin sensitivity.  This preliminarily suggests 
that ERK1/2- is not critical in conferring cisplatin resistance in MCF-7-CISR cells. 
 
 To further confirm the findings of SRB proliferation assay, I have also 
performed FACS cell cycle analysis to investigate the effects of PD098059 has on 
both MCF-7 cells (Figure 3-24) and MCF-7-CISR cells (Figure 3-24).  For MCF-7 
cells that were treated with 0.1 µM of cisplatin, 55.1% of cells were in the sub-G1 
population, indicating large amount of induced cell death post cisplatin treatment.  
As for MCF-7 cells treated with PD098059, G2/M population increased from 17.8% 
to 43.2% by 6h, indicating a G2/M arrest which is consistent with the role of P-
ERK1/2 needed in the activation FOXM1 needed in mitotic progression.  
Progressively, 35.1% of cells were in the sub-G1 population by 48h indicating 
substantial amount of cell death.  Interestingly, for MCF-7 cells treated with both 
PD098059 and 0.1 µM of cisplatin resulted in only 23.8% of cell death by 48 h in 
conjunction with a high level of G2/M arrest was also present at 42.8%. Therefore, 
PD098059 and cisplatin did not show significant synergistic or additive effects in 
killing MCF-7 cells.  Nonetheless, the FACS data supports the SRB results and 
indicates that MCF-7 cells required ERK-1/2 activity for cellular proliferation, and 
that cisplatin and PD098059 did not show any significant synergetic or additive 
effects. 
 
 On the other hand, for MCF-7-CISR cells that were treated with 0.1 µM of 
cisplatin, there was no significant effect on the cell cycle as they are have elevated 
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levels of FOXM1 which can confer them resistance to cisplatin.  For MCF-7-CISR 
cells treated with PD098059, there was no significant impact on cell cycle for the 
first 6 hours.  However, by 24h and 48h there was an increase in the G1 population 
cells from approximately 52.6% to 70.8%.  This suggests that cells are progressing 
slower through the cell cycle, which is consistent with the SRB assay which 
indicated a slower proliferation rate.  Moreover, MCF-7-CISR cells treated with both 
PD098059 and cisplatin displayed a similar cell cycle profile pattern, where there 
was an increase in the G1 population cells from approximately 58.9% to 73.7% by 
48h.  However, no significant amount of cell death was observed.  This reaffirms the 
notion that the inhibition of ERK-1/2 activity could not re-sensitize cisplatin resistant 
cells to cisplatin treatment, and that P-ERK1/2 activity is not crucial in cell 
proliferation for MCF-7-CISR cells. 
 
 This is surprising as the inhibition of ERK1/2 activity should render FOXM1 
inactive as FOXM1 would be constitutively located in the cytoplasm.  Without 
functional FOXM1 in the nucleus, cells would be unable to activate downstream 
gene targets in both G1 to S, and G2 to M transition or DNA repair.  This should have 
resulted in significant cell death, as results in previous chapter demonstrated the 
absolute requirement of FOXM1 in MCF-CISR cellular survival, the absence of a 
functional nuclear FOXM1 would have resulted in cell death.   Therefore, the only 
one logical possible explanation for the above experiment observations would be that 
FOXM1 has evolved the ability to translocate into the nucleus independent of ERK-
1/2 activation.  In another words, there might be a de-regulation of P-ERK1/2 and 
FOXM1 activity in acquired cisplatin resistant cells. 
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Figure 3-22 PD098059 failed to reverse cisplatin resistance in MCF-7-CISR 
cells.  Both MCF-7 and MCF7-CISR cells were treated with DMSO (vehicle 
control), 0.1µM cisplatin, 30 µM PD098059 or a combination of 0.1 µM cisplatin 
and 30 µM PD098059 for 72 h.  SRB proliferation assays were performed on 
these cells to determine the percentage of cells at each time point for A) MCF-














Figure 3-23 PD098059 induces cell death in MCF-7 breast cancer cells.  MCF-7 
cells were treated with DMSO (vehicle control), 0.1µM cisplatin, 20 µM 
PD098059 or a combination of 0.1 µM cisplatin and 20 µM PD098059 for 72 h.  
Cells were fixed at 0, 24, 48, and 72 h after treatment, and cell cycle phase 
distribution was analyzed by flow cytometry after propidium iodide staining. 
Percentage of cells in each phase of the cell cycle (sub-G1, G1, S, and G2/M) 






























Figure 3-24  PD098059 does not induce cell death in MCF-7-CISR breast cancer 
cells.  MCF-7-CISR cells were treated with DMSO (vehicle control), 0.1µM 
cisplatin, 20 µM PD098059 or a combination of 0.1 µM cisplatin and 20 µM 
PD098059 for 72 h.  Cells were fixed at 0, 24, 48, and 72 h after treatment, and 
cell cycle phase distribution was analyzed by flow cytometry after propidium 
iodide staining. Percentage of cells in each phase of the cell cycle (sub-G1, 
G1, S, and G2/M) is indicated. Representative data from three independent 
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3.3.3 Subcellular fractionation reveals cisplatin treatment can 
induce FOXM1 nuclear translocation in MCF-7-CISR but 
not in MCF-7 cells 
  
 In order to confirm whether there is an un-coupling of ERK1/2 activity and 
FOXM1 subcellular localisation, I needed to determine the sub-cellular distribution 
of FOMX1 when both MCF-7 and MCF-7-CISR cells are treated with cisplatin 
through western blotting of the subcellular distribution of proteins (Figure 3-25).  For 
both the MCF-7 and MCF-CISR cells treated with cisplatin, there was a steady up-
regulation of P-ERK1/2 protein level over the 48 h period, which is consistent with 
previous findings that P-ERK1/2 protein was up-regulated in BT474 cells following 
cisplatin treatment (Hayakawa, Depatie et al. 2003).  Furthermore, in MCF-7-CISR 
cells the FOXM1 protein expression level increased gradually in the nuclear fraction 
over 48h.  On the other hand, for MCF-7 cells treated with cisplatin, the total level of 
FOXM1 protein level decreased after 24 h.  Importantly, nuclear FOXM1 levels 
decreased markedly by 24 h whereas cytoplasmic FOXM1 levels remain more or less 
constant throughout the 48 h period.  This suggests that the failure of FOXM1 
translocation in MCF-7 cells, coupled with the reduction in its expression level is 
possibly responsible for its failure to over-come cytotoxic effects induced by 
cisplatin.  Interestingly, although P-ERK-1/2 activity was induced in MCF-7 cells 
treated with cisplatin, it was insufficient to promote nuclear FOXM1 translocation 
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 Confocal microscopy was also performed to validate the sub-cellular 
fractionation experiments in tracking the expression levels and changes of FOXM1 
subcellular localisation in both MCF-7 and MCF-7-CISR cells in response to cisplatin 
treatment.  Confocal microscopy revealed that MCF-7 cells treated with cisplatin for 
24 h had a much lower levels of FOXM1 fluorescence relative to MCF-7-CISR cells.  
This indicated that the expression of FOXM1 was maintained when MCF-7-CISR 
cells, but not in MCF-7 cells.  Moreover, in MCF-7-CISR cells, there was a notable 
increase in FOXM1 immunofluorescence staining in the nucleus at 24 h (Figure 
3-26).  Therefore, consistent with western blot analysis that nuclear FOXM1 
translocation in MCF-7-CISR is an important cellular response against cisplatin 
treatment, but whether this translocation had become independent on ERK-1/2 
activity will require treating them with the ERK-1/2 inhibitor PD0980959 alone, 
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Figure 3-25  The translocation of FOXM1 into the nucleus after treatment with 
0.1 µM of cisplatin was only observed in MCF-7-CISR cells.  Both MCF-7 and 
MCF-7-CISR cells were treated with 0.1 µM of cisplatin for 48 h.  Approximately 
75% of the cellular protein extracts harvested were then subjected to 
subcellular fractionation to obtain the cytoplasmic and nuclear fractions, 
whereas the remaining 25% portion was harvested under normal conditions 
prescribed in the protocol section.  Subsequently, the protein levels of P-ERK-
1/2, ERK, and FOXM1 were determined by western blot analysis.  Sp1 was the 
loading control for the nuclear protein fraction, while tubulin was the loading 
control for the cytoplasmic fraction. 
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Figure 3-26 FOXM1 is translocated into the nucleus after treatment with 0.1 µM 
of cisplatin only in MCF-7-CISR cells.  Both MCF-7 and MCF-7-CISR cells were 
treated with 0.1 µM of cisplatin for 0h, 6h and 24h and stained with anti-
FOXM1-FITC antibody and DAPI nuclear staining. Images were visualized by 
confocal microscopy.  The pictures illustrated here was the best 
representative of at least 8 independent images taken per condition.  Original 













DAPI FITC-FOXM1 Merged 
  - 196 - 
3.3.4 Deregulation of ERK1/2 activity and nuclear FOXM1 
localisation is observed in MCF-7-CISR cells 
 
 In order to determine whether there was indeed an uncoupling of ERK-1/2 
activity and subcellular FOXM1 distribution, both MCF-7 and MCF-7-CISR cells 
were treated with 20 µM of PD098059 for 48 h (Figure 3-27).   
 
 For MCF-7 cells treated with 20 µM of PD098059, there was a rapid decrease 
in both the P-ERK-1/2 and ERK-1/2 protein levels by 4h.  Furthermore, FOXM1 
protein expression was predominantly detected in the cytoplasm fraction by 24 h and 
no significant amount of FOXM1 was detected in the nuclear fraction.  This indicates 
that the inhibition of ERK-1/2 activity resulted in the detainment of FOXM1 in the 
cytoplasmic fractions, suggesting that ERK-1/2 activity is indispensable for FOXM1 
nuclear translocation.  This is consistent with previous experimental observations 
performed by Ma et al (Ma, Tong et al. 2005).   
 
 Similarly, MCF-7-CISR cells treated with 20 µM of PD098059 also showed a 
very rapid decrease in both P-ERK1/2 and ERK-1/2 protein levels by 4h.  
Interestingly, the total FOXM1 protein level increases throughout the 48 h period.  
Unlike MCF-7 cells where FOXM1 is arrested in the cytoplasm, there was an 
increase of FOXM1 protein levels in both the cytoplasmic and nuclear faction.  This 
suggests that for MCF-7-CISR cells, FOXM1 has evolved the ability to translocate 
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 Confocal microscopy was also performed to validate the sub-cellular 
fractionation experiments in tracking the expression levels and changes of FOXM1 
subcellular localisation in both MCF-7 and MCF-7-CISR cells in response to cisplatin 
treatment (Figure 3-29).  Confocal microscopy revealed that MCF-7 cells prior to 
PD098059 treatment had a more or less similar cytoplasmic and nuclear distribution 
of FOXM1 levels, but by 24h here was an increase in cytoplasmic FOXM1 
immunofluorescence staining.  This indicates that FOXM1 subcellular distribution is 
confined to the cytoplasm when ERK-1/2 activity is inhibited, which is consistent 
with the previous western blot analysis.  However, for MCF-7-CISR cells treated 
with PD098059, there was no significant impact on the subcellular distribution of 
FOXM1.  FOXM1 immunofluorescence staining was more or less evenly distributed 
throughout the cytoplasm and nucleus over the 24h treatment period.  The correlation 
observed strongly suggests that FOXM1 translocation had become independent on 
ERK-1/2 activity. 
 
 To preclude the possibility that FOXM1 might be trapped in the nuclear 
fraction in MCF-7-CISR cells due to the loss of downstream expression gene targets 
of P-ERK-1/2, I then performed a functional study involving cell synchronisation to 
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Figure 3-27  The relationship between ERK-1/2 activity and nuclear FOXM1 
localisation is uncoupled in MCF-7-CISR cells.  Both MCF-7 and MCF-7-CISR 
cells were treated with 20 µM of PD098059 for 48 h.  Approximately 75% of the 
cellular protein extracts harvested were then subjected to subcellular 
fractionation to obtain the cytoplasmic and nuclear fractions, whereas the 
remaining 25% portion was harvested under normal conditions prescribed in 
the protocol section.  Subsequently, the protein levels of P-ERK-1/2, ERK, and 
FOXM1 were determined by western blot analysis.  Sp1 was the loading 
control for the nuclear protein fraction, while tubulin was the loading control 
for the cytoplasmic fraction. 
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Figure 3-28  Nuclear FOXM1 translocation was not affected by the inhibition of 
ERK-1/2 activity in MCF-7-CISR.  Both MCF-7 and MCF-7-CISR cells were 
treated with 20 µM of PD098059 for 0h, 6h and 24h and stained with anti-
FOXM1-FITC antibody and DAPI nuclear staining. Images were visualized by 
confocal microscopy.  The pictures illustrated here was the best representative 
of at least 8 independent images taken per condition.  Original magnification X 
40.
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3.3.5 Synchronized MCF-7-CISR cells shows that FOXM1 
translocation into the nucleus is independent of P-ERK1/2 
activity  
  




 The functional experiment required to show definitively that there was an 
uncoupling of ERK-1/2 activity and FOXM1 will be performed by synchronizing 
MCF-7 cells in the late G1 or S phase of the cell cycle.  This would restrict FOXM1 
distribution to the cytoplasm prior to P-ERK-1/2 phosphorylation during the G2 
phase of the cell cycle.  Upon the release of synchronized cells in the presence of 
PD098059, cell cycle progression should be retarded in MCF-7 cells as FOXM1 
would be restricted to the cytoplasmic faction, whereas in MCF-7-CISR cells, 
FOXM1 should still be able to translocate into then nucleus in the absence of ERK-




 Mimosine [α-amino-β-(3-hydroxy-4-oxo-1,4,dihydropyridine-1-yl) propanoic 
acid], also commonly known as L-Mimosine, Leucaenine, Leucaenol, Leucenine, 
Leucenol or Mimosin is a type of toxic non-protein amino acid present in the leaves 
and seeds of the plants belonging to the genera Mimosa and Leucena (Figure 3-29).  
It a well established compound that can arrest cells in the G1/S phase of the cell cycle 









    
 
Figure 3-29  The chemical Structure of mimosine.  Mimosine is a toxic non-





 Its exact mode of action is debatable, but different lines of evidence have 
indicated that it could inhibit G1 to S phase transition by repressing the formation of 
hypusine, a rare amino acid in the eukaryotic translation factor 4D (Hoffman, 
Hanauske-Abel et al. 1991) or by chelating iron, which is a cofactor for 
ribonucleotide reductase, reducing its ability to form dNTPs which can lead to the 
stalling of replication fork in the S phase (Tsai and Ling 1974; Megarrity 1978; 
Kontoghiorghes, Piga et al. 1986).  Nonetheless, previous work has demonstrated 
mimosine’s ability to synchronize higher eukaryotic cells at an optimal concentration 
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3.3.5.2 Synchronized MCF-7 cells treated with PD098059 failed to re-enter cell 
cycle as FOXM1 fails to translocate into nucleus 
 
 MCF-7 cells were synchronized with 0.5 mM of mimosine treatment for 24h.  
The cells were then washed twice with PBS prior to the replacement with new media 
to release the synchronized cells.  Following the release of synchronized cells from 
cell cycle, cells were immediately subjected to the treatment of either DMSO 
(vehicle control) or 20 µM of PD098059.  Confocal fluorescent microscopy was used 
to track the cellular location of FOXM1, whilst FACS cell cycle analysis was 
performed alongside to track changes in the cell cycle profile.   
 
 In the control experiment where MCF-7 cells were released from G1 arrest in 
the absence of PD098059, FACS cell cycle revealed that cells began to enter the S 
phase of the cell cycle gradually at 2h and S-phase population peaked at 51.5% by 
10h (Figure 3-30).  Confocal microscopy data also revealed that cytoplasmic 
FOXM1 expression peaked at 10h.  Subsequently, a majority 73.5% of cells then 
went into G2/M phase of the cell cycle before re-entering G1 phase by 20h.  During 
this period, confocal microscopy revealed that FOXM1 immunofluoresecent staining 
was predominant in the nuclear fraction of the cell at 12h, and its expression level 
diminished by 20h as cells re-enter G1 phase of the cell cycle.   
 
 Although my experimental observations are consistent with the data reported 
in previous literature that FOXM1 translocation into the nucleus is dependent on P-
ERK1/2 phosphorylation at late S phase prior to cell cycle entry into G2/M phase of 
the cell cycle (Ma, Tong et al. 2005), in contrast to previous literature reports, 
immunofluorescence confocal microscopy also revealed that FOXM1 was 
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translocated into the nucleus as early as 2 h upon release from cell cycle progression, 
which corresponds to the G1-S progression of the cell cycle.  However, the complete 
translocation of FOXM1 only occurred at 10 h when cells were at beginning to move 
into G2/M phase of the cell cycle, consistent with the role that P-ERK-1/2 plays in 
FOXM1 nuclear translocation.  Hence, this putatively suggests that alternative 
mechanisms at the G1 phase of the cell cycle can also regulate of FOXM1 nuclear 
entry. 
 
 As for MCF-7 cells treated with PD098059, FACS cell cycle analysis 
revealed a majority of cells (~85% to 92%) remained in the G1 phase for the first 6 
h.  By 10 h, 35.8 % of cells entered S phase of the cell cycle, and a gradual S-phase 
arrest was observed as cells continue to accumulate in S phase of the cell cycle, with 
only a small percentage managing to enter G2/M phase of the cell cycle.  Therefore, 
the abrogation of ERK-1/2 activity in MCF-7 cells resulted in S phase cell cycle 
arrest and prevented MCF-7 cells from undergoing a complete cell cycle progression 
(Figure 3-31).  Interestingly, confocal microscopy revealed that a small amount of 
FOXM1 entered the nucleus between 2 to 10 h, but a majority of FOXM1 remained 
in the cytoplasm until 24 h.  Therefore, my findings indicated that the abrogation of 
ERK-1/2 mediated FOXM1 nuclear translocation observed is consistent with 
previous report that nuclear translocation is pertinent for mitotic progression (Ma, 
Tong et al. 2005).  However, the observation that a portion of FOXM1 is also 
translocated into the nucleus at G1 phase of the cell cycle, which is independent of 
ERK-1/2 activity, suggests that the regulation of nucleocytoplasmic shuttling of 
FOXM1 is more complex than previously thought. 
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 In summary, this experiment is consistent with previous finding that the 
ERK-1/2 activity is needed for nuclear translocation of FOXM1 at S phase of the cell 
cycle, and the abrogation of ERK-1/2 activity via PD098059 will lead to G2/M delay.  
However, the novel observation that a portion of cytoplasmic FOXM1 is also 
translocated into the nucleus as early as G1 phase of the cell cycle, which is 
independent of ERK-1/2 activity will additional up-stream up-regulators that might 
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Figure 3-30  FOXM1 is translocated into the nucleus prior to entering G2/M 
phase of the cell cycle.  MCF-7 cells were synchronized with 0.5 mM of 
mimosine for 24h.  MCF-7 cells were then released by the removal of 
mimosine.  At different time intervals, cells were harvested and either stained 
with propidium iodide for FACS cell cycle profile analysis, or with DAPI and 
immunofluorescent αFOXM1-FITC stain to visualise subcellular localisation of 
FOXM1.    Synchronized cells entered begin to enter S phase at 6h, G2/M at 
10h and completing one round of mitotic division by 24h.  Confocal 
microscopy also revealed that FOXM1 translocated into the nucleus prior at 
2h, prior to cells entering S and G2/M phase, which is consistent with its role 
in G1/S and G2/M cell cycle transition.  The FOXM1 expression diminished as 
cells re-enter G1 phase of cell cycle after mitotic division, consistent with its 









Figure 3-31 FOXM1 failed to translocate into the nucleus and remained in G1 
arrest with 20 µM treatment of PD098059.  MCF-7 cells were synchronized with 
0.5 mM of mimosine for 24h.  MCF-7 cells were then released by the removal 
of mimosine and treated with 20 µM of PD098059 immediately  At different 
time intervals, cells were harvested and either stained with propidium iodide 
for FACS cell cycle profile analysis, or with DAPI and immunofluorescent 
αFOXM1-FITC stain to visualise subcellular localisation of FOXM1.    
Synchronized cells entered begin to enter S phase at 6h, G2/M at 10h and 
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3.3.5.3 Synchronized MCF-7-CISR cells treated with PD098059 did not prevent 
FOXM1 nuclear translocation and cell cycle progression 
 
 
 Similarly, MCF-7-CISR cells were synchronized with 0.5 mM of mimosine 
treatment for 24h.  The cells were then washed twice with PBS prior to the 
replacement with new media to release the synchronized cells.  Following the release 
of synchronized cells from cell cycle, cells were immediately subjected to the 
treatment of either DMSO (vehicle control) or 20 µM of PD098059.  Confocal 
fluorescent microscopy was used to track the cellular location of FOXM1, whilst 
FACS cell cycle analysis was performed alongside to track changes in the cell cycle 
profile.   
 
 As a control, MCF-7-CISR cells released from mimosine induced G1 arrest in 
the absence of PD098059.  FACS cell cycle revealed that cells began to enter the S 
phase of the cell cycle gradually ay 2 h and S phase population peaked at 34.1 % by 
6 h (Figure 3-32).  Subsequently, a majority of 72.9% of cells progressed through the 
G2/M phase of the cell cycle by 12 h, before 71.4 % of them re-entered G1 phase by 
20h again as they successfully underwent a round of complete cell cycle division.   
Interestingly, confocal microscopy data revealed that nuclear FOXM1 translocation 
happened by 2 h, similar to what was observed in MCF-7 cells.  However, in MCF-
7-CISR, it seemed like most of the FOXM1 had already translocated into the nucleus 
by 2h and a predominant nuclear FOXM1 immunofluorescence was present 
throughout the 24 h period after cells were released from G1 arrest.  This tentatively 
indicates that an alternative mechanism is present in MCF-7-CISR cells, which is 
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responsible for an almost complete FOXM1 translocation into the nucleus as early as 
in G1 of the cell cycle.  
 
   As for MCF-7-CISR cells treated with PD098059, FACS cell cycle analysis 
also revealed that cells began entering S phase of the cell cycle gradually ay 2 h and 
S phase population peaked at 49.2 % by 6 h (Figure 3-33).  Subsequently, a majority 
of 72.9% of cells progressed through the G2/M phase of the cell cycle by 12 h, before 
67.1 % of them re-entered G1 phase by 20 h again as they successfully underwent a 
round of complete cell cycle division.  Confocal microscopy data also revealed that 
an almost complete nuclear FOXM1 translocation has also happened by 2 h and a 
predominant nuclear FOXM1 immunofluorescence was present throughout the 24 h 
period after cells were released from G1 arrest.  This suggests that an alternative 
mechanism is present in MCF-7-CISR cells, which is responsible for an almost 
complete FOXM1 translocation into the nucleus as early as in G1 of the cell cycle.  
Therefore, the inhibition of ERK-1/2 activity by PD098059 will have no effect on 
MCF-7-CISR cells because FOXM1 would have been already be in the nucleus by G1 
phase, without the need to wait for it to be phosphorylated by P-ERK-1/2 at G2 phase 
prior to mitotic entry.  Thus, this functional study has demonstrated that relationship 
ERK-1/2 activity and FOXM1 nuclear translocation has uncoupled, and this is an 
additional cisplatin resistance mechanism to encourage the early nuclear 








Figure 3-32  FOXM1 is translocated into the nucleus prior to entering G2/M 
phase of the cell cycle.  MCF-7-CISR cells were synchronized with 0.5 mM of 
mimosine for 24h.  MCF-7-CISR cells were then released by the removal of 
mimosine.  At different time intervals, cells were harvested and either stained 
with propidium iodide for FACS cell cycle profile analysis, or with DAPI and 
anti α-FOXM1-FITC stain to visualise subcellular localisation of FOXM1.    
Synchronized cells entered begin to enter S phase at 6h, G2/M at 10h and 









Figure 3-33 FOXM1 is translocated into the nucleus prior to entering G2/M 
phase of the cell cycle.  MCF-7-CISR cells were synchronized with 0.5 mM of 
mimosine for 24h.  MCF-7-CISR cells were then released by the removal of 
mimosine and treated with 20 µM of PD098059 immediately.  At different time 
intervals, cells were harvested and either stained with propidium iodide for 
FACS cell cycle profile analysis, or with DAPI and immunofluorescent 
αFOXM1-FITC stain to visualise subcellular localisation of FOXM1.    
Synchronized cells entered begin to enter S phase at 6h, G2/M at 10h and 
completing one round of mitotic division by 24h.   
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3.3.6 Targeting FOXM1 is better than ERK-1/2 for overcoming 




 Having established that ERK-1/2 activity and nuclear FOXM1 translocation 
is deregulated in MCF-7-CISR cells, I reason that rather than targeting ERK-1/2, the 
direct repression of FOXM1 expression would be a better method for circumventing 
acquired cisplatin resistance in breast cancer cells.  
 
 As a control, MCF-7 cells treated with both 0.1 µM of cisplatin and 20 µM of 
PD098059, there is a rapid decrease in both P-ERK1/2 and FOXM1 protein level by 
4h (Figure 3-34).  Furthermore, there was no significant quantities of FOXM1 
detected in the nuclear fraction, instead FOXM1 was localised and accumulated in 
the cytoplasm.  Interestingly, for MCF-7-CISR cells treated with 20 µM of 
PD098059, a rapid decrease in both P-ERK1/2 was also observed.  However, 
FOXM1 was still present in both the cytoplasmic and nuclear fraction.  This 
indicates that in for MCF-7-CISR cells the inhibition of P-ERK1/2 failed to rescue 
cisplatin sensitivity in breast cancer cell lines because FOXM1 has evolved the 
ability to translocate into the nucleus in the absence of P-ERK1/2.  Confocal 
microscopy also revealed that there was a similar distribution between cytoplasmic 
and nuclear fractions in MCF-7-CISR cells, but not in MCF-7 cells (Figure 3-35).  
Therefore, unlike the ability of thiostrepton to circumvent cisplatin resistance 
through targeting FOXM1 expression, the inhibition of ERK-1/2 failed to circumvent 
cisplatin resistance in breast cancer cells under in vitro conditions.  This suggests that 
the direct targeting of FOXM1 at the promoter level could be a better therapeutic 
strategy. 
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Figure 3-34  ERK-1/2 failed to circumvent acquired cisplatin resistance in 
MCF-7-CISR cells.  Both MCF-7 and MCF-7-CISR cells were treated with 20 µM 
of PD098059 for 48 h.  Approximately 75% of the cellular protein extracts 
harvested were then subjected to subcellular fractionation to obtain the 
cytoplasmic and nuclear fractions, whereas the remaining 25% portion was 
harvested under normal conditions prescribed in the protocol section.  
Subsequently, the protein levels of P-ERK-1/2, ERK, and FOXM1 were 
determined by western blot analysis.  Sp1 was the loading control for the 
nuclear protein fraction, while tubulin was the loading control for the 
cytoplasmic fraction. 
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Figure 3-35  Nuclear FOXM1 translocation was not affected by the inhibition of 
ERK-1/2 activity in MCF-7-CISR.  Both MCF-7 and MCF-7-CISR cells were 
treated with 20 µM of PD098059and 0.1 µM of cisplatin for 0h, 6h and 24h and 
stained with anti-FOXM1-FITC antibody and DAPI nuclear staining. Images 
were visualized by confocal microscopy.  The pictures illustrated here was the 
best representative of at least 8 independent images taken per condition.  
Original magnification X 40. 
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3.3.7 Summary 
 
 In the final chapter of my thesis, I have demonstrated that ERK-1/2 was not 
required for proliferation in MCF-7-CISR cells.  SRB assays showed that the 
proliferation of MCF-7 cells was inhibited when treated with the ERK-1/2 inhibitors 
– U0126 and PD098059, whereas MCF-7-CISR cells showed no significant reduction 
in proliferation or cell death, suggesting that they have evolved other mechanisms to 
compensate for a loss of P-ERK-1/2 activity.  Moreover, subcellular fractionation 
and immunochemical staining results revealed by confocal microscopy showed that 
the lack of sensitivity of MCF-7-CISR towards PD098059 treatment is correlated 
with the uncoupling of FOXM1 and ERK-1/2 activity in MCF-7-CISR cells.  
Subsequent synchronization experiments revealed that in MCF-7 cells, the treatment 
of PD098059 leads to a reduction in nuclear accumulation of FOXM1, resulting in an 
increased amount of cell death as cells failed to undergo normal cell cycle 
progression.  However, when MCF-7-CISR cells were treated with PD098059, the 
nuclear accumulation of FOXM1 was unaffected, enabling cells to go through 
normal cell cycle progression.  Unsurprisingly, PD098059 also failed to rescue 
cisplatin sensitivity in MCF-7-CISR cells as the continual FOXM1 translocation 
prevented MCF-7-CISR cells from cisplatin induced cell death. 
 
 The final study also revealed a few interesting observations which warrants 
further investigation.  For example, it was interesting to note that nuclear FOXM1 
translocation was observed as early as 2h after release from cell synchronization, 
prior to the cells even entering S phase in both MCF-7 and MCF-7-CISR cells.  
Therefore, this potentially suggest that another kinase or alternative mechanism is 
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responsible for the translocation of FOXM1 into cell cycle prior to S phase entry, 
which is independent of ERK-1/2 mediated phosphorylation of FOXM1 during G2-M 
transition discovered earlier (Ma, Tong et al. 2005).  However, their study also 
showed that there was no observable FOXM1 protein band shift during its G1 phase, 
suggesting that non-post-translational alternative mechanisms were responsible for 
its translocation.  This further suggests that FOXM1 could be translocated into the 
nucleus at G1 phase of the cell cycle through a non-post-translational modification 
mechanism.  Consistent with this notion, it is known that FOXM1 contains a putative 
nuclear localisation signal (NLS) within the amino acids sequence 341 to 422.  The 
NLS sequence RRNMTIKTELPLGARRKMK matches the consensus sequence of a 
classical bipartite NLS - BBX10-12(B3X2; B denotes a basic K or R residue; X denotes 
any amino acid; letters within the parentheses indicates that the order of the amino 
acids is not important) (Robbins, Dilworth et al. 1991).  It has also been established 
that proteins which possess NLS can bind to soluble receptors (“cargo carriers”) like 
importins and transportin, which then binds and translocate into the nucleus through 
nuclear pore complexes (NPCs) (Macara 2001).  NPCs are symmetrically octagonal 
structures which are made up of proteins called nuceloporins, adopting a cylindrical 
channel attaching to an exterior rim by eight spokes (Davis 1995; Pante and Aebi 
1996; Fabre and Hurt 1997; Stoffler, Fahrenkrog et al. 1999; Rout, Aitchison et al. 
2000).    There are approximately 4000 NPCs distributed across the nuclear 
membrane of mammalian cells, acting as a gateway for nucelocytoplasmic shuttling 
of proteins (Maul 1977; Rout and Blobel 1993). Therefore, any alterations to the 
regulation of NLS sequence or its ability to pass through NPCs could result in a 
change in the dynamics of FOXM1 nucleocytoplasmic shuttling.  Nonetheless, this 
would require further experimental confirmation but it is worth noting that it has 
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been shown that in another closely related member of the FOX family - FOXO4, its 
subcellular distribution and activity is dependent on its NLS (Brownawell, Kops et 
al. 2001).  Further experimental work is required to determine the importance of the 
putative NLS sequence embedded within FOXM1. 
 
 Nonetheless, it is logical that FOXM1 is translocated into the nucleus prior to 
cell cycle entry into S phase as FOXM1 plays important roles in activating 
downstream targets like JNK, c-myc, KIS and Skp2/Cks1 which are all needed for 
G1-S phase transition.  However, the ability for MCF-7-CISR cells to translocate 
most of the cytoplasmic fraction of FOXM1 into the nucleus at G1 phase of the cell 
cycle independent of ERK-1/2 activity must have contributed to a selective survival 
in the presence of cisplatin treatment.  Interestingly, consistent with my findings are 
that in B474 breast cancer cell line treated with cisplatin, ERK-1/2 activity has been 
shown not to be critical in cellular response to cisplatin (Hayakawa, Depatie et al. 
2003).   Instead, the study revealed that JNK, a stress response kinase which is a 
direct downstream target of FOXM1 is involved promotes cisplatin resistance 
through increasing the phosphorylation of Activating Transcription Factor 2 (ATF2) 
(Hayakawa, Depatie et al. 2003).  The phosphorylation of ATF2 enhances its 
transactivation ability and accelerates DNA damage repair.  However, its exact 
downstream effectors are unknown, but DNA repair genes possessing putative 
binding sites ATF2 include DNA polymerase-β and DNA topoisomerase I were 
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 In summary, the ability to translocate a larger proportion of FOXM1 into the 
nucleus at an early G1 independent of ERK-1/2 could confer enhance cisplatin 
resistance, possibly by allowing FOXM1 to activate a larger repertoire of distant 
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3.3.8   Discussion 
 
3.3.8.1 The de-regulation of FOXM1 from its up-stream regulators could be a 
common theme in breast cancer cells 
 
 
 In the last chapter of my thesis, I have unravelled that the uncoupling of the 
tight relationship between P-ERK1/2 and FOXM1 in MCF-7-CISR, making P-
ERK1/2 mediated FOXM1 nuclear translocation indispensible, as MCF-7-CISR has 
evolved alternate mechanisms to translocate FOXM1 into the nucleus early on at G1 
phase of the cell cycle. 
 
 Interestingly, the uncoupling of FOXM1 and its upstream regulators have 
also been observed in different circumstances.  For instance, breast cancer cells 
expressing ERα, a member of the superfamily of steroid nuclear receptor 
transcription factor that binds to target promoter genes and facilitate in the 
recruitment of the general transcriptional machinery (Mangelsdorf, Thummel et al. 
1995).  The activation of ERα transcriptional activity can promote mitogenic growth 
signalling pathways, stimulating the growth of breast cancer cells (Ali and Coombes 
2002).  Recently, it has been identified that ERα can activate FOXM1 expression by 
binding to two estrogens responsive elements (ERE) within the FOXM1 promoter 
regions (Millour, Constantinidou et al. Under review).  Furthermore, in a sample of 
clinical breast cancer tissues, it was discovered that lower grade breast cancer 
tumours expressing lower levels of FOXM1 mRNA significantly correlated with 
ERα according to the Spearman rank correlation statistical test.  However, higher 
grade breast cancer tumour expressing elevated levels of FOXM1 mRNA no longer 
correlated with ERα, indicating that in more aggressive breast cancer tumours, 
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FOXM1 has evolved the ability to uncouple with ERα regulation (Millour, 
Constantinidou et al. Under review). 
 
 Thereforth, since both ERα and ERK-1/2 belongs to mitogenic signalling 
pathways, the de-regulation of FOXM1 might lead to more aggressive tumour 
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3.3.8.2 The de-regulation of FOXM1 and ERα is also observed in tamoxifen 
resistance breast cancer cell lines 
 
 Furthermore, over 75% of human breast cancer cases are diagnosed as ERα 
positive, and the administering of tamoxifen, an antagonist against ERα is routinely 
used as a first line endocrine treatment (Osborne 1998).  Tamoxifen competes with 
estradiol (E2 or 17β-estradiol) and binds to ERα receptor, displacing its normal E2 
ligand.  The ERα-tamoxifen complex then binds to promoter regions of target genes 
and recruits co-repressors like nuclear receptor co-repressor 2 (NcoR) or silencing 
mediator for retinoid or thyroid-hormone receptors (SMRT) to repress activation of 
downstream mitogenic signaling targets (Shang, Hu et al. 2000).  However,  over 
half of the patients will eventually develop endocrine resistance (Hull, Clark et al. 
1983; Encarnacion, Ciocca et al. 1993). 
 
  ERα is also an established up-stream regulator of FOXM1 and ChIP analysis 
had shown that ERα can bind directly to FOXM1 promoter to transactivate its 
expression, engaging in a positive feedback loop (Madureira, Varshochi et al. 2006; 
Millour, Constantinidou et al. Under review).  Recently, results that have involved 
some of my experimental input have shown that two tamoxifen resistant cell lines 
MCF-7-TAMR4 and MCF-7-TAMR7 maintained FOXM1 expression post treatment 
with tamoxifen but not in parental MCF-7 cell lines, suggesting that the requirement 
for ERα activation of FOXM1 was abrogated in tamoxifen resistance cell lines 
(Millour, Constantinidou et al. Under review).  Furthermore, the introduction of ∆N-
FOXM1 rescues tamoxifen sensitivity and prevented tamoxifen induced G1 arrest 
(Millour, Constantinidou et al. Under review).   
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 Therefore, the de-regulation of FOXM1 and P-ERK1/2 activity could play a 
role in cisplatin resistance, akin to the de-regulation of FOXM1 and ERα observed in 
tamoxifen-resistance cell lines.  It is evident from my various observations that the 
de-regulation of FOXM1 can involve several different ways – elevation at mRNA 
and protein level, enhanced phosphorylation by CHK2 or the deregulation of 
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3.3.8.3 FOXM1 might also play a role in de novo resistance of Trastuzumab 
(Herceptin) -resistance in breast cancer patients? 
 
  Interestingly, recently it is revealed that there is a significant correlation 
between nuclear FOXM1 staining and elevated expression of the Human Epidermal 
growth factor Receptor (HER2) (Bektas, Haaf et al. 2008).  Further studies 
performed also confirmed that FOXM1 is a downstream target of the HER2 receptor 
(Francis, Myatt et al. 2009). 
 
HER2 is a member of the ErbB receptor tyrosine kinases involved in the 
regulation of cell proliferation (Yarden and Sliwkowski 2001).  HER2 amplification 
happens in approximately 25 % of all breast cancer patients and correlates strongly 
with poor prognosis in breast cancer patients (Slamon, Clark et al. 1987; van de 
Vijver, van de Bersselaar et al. 1987).  Currently, HER2 receptor positive patients are 
given Herceptin (trastuzumab), a humanized antibody that binds directly between the 
region of 529–626 of amino acids in the HER2 ectodomain (Carter, Presta et al. 
1992).  However, over two thirds of metastatic breast cancer patients with HER2 
over-expression do not respond to Herceptin (Arteaga 2003).  Therefore, the de-
regulation of FOXM1 and HER-2 activity might also lead to Herceptin-resistance in 
breast cancer cells.  This warrants further investigation. 
 
 In summary, there is a growing body of evidence suggesting that FOXM1 
could play a wider role in the general phenomenon of acquired chemoresistance and 
Herceptin® resistance in beast cancer. 
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 Another interesting observation made in this study was the observation of a  
dynamic biphasic mode for nuclear FOXM1 translocation.  In the first phase, it was 
observed that in G1 phase of the cell cycle, FOXM1 begun to translocate into the 
nucleus prior to S phase entry mediated by an unknown mechanism.  Upon the 
completion of G1/S phase transition, FOXM1 is then phosphorylated at the G2 phase 
of the cell cycle prior to entry into the mitotic phase of the cell cycle as proposed by 
Ma et al (Ma, Tong et al. 2005). 
 
 Consequently, this observation leads rise to another interesting question – 
how is FOXM1 selected for nuclear translocation before both phases.  It is pertinent 
to highlight that in the first phase, FOXM1 needs to selectively activate downstream 
genes like Plk-1, KIS kinase or c-myc which are needed in G1/S phase transition.  
However, in the second wave of FOXM1 translocation, FOXM1 needs to selectively 
activate downstream genes like cyclinB1 and cdc25b which are needed in G2/M 
phase transition.  What is the regulating FOXM1’s selectively at these individual 
phases of the cell cycle?  A reasonable proposal is that FOXM1 could bind to 
additional co-factor complexes that can influence FOXM1 dynamics in nuclear 
import.  Indeed, a major body of research in the literature is supporting the notion 
that FOXM1 does not act alone in the regulation of downstream targets. 
 
 For instance, in yeast Sacchromyces cerevisiae, the transcriptional complex 
Fhk2/Fhk1/Mcm1/Ndd1 had been shown to regulate the expression gene cluster 
CLB2 responsible for G2/M transition of the cell cycle (Koranda, Schleiffer et al. 
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2000; Kumar, Reynolds et al. 2000; Pic, Lim et al. 2000).  Fhk1/2 is the evolutionary 
ancestors of the Forkhead family in metazoan evolution.  Since FOXM1 also controls 
the G2/M transition of the cell cycle, FOXM1 could also bind to other co--
transcription factors like serum response factor (SRF), which is human homologue of 
Mcm1.  SRF belongs to a family of transcription factor which contains MADS box 
domain including transcription factors like MEF2A, B and C.  SRF is known to 
activate a number of immediate downstream genes like c-fos, fosB and junB (Chai 
and Tarnawski 2002).  Interestingly, it has been shown that FOXM1c binds directly 
to another transcription factor Sp1, to transactivate the P1 and P2 promoters of 
human c-myc promoter synergistically (Wierstra and Alves 2007).  Furthermore, 
there is also evidence that there is interplay between members of the same Forkhead 
family.  For instance, FOXO3A and FOXM1 have been shown to interact in vivo to 
regulate gene expression of ERα in breast cancer cells (Madureira, Varshochi et al. 
2006).  This suggested that FOXM1 could also interact with other members of its 
own forkhead family to regulate the downstream gene expression. Moreover, a yeast 
two-hybrid screen has identified that the human papillomas virus (HPV) 16 E7 
protein also binds to its co-transcription factor FOXM1 to enhance the 
transformation and transactivation of HPV under both in vitro and in vivo conditions 
(Luscher-Firzlaff, Westendorf et al. 1999). 
 
 In order to identify the different two different types of “FOXM1-complexes” 
present in the cytoplasm that allows for selectivity in nuclear translocation and 
activation of different genes, I propose the use of the tandem affinity tandem 
technique (TAP).  The technique was developed in 2001 by Puig et al have 
developed and optimized a standard method for protein purification by using the 
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tandem affinity purification (TAP) tag (Puig, Caspary et al. 2001). The TAP tag 
consists of two IgG binding domains of Staphylococcus aureus protein A (ProtA), a 
TEV protease cleavage site and calmodulin binding peptide domain (Puig, Caspary 
et al. 2001).  The TAP tag could be fused into the C or N terminal of the protein of 
interest.  The recombinant fusion construct could then be introduced into a host cell 
or organism.  The recombinant protein would then be maintained at a natural level of 
expression for optimal results.  This is because an overexpression of the recombinant 
protein often induces the binding of non-natural endogenous binding partner like heat 
shock proteins and proteasome.  Cell extracts could then be prepared and a two-step 
purification process through the IgG affinity beads and the calmodulin affinity beads 
would then recover the fusion protein and its binding partners.  The protein complex 
obtained could then be further characterized by running the protein lysate on a SDS-
PAGE prior to identification by mass spectrometry.  The TAP method allows the 
identification of the binding stoichiometry of protein complexes.  Due to the fact that 
the purifications steps involved are all performed in a gentle native manner, the 
active purified protein complexes could also be used for structural analysis or other 
functional assays.  To this end, I have successfully cloned a plasmid containing a C-
terminal fused TAP tag based on the parental pCTAP-A vector (Kwok 2010) using 
the BamHI and NotI multiple cloning sites. This could be either transiently or stable 
transfected into MCF-7 cells for further elucidation into any differences in co-
transcriptional factor complexes during the G1 and G2 different phases of the cell 
cycle to gain a further understanding into my hypothetic conceptualization of 
biphasic model for the regulation of FOXM1 nuclear translocation during cell cycle 
progression (Figure 3-36).  
 




Figure 3-36  A proposed hypothetical model for the biphasic model nuclear 
translocation of FOXM1.  During early G1 phase of the cell cycle, a specific G1 
FOXM1 complex containing a subset of co-transcriptional factors are selectively 
translocated into the nucleus to activate specific G1/S targets.  Following entry 
into the G2 phase of the cell cycle, ERK-1/2 can then phosphorylate the 
remaining specific G2 FOXM1 complex containing a subset of co-transcriptional 
factors are selectively and translocate them into the nucleus to activate specific 
G2/M targets.  As cells leave mitosis, FOXM1 is then ubiquitinated and 




  - 227 - 
Chapter 4 Final discussion 
 
 
 FOXM1 is a master transcription factor involved in the regulation of several 
fundamental processes in the regulation of cell proliferation, cell death, DNA repair, 
metastasis and angiogenesis.   The elevation of FOXM1 expression has been widely 
observed in several type of cancer, including primary breast cancer.  FOXM1 is a 
very attractive molecular because it is only expressed in actively proliferating cells, 
and its expression is not present in terminally differentiated cells.  Therefore, 
administering compounds which can target FOXM1 specifically can selectively 
induce cell death cancer cells with minimal side effects. 
 
 In this thesis, as a proof of concept, I have documented the pioneering of a 
novel thiazole antibiotic thiostrepton which can specifically repress the transcription 
activity of FOXM1 promoter, alongside demonstrating efficacy in inducing cell 
death in an array of breast cancer cell lines under in vitro conditions.  Moreover, 
thiostrepton failed to induce cell death in untransformed MCF10-A breast cells, 
further suggesting that the inhibition of FOXM1 exhibits minimal toxicity.  This is 
consistent with previously published data indicating that the employment of p19ARF 
peptide inhibitor to repress FOXM1 activity in transgenic mice to treat HCC 
demonstrated no in vivo toxicity (Gusarova, Wang et al. 2007).  The minimal side 
effect renders FOXM1 an attractive target for cancer therapeutic intervention.  
Consistent with my study, later publications have also demonstrated the specificity of 
thiostrepton in the repression of FOXM1 and that it has potent anti-cancer properties 
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against a wider range of cancer cell lines including neuroblastoma, liver and skin 
cancer cell lines  under in vitro conditions (Bhat, Halasi et al. 2009). 
 
 Alongside with the search of FOXM1 inhibitors, there has been a recent surge 
in interest and reasonable success in clinical trials for utilising combinatorial 
cisplatin treatment regimes in metastatic breast cancer patients.  However, acquired 
cisplatin resistance is proving to be a major obstacle.  Hitherto, the role of FOXM1 
plays in acquired chemoresistance is unknown, I hypothesized that FOXM1 could be 
important role conferring cisplatin resistance through the up-regulation of its 
downstream DNA damage repair targets – BRCA2 and XRCC1 which are often up-
regulated in cisplatin resistance cancer cell lines.  If FOXM1 were to be found 
important in conferring acquired chemoresistance, thiostrepton could also potentially 
be used to circumvent cisplatin resistant breast cancers.  
 
 Indeed, I have unravelled that both FOXM1 mRNA and protein expression 
levels are cisplatin resistance cells.  In response to cisplatin treatment, MCF7-CISR 
cells further up-regulated both FOXM1 mRNA and protein level but sensitive MCF7 
cells showed a decrease in FOXM1 mRNA and protein level.  Furthermore, the 
introduction of an ectopic constitutive active form of FOXM1 - ∆N-FOXM1 alone is 
sufficient to confer cisplatin resistance in breast cancer cells.  My studies have also 
indicated that the BRCA2 and XRCC1, may have other upstream co-regulators and 
that they are not the sole mediators for DNA repair, as the inhibition of FOXM1 still 
resulted in an increase in DNA damage repair despite the expression of BRCA2 and 
XRRC1.   Furthermore, my in vitro data also hinted that the direct targeting of 
FOXM1 resulted in a more significant amount of cell death in comparison to the 
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targeting of individual component of the DNA damage repair pathways like BRCA2 
and XRCC1, suggesting that the other roles of FOXM1 like cell proliferation could 
also enhance cisplatin resistance by amplifying pro-survival biochemical signalling 
pathways.  This is consistent with in vitro studies performed in ovarian cisplatin 
resistant cancer cell lines to demonstrate that DNA repair mechanisms is not 
ubiquitously present in all cisplatin resistant cell lines, and when present it 
contributes to approximately a small, but significant 1.75 fold increase in cisplatin 
resistance (Schmidt and Chaney 1993).  Therefore, the direct targeting of a master 
transcription factor like FOXM1 could target multiple carcinogenic pathways 
simultaneously, which is a better way to overcome acquired cisplatin resistance in 
breast cancer cells.  I have also demonstrated that the employment of thiostrepton 
alone can induce cell death in MCF-7-CISR cells, and that it also showed synergy 
with cisplatin under in vitro conditions by repression FOXM1 expression. 
 
Having discovered that the direct up-regulation of FOXM1 mRNA and 
protein levels was important in conferring acquired cisplatin resistance, I then 
wanted to determine whether other post-translational modifications could also play a 
role in conferring cisplatin resistance.  The upstream MAPK regulator of FOXM1 - 
ERK-1/2 has also been shown to also be elevated in primary breast cancer tissues by 
the use of MAP kinase enzyme assay, western blotting and immunohistochemical 
methods (Sivaraman, Wang et al. 1997; Salh, Marotta et al. 1999; Mueller, Flury et 
al. 2000).  Furthermore, current studies have also implicated that ERK-1/2 could also 
confer cisplatin resistance in ovarian cell lines (Wang, Zhou et al. 2007; Chan, Liu et 
al. 2008).  Given that FOXM1 is a direct downstream target of ERK-1/2, I 
hypothesized that an increase in ERK1/2 activity could also contribute to the 
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phenomenon of acquired cisplatin resistance by enhancing nuclear FOXM1 
translocation.  Therefore, with an increase in levels of nuclear FOXM1, it could help 
to confer cisplatin resistance by preventing cisplatin-adduct induced cell death.  
 
  Surprisingly, I discovered that ERK-1/2 is not needed in MCF7-CISR cell 
proliferation.  Furthermore, the employment of a specific MEK inhibitor PD098059 
induces cell death in MCF-7 cells but not in MCF-7-CISR cells.  This indicated that 
MCF-7-CISR cells have evolved the ability to by-pass the functional requirement of 
an active P-ERK1/2 medicated pathway in cell proliferation. Furthermore, both 
subcellular fractionation and confocal microscopy experiments have revealed that 
FOXM1 is still translocated into the nucleus of MCF7-CISR cells, but not MCF-7 
cells after treatment with PD098059.   This indicates that in the acquired cisplatin 
resistance cells, they have evolved a mechanism to allow nuclear FOXM1 
translocation independent of P-ERK activity.  The de-regulation of FOXM1 and its 
up-stream regulator P-ERK1/2 in acquired cisplatin resistant cell lines, is a parallel to 
the un-coupling of ERα and FOXM1 observed in tamoxifen resistant cell lines 
(Millour, Constantinidou et al. Under review).  In addition, I have also discovered 
that FOXM1 is translocated into the nucleus of both MCF-7 and MCF-7-CISR earlier 
than previously documented, at G1 phase of the cell cycle rather than at G2 prescribed 
by Ma et al.  
 
 In conclusion, I have identified that the novel thiazole antibiotic thiostrepton 
can repress transcription activity of FOXM1 and that it exhibits a potent anti-tumour 
effect against a panel of breast cancer cell lines under in vitro conditions.  The future 
development and modifications of the thiostrepton pharmacophore could lead to 
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suitable pre-clinical candidates that can be further under in vivo animal studies.  
Furthermore, I discover that the de-regulation of ERK-1/2 activity and FOXM1, 
coupled with the ability of MCF-7-CISR cells to up-regulate FOXM1 expression 
levels in the presence of cisplatin can confer cisplatin resistance through both DNA 
damage repair dependant and independent pathways.  The wider implication of my 
study also suggests that up-regulation of FOXM1 could also play a role in other 
common clinical therapeutic agents like doxorubicin, epirubicin, tamoxifen and 
Herceptin® and that thiostrepton could potentially be utilised on other types of cancer 
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